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Summary 
Posttranslational modifications (PTMs) affect fundamental cellular functions of the human malaria 
parasite Plasmodium falciparum, including regulation of protein stability, metabolism, proliferation, 
apoptosis and signal transduction. This study investigates the importance of phosphorylation and 
ubiquitination in modulating the parasite intraerythrocytic development, as well as their implication 
in antimalarial drug resistance.   
The chloroquine resistance transporter PfCRT is a drug-metabolite carrier annotated as a prominent 
determinant of parasite’s reduced susceptibility to quinoline drugs. PfCRT is posttranslationally 
modified by phosphorylation and palmitoylation. However, the role of these PTMs in regulation of 
PfCRT function is not fully resolved. Chemical and genetic approaches employed in the current study 
revealed the relevance of PfCRT phosphorylation at serine 33 in regulating the drug resistance-
mediating function of this transporter and in vitro fitness of the parasite. The PfCRT allelic exchange 
mutants, in which serine 33 was replaced by alanine showed increased sensitivity to chloroquine and 
quinine. Moreover, PfCRT serine 33 substitution by phospho-mimicking amino acids, glutamic and 
aspartic acid, could respectively partially and fully, restore the resistance phenotype. The fitness 
variation between the PfCRT mutants was linked to differences in merozoite numbers and their 
invasion efficiencies, with alanine mutants displaying a significant advantage in this regard. 
Identification of a kinase implicated in this phenomenon is desired, as its inhibition in combination 
with chloroquine could reduce or prevent the further spread of resistance. 
A HECT E3 ubiquitin ligase, termed ubiquitin transferase PfUT, is a novel candidate gene for 
multifactorial resistance to quinine. PfUT was shown to localize to the parasite’s ER/Golgi complex, 
but its role in reduced susceptibility to quinine and its physiological function remain unclear. 
Characterization of PfUT was attempted by a glmS ribozyme-based conditional knockdown of 
encoding it gene, generated using the CRISPR-Cas9 genome editing technology. Unexpectedly, 
integration of the glmS sequence resulted in a 2-fold increase in PfUT transcripts correlated with 
protein levels. PfUT overexpression, in turn, led to S phase-associated lengthening of parasite’s cycle, 
reflected in impaired growth. Glucosamine-induced incomplete downregulation partially restored 
the wild type phenotype. Moreover, the transgenic parasites exhibited an enhanced susceptibility to 
quinine and quinidine. An alternative disruption of the pfut locus via a selection-linked integration 
(SLI-TGD) strategy was unsuccessful, despite multiple attempts. These results underline the 
importance of PfUT in parasite proliferation and survival. However, a direct proof of PfUT’s 
association with quinine resistance and identification of its biological substrates await further 
investigation.
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Zusammenfassung 
Die posttranslationalen Modifikationen (PTMs) wirken sich signifikant auf die grundlegenden 
zellulären Funktionen des humanen Malaria-Parasiten Plasmodium falciparum aus, einschließlich der 
Regulierung von Proteinstabilität, Stoffwechsel, Proliferation, Apoptose und Signaltransduktion. 
Diese Studie untersuchte die Bedeutung von Phosphorylierung und Ubiquitinierung bei der 
Modulation der intraerythrozytären Entwicklung des Parasiten sowie deren Auswirkungen auf die 
Resistenz gegen Malariamedikamente.   
Der Chloroquin-Resistenz-Transporter PfCRT ist ein Wirkstoff-Metabolit-Transporter, der als 
prominente Determinante der reduzierten Anfälligkeit des Parasiten für Chinolin-Medikamente 
beschrieben ist. PfCRT wird posttranslational durch Phosphorylierung und Acetylierung modifiziert. 
Die Rolle dieser PTMs bei der Regulierung der PfCRT-Funktion ist jedoch noch nicht vollständig 
geklärt. Chemische und genetische Ansätze, die in der aktuellen Studie eingesetzt wurden, zeigten 
die Relevanz der PfCRT-Phosphorylierung des Serin 33 in der Regulierung der resistenzassoziierten 
Funktion dieses Transporters und der in vitro Fitness des Parasiten. Die PfCRT-Allel-
Austauschmutanten, in denen Serin 33 durch Alanin ersetzt wurde, zeigten eine erhöhte 
Empfindlichkeit gegenüber Chloroquin und Chinin. Darüber hinaus konnte die Substitution von PfCRT 
Serin 33 durch phospho-ähnliche Aminosäuren, Glutamin und Asparaginsäure, jeweils teilweise und 
vollständig, den Resistenzphänotyp wiederherstellen. Die Fitnessvariation zwischen den PfCRT-
Mutanten war mit Unterschieden in der Merozoitenzahl und deren invasiver Effizienz verbunden, 
wobei Alanin-Mutanten in dieser Hinsicht einen signifikanten Vorteil aufwiesen. Die Identifizierung 
einer an diesem Phänomen beteiligten Kinase wäre wünschenswert, da durch ihre Hemmung in 
Kombination mit Chloroquin eine weitere Ausbreitung von Resistenzen reduziert oder verhindern 
werden könnte. 
Eine HECT E3 Ubiquitin-Ligase, die so genannte Ubiquitin-Transferase PfUT, ist ein neuartiges 
Kandidatengen für die multifaktorielle Resistenz gegen Chinin. Es wurde gezeigt, dass PfUT im 
ER/Golgi-Komplex des Parasiten lokalisiert ist, aber seine Rolle bei der reduzierten Anfälligkeit für 
Chinin und seine physiologische Funktion bleibt unklar. Die Charakterisierung von PfUT wurde durch 
einen glmS ribozym-basierten, konditionellen Knockdown des kodierenden Gens untersucht, der mit 
der CRISPR-Cas9 Genombearbeitungstechnologie erzeugt wurde. Unerwartet führte die Integration 
der glmS-Sequenz zu einem 2-fachen Anstieg des PfUT-Transkripts, das mit dem Proteingehalt 
korreliert. Die Überexpression von PfUT wiederum führte zu einer Verlängerung der S-Phase des 
Zyklus des Parasiten, die sich auch im beeinträchtigten Wachstum widerspiegelt. Die durch 
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Glukosamin induzierte unvollständige Herunterregulierung stellte den Phänotyp des Wildtyps 
teilweise wieder her. Darüber hinaus zeigten die transgenen Parasiten eine erhöhte Anfälligkeit für 
Chinin und Chinidin. Eine alternative Unterbrechung des pfut-Locus durch eine Selection-Linked 
Integration (SLI-TGD)-Strategie blieb trotz mehrfacher Versuche erfolglos. Diese Ergebnisse 
unterstreichen die Bedeutung von PfUT für die Proliferation und das Überleben des Parasiten. Ein 
direkter Beweis für die Assoziation von PfUT mit der Chininresistenz und der Identifizierung seiner 
biologischen Substrate steht jedoch noch aus. 
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1. Introduction 
1.1. The biology of Plasmodium 
Plasmodium species, the causative agents of malaria are unicellular protozoan parasites belonging to 
the phylum Apicomplexa. Apicomplexan parasites are characterized by a presence of apical 
organelles found at certain stages of their life cycles. These organelles are especially important for 
host cell invasion. Vertebrate host vulnerable to Plasmodium infection include mammals, reptiles 
and birds (Aravind et al., 2003). Amongst the 200 Plasmodium species, only five routinely infect 
humans, comprising Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium 
ovale and Plasmodium knowlesi. Of the five species, P. falciparum is the most virulent and 
responsible for the vast majority of fatal cases, whereas P. vivax is the most geographically 
widespread (WHO, 2017). In recent years, the global malaria burden has promisingly begun to 
decline, mainly due to the distribution of insecticide-treated bed nets and administration of 
antimalarial drug-based combination therapies (Tizifa et al., 2018). Nevertheless, malaria remains 
one of the most life-threatening infectious diseases, with over 200 million cases and 400 000 deaths 
reported annually, mainly in the sub-Saharan Africa (WHO, 2018b). 
1.1.1. The life cycle of P. falciparum 
The life cycle of P. falciparum is divided between the insect vector and the human host. The parasites 
are transmitted in the digestive system of the mosquito from the genus Anopheles. During a blood 
meal of Plasmodium-infected mosquito, parasites are injected from the salivary gland of the vector 
into the host’s skin, further migrating via the bloodstream to the liver, where they infect hepatocytes 
(Fig. 1.1) (Aravind et al., 2003). After extensive proliferation, infected liver cells release merozoites, 
initially contained inside host cell-derived vesicles called merosomes, into the blood vessels. 
Liberated merozoites subsequently invade red blood cells, where again they undergo multiple rounds 
of asexual replication (Baer et al., 2007; Miller et al., 2013). The first symptoms of the disease occur 
with a rupture of mature parasitized erythrocytes, releasing millions of invasive merozoites into the 
bloodstream. Clinical manifestations of uncomplicated P. falciparum-infection include fever, chills, 
headache, fatigue and nausea, whereas severe malaria is associated with acute anemia, pulmonary 
oedema, jaundice or coma (Church et al., 1997; White et al., 2014). While the majority of the 
released merozoites will continuously repeat the intraerythrocytic developmental cycle, a small 
proportion differentiates into gametocytes. Gametocytes, as the malaria transmission forms are 
ingested by a mosquito during a blood meal, initiating the sexual development inside the vector. In a 
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process called sporogony, male and female gametes fuse, in the end giving rise to thousands of 
motile sporozoites. The new cycle begins with the mosquito bite inoculating saliva containing the 
invasive sporozoites to another human host (Aravind et al., 2003).  
 
 
Figure 1.1. The life cycle of human malaria parasite P. falciparum. The infection begins with a bite of 
a female Anopheles mosquito inoculating sporozoites into the human host (1). Within 30-60 min 
sporozoites reach the liver, where they multiply and re-differentiate generating thousands of 
merozoites (2). Merozoites released into the bloodstream invade host’s erythrocytes, initiating the 
blood stage of the infection (3). Parasite develops inside the red blood cell (RBC) through the stages 
of ring, trophozoite and schizont. A mature schizont eventually burst releasing daughter merozoites, 
which further invade new erythrocytes. At the same time, some of the merozoites will differentiate 
into gametocytes. Gametocytes will be further transmitted to the mosquito vector after being 
ingested during a blood meal (4). Inside the mosquito gut, gametocytes mature into gametes. 
Fertilized female gametes develop into ookinetes, which further forms oocysts. Multiple mitotic 
nuclear divisions inside the oocyst result in the generation of numerous invasive sporozoites. Upon 
oocyst rupture, sporozoites find their way to the salivary gland (5). The new malaria cycle starts again 
once a mosquito carrying the parasites bites another human host. Adapted from Phillips et al. (2017). 
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1.1.2. The blood stage development 
The most thoroughly studied amongst the three P. falciparum life stages is the intraerythrocytic 
developmental cycle, primarily due to its ease to be maintained in the in vitro culture and as the 
majority of available antimalarials target this stage of infection (Wilson et al., 2013). During each 
cycle taking approximately 48 h, growth of a single merozoite inside the red blood cell proceeds 
through the subsequent cellular stages of ring, trophozoite and schizont (Fig. 1.2.A and B). In order to 
grow and proliferate, P. falciparum degrades the host’s haemoglobin in the digestive vacuole (food 
vacuole). While converting the toxic heme into a hemozoin crystal, the parasite generates amino 
acids, which can be subsequently used for its reproduction (Fong & Wright, 2013). In a process called 
schizogony, a single nucleated parasite replicates forming between 8 and 24 daughter merozoites in 
a mature parasitized erythrocyte. Apart of sporozoites and ookinetes, merozoites are amongst the 
parasite forms possessing the apical organelles, required for P. falciparum host cell invasion (Fig. 
1.2.C). The two main secretory organelles localizing to the merozoite’s apical end, rhoptries and 
exonemes, are filled with proteins involved in invasion and egress, respectively (Counihan et al., 
2013; Janse & Waters, 2007).  
 
Figure 1.2. The P. falciparum intraerythrocytic development. A. The different stages of the parasite 
blood stage development including ring (0-24 h), trophozoite (24-36 h) and schizont stages (40-48 h), 
depicted in Giemsa-stained thin blood smears. B. Cellular architecture of the trophozoite-infected 
erythrocyte. C. Structure of the invasive merozoite. ER - endoplasmic reticulum; DV - digestive 
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vacuole; IMC - inner membrane complex; MC -Maurer’s cleft; PPM - parasite plasma membrane; 
PVM - parasitophorous vacuole membrane; RBCM - red blood cell membrane; TVN - tubovesicular 
network. Adapted from Flammersfeld et al. (2018). 
 
The intraerythrocytic cycle ends with an event known as parasite egress, in which mature schizonts 
burst releasing the daughter merozoites.  Within a minute, free merozoites bind and actively invade 
new red blood cells (Fig. 1.3) (Lehmann et al., 2018; Miller et al., 2013).  
 
Figure 1.3. Merozoites egress and invasion into new red blood cells. The release of merozoites from 
a mature schizont, known as egress, is preceded by degradation of the parasitophorous vacuole 
membrane (PVM) and the red blood cell membrane (RBCM). Invasion of a new erythrocyte by a 
released merozoite takes less than a minute. It involves the recognition of the receptors on the 
RBCM, attachment to the RBCM, reorientation of merozoite apical end towards the RBCM and finally 
the active entry, during which the parasitophorous vacuole (PV) is formed. Afterwards parasite 
growths and replicates within the PV, isolated from the red blood cell cytosol. Adapted from Maier et 
al. (2009). 
1.2. Antimalarial drugs 
A variety of drugs, belonging to the different families and inhibiting distinct stages of parasite’s 
development, is available for prevention and treatment of malaria. With regard to their chemical 
structure and mode of action, current antimalarials can be classified into quinoline derivatives 
(quinine, quinidine, chloroquine, amodiaquine, mefloquine, halofantrine, lumefantrine, primaquine, 
piperaquine), antifolates (sulphonamides, pyrimethamine, proguanil), hydroxynaphthaquinones 
(atovaquone), antimicrobials (tetracycline, doxycycline, clindamycin), and artemisinin derivatives 
(artemisinin, dihydroartemisinin, artemether, arteether, artesunate) (Müller & Hyde, 2010; Travassos 
& Laufer, 2016). The prophylaxis and malaria treatment have become challenging due to the 
development of drug resistance. In response to the parasites acquiring resistance to antimalarials 
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used as a monotherapy, various combination strategies have been introduced, with an artemisinin-
based combination therapy (ACT) recommended as a first line treatment of uncomplicated P. 
falciparum malaria (WHO, 2018a). ATC consists of two antimalarials differing in the mechanism of 
action, a fast acting artemisinin-based compound and a partner drug displaying a long half-life (WHO, 
2018a). Despite the significant improvements made towards vaccine development in recent years, 
with candidate RTS,S/AS01 reaching phase III clinical trial, an efficient vaccine providing long-term 
protection especially against severe malaria, is not yet available (Neafsey et al., 2015; Olotu et al., 
2016).  
1.2.1. Mode of action 
Depending on the stage of action, specific drugs can be used to prevent or cure the symptoms of the 
disease. Antimalarials can be categorized depending on their activity into the liver and blood 
schizonticides, gametocytocides and sporontocides (Bruce-Chwatt, 1962). Quinolines exhibit activity 
mainly against the asexual erythrocytic stages of malaria infection. These drugs accumulate in the 
parasite’s digestive vacuole, where they interfere with the conversion of toxic heme into hemozoin, 
by inhibiting the heme polymerase activity. In spite of its blood stage activity, primaquine also 
eliminates hepatic schizonts, dormant liver forms (hypnozoites), as well as gametocytes (Arrow et al., 
2004; Travassos & Laufer, 2016). Antifolates are blood schizonticides, blocking the enzymes of the 
parasite’s folate biosynthesis pathway, dihydrofolate reductase (DHFR) and dihydropteroate 
synthase (DHPS). Atovaquone, administered as a partner drug of the antifolate proguanil, binds to 
the mitochondrial cytochrome bc1 complex, thus interfering with electron transport and disrupting 
the membrane potential (Antony & Parija, 2016; Müller & Hyde, 2010). While antimicrobials display 
antiplasmodial activity by targeting parasite’s apicoplast, they act relatively slow. Thereby, their use 
is recommended in combination with fast acting antimalarials, such as quinine (Arrow et al., 2004; 
Okombo & Chibale, 2018). Artemisinin compounds are the fastest acting amongst the available 
antimalarial drugs, killing blood stage parasite forms and suppressing gametocyte transmission 
(Okombo & Chibale, 2018; Travassos & Laufer, 2016). The mechanism of action of artemisinins is 
associated with a peroxide bridge within their chemical structure. Upon binding of iron, the peroxide 
bridge breaks, releasing free radicals that damage membrane proteins, ultimately leading to the 
parasite death (Saifi, 2014; Travassos & Laufer, 2016). 
1.2.2. Resistance 
The efficacies of antimalarial medicines in the treatment of the disease are limited by a widespread 
of resistance. Plasmodium parasites have developed resistance to all antimalarials in current use, 
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becoming a global concern, as it affects the vast majority of the malaria endemic countries (Fig. 1.4) 
(WHO, 2018b).  
 
Figure 1.4. Geographic distribution of P. falciparum occurrence and antimalarial drug resistance. 
Blue colour highlights the countries in which malaria is endemic. Darker blue points to the worldwide 
spread of resistance to chloroquine (CQ), whereas navy blue indicates the resistance to artemisinin-
based combination therapies (ACTs) in the South-East Asia. Orange and red arrows display the 
widespread resistance to CQ and pyrimethamine. Black arrow shows the expansion of a new 
multidrug-resistant malaria parasite lineage PfPailin, resistant to artemisinin and its partner drug 
piperaquine. Adapted from Carlton (2018). 
The resistance appears to occur through spontaneous de novo mutations or gene duplications. Under 
selective drug pressure, the resistant parasites exhibit a survival advantage over the sensitive strains. 
However, conferring resistance might be associated with a fitness cost. Thus, in the absence of a 
drug, the susceptible parasites might overgrow the resistant mutants (Bloland, 2001; Arrow et al., 
2004; White, 2004).  
The emergence and spread of resistance depends on several factors, including the parasite mutation 
rate, the number of parasites exposed to the drug, the fitness cost of acquired resistance, the 
concentration of the administered antimalarial and the treatment in the presence or absence of a 
partner drug, to which the parasite is sensitive (Arrow et al., 2004; White, 2004). 
Resistance to the majority of antimalarials has developed either through alteration in predicted 
parasite transporters or via mutations in components of the pathways critical for parasite survival  
(Cui et al., 2015). Chloroquine resistance has been acquired by specific mutations in the gene 
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encoding P. falciparum chloroquine resistance transporter PfCRT, located in the parasite’s digestive 
vacuole. A lysine to threonine substitution at PfCRT’s position 76 (K76T) has been identified as a 
primary mediator of the reduced susceptibility (Lakshmanan et al., 2005). The best studied P. 
falciparum ATP-binding cassette (ABC) transporter is the P-glycoprotein homologue 1 (PfPgh-1), 
another drug carrier localizing to the food vacuole membrane. Polymorphisms in the gene encoding 
PfPgh-1, namely the multidrug resistance-1 gene (pfmdr1), was found to modulate the sensitivity to 
multiple antimalarials including chloroquine, amodiaquine, lumefantrine, mefloquine and 
artemisinins (Hayward et al., 2005; Sidhu et al., 2005; Veiga et al., 2016). Moreover, increased copy 
number of pfmdr1 has been linked with resistance to mefloquine, quinine, lumefantrine and 
artemisinin (Chavchich et al., 2010; Duraisingh & Cowman, 2005; Ferreira et al., 2011; Reed et al., 
2000). A point mutation in another ABC transporter, the multidrug resistance protein-1 PfMRP1, 
which localizes to the parasite plasma membrane, is implicated in the reduced susceptibility to 
chloroquine, mefloquine, lumefantrine and quinine (Gupta et al., 2014; Mok et al., 2014). Reduced 
quinine efficacy has also been associated with a highly polymorphic sodium–hydrogen exchanger 
PfNHE, localizing to the parasite plasma membrane like PfMRP1 (Pascual et al., 2013). Parasites have 
acquired resistance to the treatment with two combined antifolates, pyrimethamine and sulfadoxine 
via mutations in their target enzymes, dihydrofolate reductase (DHFR) and dihydropteroate synthase 
(DHPS), respectively (Oguike et al., 2016; Sharma et al., 2016). Decreased susceptibility to 
atovaquone is conferred by single-point mutations within the cytochrome b gene (pfcytb) (Goodman 
et al., 2016). Amongst the aforementioned antibacterial agents, resistance has been reported for 
clindamycin, as a result of two point mutations in the apicoplast-encoded 23S rRNA (Dharia et al., 
2010). The parasites’ unresponsiveness to artemisinin has been related to the mutation in the 
propeller domain of the P. falciparum Kelch 13 PfK13, a substrate adapter of an E3 ubiquitin ligase 
(Fig. 1.5) (Ariey et al., 2014; Mbengue et al., 2015). Nonetheless, several studies have reported a K13-
independent artemisinin resistance, involving mutations in a mu chain of the adaptor protein 2 
PfAP2-mu (Henriques et al., 2015), or in an actin-binding coronin PfCoronin (Demas et al., 2018). An 
enhanced parasite survival to artemisinin treatment raises the concern of developing resistance 
against partner antimalarial drugs. A spread of a multidrug resistant strain, denoted as PfPalain (after 
the geographic region, where it was first identified), has been recently reported in malaria endemic 
countries in the South-East Asia (Imwong et al., 2017). PfPalain exhibits resistance to both drugs co-
administered in ACT, artemisinin and piperaquine (Imwong et al., 2017). 
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Figure 1.5. Antimalarial drugs targets and resistance mechanisms. Parasites have acquired 
resistance to various antimalarials targeting components of the digestive vacuole (DV), cytosolic 
folate biosynthesis pathway and mitochondrial respiratory chain. Chloroquine (CQ), quinine (QN), 
piperaquine (PPQ) and amodiaquine (AQ) accumulate inside the DV, where they block heme 
detoxification into hemozoin. Iron released during protease-mediated degradation of host 
haemoglobin (Hb) activates artemisinin compounds (ART) by breaking its endoperoxide bridge 
(yellow polygonal star symbol). Point mutations (pink dots) in the chloroquine resistance transporter 
(PfCRT) and the multidrug resistance transporter-1 (PfMDR1) are determinants of resistance to CQ 
and AQ. Decreased susceptibility to PPQ is linked to the overexpression of the hemoglobinases 
plasmepsin 2 and 3 (PM2/PM3), in the DV, and might be modulated by mutant PfCRT. Increased copy 
number of pfmdr1 along with the mutant variants of PfCRT and PfMDR1 alter parasite 
responsiveness to QN, lumefantrine (LMF) and mefloquine (MFQ), and can regulate ART activity. 
Polymorphisms in K13-propeller are the primary mediators of ART resistance, observed in the ring 
stage parasites. Mutations in the dihydropteroate synthase (DHPS) and dihydrofolate reductase 
(DHFR) confer resistance to antifolates sulfadoxine (SDX) and pyrimethamine (PYR), respectively. 
Atovaquone (ATQ) disrupts electron transport in the mitochondrion, by binding to the cytochrome b 
(CYTb), mutations of which enhance the levels of ATQ resistance. Electron transport chain has a 
critical function in P. falciparum blood stages, as it supports de novo pyrimidine biosynthesis, by 
providing electrons for the ubiquinone-dependent dihydroorotate dehydrogenase (DHODH). 
Antimicrobials such as clindamycin (CLD) and doxycycline (DOX) target protein translation inside the 
apicoplast. Resistance to CLD has been linked to point mutations in the apicoplast 23S rRNA. Adapted 
from Blasco et al. (2017). 
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Resistance has rendered all antimalarials currently in use ineffective for curing malaria. Therefore, to 
mitigate the further decline of the drug susceptibility, it is desired to sustain the efficacy of available 
antimalarial medicines, to continuously distribute preventive measures such as bed nets and to 
develop new antimalarial compounds. Regular monitoring of drug resistance profiles, along with 
research focused on the diverse contributing factors is crucial for malaria control and elimination.  
1.2.3. The first to treat malaria: quinine and chloroquine  
Two quinoline derivatives, quinine and chloroquine deserve a special attention as they were the first 
medications used to cure malaria, effective for a long time before the resistance against them has 
emerged. 
Quinine is a naturally occurring alkaloid extracted from the bark of Peruvian cinchona tree. The use 
of this aryl amino alcohol for treating fevers was first documented as early as the 1630s (Achan et al., 
2011). Although it is the oldest antimalarial drug, quinine (QN) is still highly appreciated nowadays 
for treatment of severe malaria cases, and recommended as a drug of choice for woman in the first 
trimester of pregnancy as well as in case the ACT is not available (WHO, 2017). A diasteroisomer of 
QN, quinidine, is an anti-arrhythmic agent used as alternative to QN and ACT for treatment of severe 
P. falciparum infections (WHO, 2017). The mechanism by which QN kills the parasite has recently 
been linked to binding of this quinoline drug to the P. falciparum cytosolic purine nucleoside 
phosphorylase (PfPNP), an enzyme with a critical function for the purine salvage pathway (Dziekan et 
al., 2019). On the other hand, it has been previously shown that QN accumulates to the parasite’s 
digestive vacuole, where unlike chloroquine it does not lead to the heme build-up (Fitch, 2004). 
Moreover, phospholipids have also been suggested as a possible molecular target of quinine (Porcar 
et al., 2003). To enhance the antiplasmodial activity of this short half-life antimalarial, QN is often 
administered with an antibiotic (clindamycin, doxycycline, or tetracycline), particularly in the areas of 
emerging QN resistance (WHO, 2017). The reduced susceptibility to QN has evolved slowly and was 
not reported until 1910 (Peters, 1982). Although the mechanisms underlying the enhanced parasites 
survival to QN is not fully understood, it seems that it has a complex and multifactorial nature. 
Resistance to QN has been acquired by mutating the genes encoding several transporter proteins, 
such as PfCRT, PfMDR1, PfNHE (Cooper et al., 2002, 2007; Ferdig et al., 2004; Nkrumah et al., 2009; 
Sidhu et al., 2005) and by increasing the copy number of pfmdr1 (Reed et al., 2000). Nevertheless, a 
potential involvement of other yet undefined genes in this phenomenon cannot be ruled out. Due to 
the dose-dependent side-effects associated with a long regimen of QN treatment, it has been later 
replaced by its synthetic derivative, chloroquine, displaying substantially reduced toxic properties 
(Achan et al., 2011). 
  
10 
Belonging to the 4-aminoquinolines, chloroquine (CQ) was the first antimalarial medication produced 
on a large scale, and a drug of choice until the introduction of ACT (Fig. 1.6). Due to its efficacy, 
inexpensiveness and safety, CQ has been the most widely used amongst all antimalarials for 
chemoprophylaxis and treatment of all types of Plasmodium infections (Bloland, 2001; Arrow et al., 
2004; WHO, 2017). The mode of CQ’s action remains a subject of debate. Being alkaline, CQ 
accumulates in high concentrations in the acidic food vacuole, where it gets di-protonated, what 
stops its free diffusion across the vacuolar membranes. Trapped inside the digestive vacuole, CQ 
binds to a ferriprotoporphyrin IX (FP), also known as ferric heme or hematin, forming a FP-CQ 
complex, thereby blocking conversion of toxic heme into a malaria pigment (hemozoin). As a 
consequence, a build-up of reactive free heme leads to membrane disruption and eventually parasite 
death. It has also been suggested that this antimalarial inhibits DNA and RNA biosynthesis, and as a 
result protein synthesis (Ridley, 1998; Petersen et al., 2011; Saifi, 2014). Resistance to CQ arose 
slowly, taking almost 20 years since the introduction of the drug, despite its extensive use for 
treatment of the disease. This suggests that alteration of several genes was required to confer a 
resistance phenotype (Saifi, 2014). As mentioned previously, reduced CQ susceptibility has been 
linked to mutations in genes encoding transporters PfCRT, PfMDR1 and PfMRP1 (Blasco et al., 2017; 
Travassos & Laufer, 2016). 
 
Figure 1.6. Chemical structures of the first antimalarial agents, quinine and chloroquine, in 
comparison to the main component of the ACT, artemisinin. 
1.3. Posttranslational modifications (PTMs) 
Maintaining the cellular homeostasis and control of stress responses is governed by numerous 
regulatory networks at epigenetic, transcriptional, posttranscriptional and posttranslational level. 
These mechanisms are important for coordinated gene expression and, hence, Plasmodium 
development. However, the major aspects of life cycle transitions and response to environmental 
stimuli seem to be modulated posttranslationally (Chung et al., 2009; Doerig et al., 2018).  
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Posttranslational modification (PTM) refers to a covalent alteration of specific amino acid(s) within a 
protein, through an enzyme-mediated attachment or removal of a functional group, following 
protein synthesis. Due to the reversible nature, the PTMs provide a dynamic regulation of protein 
functions. By changing a protein mass, charge and/or conformation, the PTMs can modulate 
protein’s enzymatic activity and stability, localization and binding affinity (Chung et al., 2009; Doerig 
et al., 2015). Thereby, they not only generate diversity and complexity of the proteome but also play 
critical roles in numerous cellular processes and in parasite survival. The most widely described PTMs 
in Plasmodium, include phosphorylation (Solyakov et al., 2011; Pease et al., 2013), acetylation 
(Filisetti et al., 2013), methylation (Ponts et al., 2013) and lipidation such as prenylation, 
palmitoylation and GPI-anchoring (Jones et al., 2012; Doerig et al., 2015). Phosphorylation and 
lipidation have been shown to influence parasite motility, invasion, intraerythrocytic development 
and egress. Histone methylation and acetylation are believed to regulate expression of var genes, 
encoding the P. falciparum erythrocyte membrane proteins PfEMPs, in asexual blood stages (Doerig 
et al., 2015). Among other types of PTMs identified in malaria parasites are ubiquitination, 
SUMOylation (Issar et al., 2008), glycosylation (Kimura et al., 2000; Macedo et al., 2010), 
nitrosylation (Wang et al., 2014) and glutathionylation (Kehr et al., 2011). Another form of plasmodial 
PTMs is proteolytic processing, shown to have critical functions in haemoglobin degradation, as well 
as during parasite egress and invasion events (Chung et al., 2009). Moreover, some types of PTMs, 
such as phosphorylation or ubiquitination, have multiple roles, relatively high abundances and broad 
substrate specificities. On the contrary, other ones such as acetylation exhibit highly specific 
functions and relatively low abundances, targeting only one or a handful of proteins. Furthermore, 
the interplay between various PTMs has received a special attention in recent years, as the key to 
understanding the dynamics and complexity of the PTM regulating the parasite biology (Aggarwal et 
al., 2017; Yakubu et al., 2018). In P. falciparum, a significant crosstalk between the phosphorylation 
and ubiquitination pathways has been suggested to have an impact on the formation of invasive 
merozoites (Lasonder et al., 2015).  
With the emergence of drug resistance to all antimalarials in clinical use, it is essential to understand 
the key regulators of Plasmodium development, including the PTMs. Due to their crucial function in 
the control of numerous cellular processes, the mediators of PTMs seem to be attractive targets for 
antimalarial drug discovery (Chung et al., 2009).  
1.3.1. Role of PTMs in drug resistance 
Distinct PTMs have been implicated in modulation of drug resistance profiles in other systems 
(Aggarwal et al., 2017; Ahmad & Glazer, 1993; Ardiani et al., 2009; Emery et al., 2018; Germann et al., 
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1996). Resistance-conferring mutations can alter a protein’s function by either gaining or losing a 
PTM site. Alternatively, the PTMs may not interact with the drug resistance-mediator directly, but 
still influence the drug susceptibility of the cells, by upstream regulation of a signalling cascade in 
which this protein is involved (Aggarwal et al., 2017). For example, a serine substitution by non-
phosphorylatable alanine residue was shown to increase drug susceptibility, dependent on 
phosphorylation of two mammalian ABC transporters (Germann et al., 1996; Xie et al., 2008). A 
recent study in another protozoan parasite, Giardia duodenalis, revealed an association between the 
drug resistance and protein acetylation (Emery et al., 2018). A potential involvement of 
palmitoylation in the reduced drug susceptibility of P. falciparum has been also considered, as the 
two main determinants of resistance to quinolines, PfCRT and PfMDR1, are modulated by this 
modification (Jones et al., 2012).  
 A thorough understanding of the role of PTMs in altering the parasite signalling pathways may 
contribute to an improved control or even elimination of drug resistance. 
1.3.2. Phosphorylation and its role in the activity of PfCRT  
Phosphorylation involves kinase-mediated addition of a phosphoryl group, principally to a serine (S), 
threonine (T) or tyrosine (Y) residue in a substrate protein. This mechanism is antagonized by the 
activity of phosphatases which remove the modification from the target protein (Chung et al., 2009). 
Reversible protein phosphorylation is one of the major regulatory mechanisms involved in the 
control of Plasmodium life cycle (Yakubu et al., 2018). This posttranslational modification has been 
shown as critical for parasite invasion into the host cell (Alam et al., 2015; Vaid et al., 2008), 
progression inside the red blood cell (Blomqvist et al., 2017; Graeser et al., 1996; Mendenhall et al., 
1988; Silva-Neto et al., 2002) and egress of merozoites (Iyer et al., 2018). Moreover, phosphorylation 
has been implicated in the control of Plasmodium sexual differentiation, as well as the host-parasite 
interactions (Chung et al., 2009).  
The role of phosphorylation in mediating the function of a transporter protein has been reported in 
numerous studies (Foster et al., 2006; Ramamoorthy et al., 2011; Stolarczyk et al., 2011). In P. 
falciparum, the chloroquine resistance transporter PfCRT could be cited as an example of a protein 
regulated by phosphorylation. PfCRT is a digestive vacuolar membrane protein containing ten 
putative transmembrane domains and N- and C- terminal lobes facing parasite’s cytosol (Fig. 1.7). 
Apart from being phosphorylated at S33, S411, T416 and S420 (Kuhn et al., 2010; Lasonder et al., 
2012; Solyakov et al., 2011), PfCRT is also palmitoylated at cysteine (C) 301 (Jones et al., 2012). 
While, the T416 phosphorylation has been associated with PfCRT’s trafficking from the ER to the food 
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vacuolar membrane (Kuhn et al., 2010), the relevance of other modifications remains to be resolved. 
Given that the PTMs were found to modulate the resistance profiles and that PfCRT is a determinant 
of parasite reduced susceptibility to quinolines, a phosphorylation or palmitoylation of this 
drug/metabolite carrier could possibly regulate the parasite’s responsiveness to antimalarials.  
 
Figure 1.7. Topology of the chloroquine resistance transporter PfCRT. pfcrt encodes a 424 amino 
acids protein localizing to the membrane of parasite’s digestive vacuole. It contains ten 
transmembrane domains and N- and C-terminal ends directed towards the parasite cytoplasm. Red 
dots highlight polymorphic residues. The K76T mutation, a molecular marker of PfCRT-mediated 
chloroquine resistance is pointed out by a red arrow. PfCRT is posttranlationally modified by 
phosphorylation at S33, S411, T416 and S420 (green) and palmitoylation at C301 (orange). A green 
“p” indicates a phosphate group, whereas an orange “p” signifies a palmitoyl group. Adapted from 
Sanchez et al. (2010). 
1.3.3. The ubiquitin pathway and PfUT-mediated ubiquitination 
Ubiquitination, also known as ubiquitylation or ubiquitinylation, refers to a posttranslational labelling 
of a substrate protein with a small regulatory protein, namely ubiquitin. It involves formation of an 
isopeptide bond between the C-terminal glycine of an ubiquitin molecule and a lysine residue on the 
target protein. Ubiquitination is a three-step process, including ubiquitin activation, conjugation and 
ligation to the substrate. It is driven by a cascade of enzymes, namely ubiquitin-activating enzymes 
(E1), ubiquitin-conjugating enzymes (E2) and ubiquitin ligases (E3) (Chung et al., 2009). The latter 
group comprises of HECT (Homologous to E6-associated protein C-Terminus), RING (Really 
Interesting New Gene)/U-box and RBR (RING-Between-RING) families, categorized according to the 
structural organization and mechanism of these E3-type ligases (Lorenz, 2018). Unlike the RING E3-
type ubiquitin ligases, the HECT and RBR catalyse the modification of a substrate protein in a two-
phase mechanism, involving the formation of a thioester intermediate between an ubiquitin and an 
E3 catalytic cysteine (Wenzel & Klevit, 2012). Similar to phosphorylation, a covalent attachment of 
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ubiquitin can be reversed by means of deubiquitinating enzymes (DUBs). P. falciparum encodes at 
least 8 E1 or E1-like proteins, 14 E2 or E2-like proteins, 54 E3 or E3-like proteins and 29 DUBs 
(Hamilton et al., 2014). 
A substrate protein can be modified by a mono-, multi- or polyubiquitination. Depending on the type 
and length of the ubiquitin chain, the labelled protein can undergo either proteasomal degradation 
or be regulated in a particular manner (Fig. 1.8.).  
 
Figure 1.8. Schematic of the ubiquitin-mediated pathways. Protein tagging with an ubiquitin moiety 
consists of three subsequent steps. Initially, ubiquitin (Ub) is activated by the ATP-dependent E1. 
Ubiquitin is then transferred from E1 to the E2. Ubiquitin-conjugated E2 binds to the E3 ligase. 
Finally, E3 mediates transfer of ubiquitin from E2 to the substrate protein. In RING and U-box ligases 
this step occurs directly, whereas the HECT and RBR families form a thioester intermediate. The type 
and length of the ubiquitin chain defines the pathway, proteasome dependent or independent, 
which the labelled protein will follow. Ubiquitin can be attached to a substrate as one or several 
monomers (mono- and multiubiquitination) or polymer (polyubiquitination). K48-linked 
polyubiquitination directs proteins for proteasomal degradation. Mono- and multiubiquitination 
mediate among others DNA repair and endocytosis. Similar processes are regulated by K63 
polyubiquitin chains, which are additionally implicated in signalling. The role of other modifications 
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associated with sequential linkage of ubiquitin’s internal lysines awaits investigation. 
Deubiquitinating enzyme (DUB) can remove an ubiquitin mono- or poly-tag from the substrate 
protein. Thereby, DUBs replenish the pool of free ubiquitin molecules required for ubiquitination 
process. Adapted from Hamilton et al. (2014). 
As ubiquitin molecule contains seven lysine (K) residues at positions 6, 11, 27, 29, 33, 48 and 63, poly-
ubiquitin chains of different topology and complexity can be formed. Specific chain types are then 
captured by ubiquitin-biding domain (UBD)-containing proteins, which target the labelled protein to 
the respective signalling pathway (Suryadinata et al., 2014). Mono- and multiubiquitination have 
been shown to modulate DNA repair, gene expression, protein transport and endocytosis (Perrett et 
al., 2011; Sadowski & Sarcevic, 2010). Ubiquitin conjugated as polymer through lysines at position 48 
(K48) predominantly targets proteins for degradation on the proteasome. Similarly, K11-mediated 
polyubiquitination can also result in proteasomal destruction. In contrast, a protein modified via K63 
follows a non-degradative pathway, associated with DNA damage tolerance, ribosomal protein 
synthesis, endocytosis, signal transduction or activation of protein kinases (Bange et al., 2007; Chung 
et al., 2009; Wang et al., 2012). The relevance of other polyubiquitin-chain types needs to be 
resolved. Considering the importance of ubiquitin-mediated protein modification in control of 
multiple cellular processes, the ubiquitin-proteasome system appears to be an attractive target for 
novel malaria intervention strategies (Ng et al., 2017). 
Apart from ubiquitin, several ubiquitin-like modifiers (UBLs) have been identified in Plasmodium. 
These include SUMO (small-ubiquitin-related modifier), NEDD8 (neural precursor cell expressed 
developmentally downregulated 8), HUB1 (homologous to ubiquitin 1), URM1 (ubiquitin-related 
modifier 1) and ATG8 (autophagy 8) proteins (Issar et al., 2008; Ponts et al., 2008; Artavanis-Tsakonas 
et al., 2010; Reiter et al., 2013). Similarly to ubiquitin, the UBLs regulate substrate proteins via E1-E2-
E3 cascade, although they display distinct enzyme specificities (Ponts et al., 2008).  
Numerous studies have reported an association between the ubiquitin pathway and the antimalarial 
drug resistance. For instance, mutations in two E3 ubiquitin ligases, belonging to the HECT and RING 
families, have been linked with reduced susceptibility of P. falciparum to pyrimethamine (Park et al., 
2012) and artemisinin (Takala-Harrison et al., 2013), respectively. Moreover, polymorphisms in genes 
encoding different deubiquitinating enzymes were found to alter the parasite’s responsiveness to 
artesunate and chloroquine (Hunt et al., 2007), as well as to artemisinin (Henriques et al., 2014). 
Furthermore, resistance to the frontline antimalarial, artemisinin, has been shown to arise from 
mutations in Kelch 13, an adaptor protein recruiting substrates for a RING E3 ubiquitin ligase (Ariey 
et al., 2014). Another component of the ubiquitin-proteasome system, the P. falciparum ubiquitin 
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transferase PfUT has been suggested to affect parasites sensitivity to quinine and quinidine (Sanchez 
et al., 2014).  
The ubiquitin transferase is one of the four P. falciparum-encoded HECT ubiquitin ligases. pfut 
encodes the 460 kDa membrane protein localizing to the ER/Golgi complex. It contains four predicted 
transmembrane domains and N- and C-terminal ends, presumably directing the parasite’s cytoplasm. 
PfUT’s carboxyl end is characterized by a presence of a HECT catalytic domain, governing the 
ubiquitination (Fig. 1.9). This domain has been proven catalytically active in vitro (Sanchez et al., 
2014). Moreover, PfUT is posttranslationally modified by phosphorylation at Y347, T372, S411 and 
S1873 (Pease et al., 2013) as well as by acetylation at K2929 (Cobbold et al., 2016). As many of the 
HECT E3 ligases do not possess obvious substrate-binding motifs or domains, the prediction of a 
target-protein recognition site may be challenging (Beaudenon et al., 2005). PfUT’s substrate binding 
region, however, seems to be localized close to its N-terminus, what could be assumed based on the 
presence of two long stretches of armadillo (ARM) repeats, typically implicated in protein-protein 
interactions (PlasmoDB). ARM repeat-containing proteins have been shown to play versatile cellular 
roles (Tewari et al., 2010). Nevertheless, the physiological function of PfUT in the Plasmodium life 
cycle remains to be established. 
 
Figure 1.9. Topological model of the ubiquitin transferase PfUT. PfUT is a 3893 amino acids protein 
integrated to parasite’s ER/Golgi membrane via four putative transmembrane domains. This HECT 
E3-type ubiquitin ligase contains a presumed N-terminal substrate binding region and a C-terminal 
HECT catalytic domain, responsible for ubiquitination. PfUT is phosphorylated at Y347, T372, S411 
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and S1873 (green) and acetylated at K2929 (blue). Black arrows point at the polymorphic residues. 
Red colour denotes polymorphisms conserved among different field isolates and laboratory strains, 
despite distinct geographic origins. Green “p” and blue “Ac” indicate a phosphoryl and an acetyl 
group, respectively. Adapted from Sanchez et al. (2014). 
1.4. Genetic manipulation of P. falciparum genome 
Genetic engineering of P. falciparum genome is critical for unravelling the mechanisms behind the 
reduced susceptibility to antimalarial drugs. Validation of a gene contribution to the resistance 
phenotype requires efficient tools enabling the modification of the parasite’s genome. Furthermore, 
uncovering the genes essential for Plasmodium pathogenesis could define new targets for malaria 
therapy (de Koning-Ward et al., 2015).  
The genetic material of P. falciparum is organized into 14 linear chromosomes (23 Mb) contained in 
the nucleus, in addition to circular genomes found in the mitochondrion (6 kb) and apicoplast (35 kb) 
(Gardner et al., 2002). The GC content estimated to 19.4% (Gardner et al., 2002), classifies this 
human malaria parasite as one of the most AT-rich eukaryotes identified to date. 
Adaptation of P. falciparum to continuous in vitro culture enables its genetic manipulation. The 
haploid genome of this apicomplexan parasite facilitates gene editing, as only a single copy needs to 
be targeted (Carvalho & Ménard, 2005). Another advantage includes accessibility to the fully 
sequenced genome of P. falciparum 3D7 strain (Chang et al., 2012). However, a particularly AT-rich 
genome composition often hinders the cloning of transfection vectors. Moreover, relatively low 
efficiency of transfection as well as low frequency of integration driven by certain integration 
methods may limit successful recombination events. Transfection of malaria parasite with a plasmid 
DNA is based on an electroporation primarily of the ring-stage forms. Transfected parasites are then 
selected for integration or episomal expression, by means of a drug resistance cassette carried in the 
plasmid backbone. The most frequently used selectable marker is a human dihydrofolate reductase 
(hDHFR), conferring resistance to the drug WR99210 (de Koning-Ward et al., 2015). 
1.4.1. Genome editing tools 
Plasmodium does not have a non-homologous end joining (NHEJ) machinery, used in other 
organisms to repair the DNA broken via double strand breaks (DSBs). Nevertheless, the parasite is 
capable of fixing the damaged DNA by accurate homologous recombination (HR), govern in the 
presence of a DNA template (Lee et al., 2014).  
With recent advances in P. falciparum molecular genetics, numerous systems are available to modify 
the P. falciparum genome. These include integration of the transfection plasmid carrying 
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homologous DNA or “trace-free” editing, mediated by a single or double crossover event, 
respectively (Fig. 1.10) (de Koning-Ward et al., 2015). 
 
Figure 1.10. Strategies for editing the P. falciparum genome. A. Traditional engineering approach is 
based on the homology-directed repair of the spontaneous double strand breaks (DSBs) in DNA, near 
the target site (black star). Recombination between plasmid and chromosomal DNA occurs in a single 
crossover event. On the contrary, site-specific nucleases drive directed DSBs, followed by a 
homology-driven repair using the donor DNA (containing two homology arms flanking the gene of 
interest) via a double crossover recombination. B. Zinc-finger nuclease (ZFN)-based manipulation. A 
pair of ZFNs consists of ZFN-L and ZFN-R, each fused to a split Fok1 domain (red dot), carried on a 
single plasmid. Following expression, their dimerization assembles a functional enzyme, which 
induces DSB at the specified target site. C. CRISPR-Cas9-mediated editing relies on simultaneous 
expression of Cas9 endonuclease and the guide RNA, directing it to the target cleavage site. A repair 
template carrying a desired DNA modification is contained in the plasmid encoding the guide RNA. 
Adapted from Lee and Fidock  (2014). 
 
Conventional approach to manipulate the gene in P. falciparum involves the on and off drug-
exposure cycles, for up to 3 months of culture before the desired recombination may occur. It is, 
nonetheless, applicable for gene disruption or allelic substitution (Fig. 1.10.A) (Lee & Fidock, 2014). 
A modernized version of a classical approach, termed selection linked integration (SLI), has been 
recently developed. SLI involves traditional homology-directed plasmid integration into the target 
locus, yet considerably improving the time-efficiency and success rate in obtaining transgenic 
parasites. Including a T2A skip peptide between the tagged gene of interest and a selectable marker 
provides separate expression of these two, even though they are regulated by the same endogenous 
promoter (Birnbaum et al., 2017). 
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The more precise, site-directed genome editing takes advantage of specific nucleases, which 
generate DSBs at the desired target sequence enabling various gene alterations. Among them are the 
zinc finger nucleases (ZFNs). These metalloenzymes comprise the catalytic domain of the Fok1 
endonuclease and multiple zinc-finger proteins (DNA-binding domains). By inducing DSBs at the 
defined DNA site, the ZFNs trigger a template-guided homologous recombination (Fig. 1.10.B). 
Despite the time-efficiency and improved precision over the conventional method, the usage of 
ZFNs-mediated approach is limited by the cost and complexity of engineering the zinc-finger proteins 
(de Koning-Ward et al., 2015). 
The P. falciparum genome editing has been revolutionized with the introduction of a robust and cost-
effective technology, comprising the CRISPR (clustered regularly interspaced short palindromic 
repeats) and the accompanying Cas9 (CRISPR-associated protein 9) (Ghorbal et al., 2014). The 
CRISPR-Cas9 system is based on the RNA-guided cleavage by Cas9 endonuclease, followed by the 
homologous end joining repair (Fig. 1.10.C). It has been adapted from the bacteria Streptococcus 
pyogenes, where it serves as a defense mechanism against viruses (Jinek et al., 2012). The guide RNA 
consists of 20 nucleotides, complementary to the target site, and a protospacer adjacent motif 
(PAM), present for cleavage. It also contains the scaffold sequence required for Cas9 binding, so 
called tracrRNA (Mali et al., 2013).  
Alternative P. falciparum genome manipulation strategy allowing for multiple alteration of a single 
gene locus, includes the Bxb1 integrase system (Balabaskaran-Nina & Desai, 2018). Bxb1 catalyses 
the irreversible recombination between the chromosomal attB site and a donor attP site, carried on 
the plasmid along with the gene of interest. The system does not require drug selection. 
Nonetheless, generation of P. falciparum line containing a silent attB site integrated into a 
nonessential cg6 gene (Nkrumah et al., 2006) or within an intron of the target gene (Balabaskaran-
Nina & Desai, 2018) is a pre-requirement of this approach, restricting its application.  
Although the genome sequence of P. falciparum has been analyzed, a considerable fraction of genes 
contained in it awaits functional investigation. High-throughput genetic screens contribute to 
unravelling the genes with critical roles for parasite’s asexual blood stage development. This, in turn 
is advantageous for the design of novel drugs and vaccines against malaria infection. An example of 
such technology involves gene mutagenesis via insertion of piggyBac transposable elements (de 
Koning-Ward et al., 2015). piggyBac transposase mediates integration of a drug resistance cassette 
into random TTAA-target sites, highly abundant in the P. falciparum genome (Balu et al., 2005; Zhang 
et al., 2018). 
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Although applied efficiently in many eukaryotic systems, the RNA interference (RNAi) is not possible 
in P. falciparum, as the parasite lacks the necessary enzymes (Baum et al., 2009).  
1.4.2. Conditional gene downregulation methods 
The haploid nature of the P. falciparum genome hinders the classical knockout of genes displaying 
critical roles in the intraerythrocytic life cycle, as it may cause parasite death. Therefore, the 
functional dissection of supposedly essential genes should be approached through a conditional 
disruption. Various methodologies have been established to conditionally manipulate gene 
expression at the genome, transcript or protein level (de Koning-Ward et al., 2015).  
One of the conditional DNA deletion systems includes the Cre-loxP. Site-specific Cre recombinase 
catalyses the excision of a DNA fragment located between the two loxP sites. The activity of Cre can 
be regulated by a tetracycline analogue, anhydrotetracycline (ATc). Removal of the ATc from the 
culture medium results in activation of weak tetracycline (Tet) promoter, thereby enhancing the 
levels of Cre-mediated recombination (Jones et al., 2016). Moreover, the DiCre (Dimerizable Cre) 
system has been developed as a more efficient alternative of the ATc-mediated Cre method. DiCre 
relies on the dimerization of the two halves of Cre, fused to the FKBP (FK506-binding protein) and 
FRB (FKBP-rapamycin binding ) proteins, driven by the presence of rapamycin (Knuepfer et al., 2017). 
A conditional alteration of P. falciparum genes can be also applied on the transcriptional level. One of 
the examples embraces the ATc-regulated Tet-Off technology (Gossen & Bujard, 1992; Meissner et 
al., 2005). In this case, the promoter of the gene of interest is replaced by a weak one, containing 
numerous tetracycline operator (TetO) sites. Binding of the transcriptional transactivator domain 
(TRAD) to TetO initiates the gene expression. Exposure to ATc inhibits this interaction, in turn 
blocking the gene expression (Meissner et al., 2005).  
A method implicating the posttranscriptional regulation of mRNA levels involves the use of 
metabolite-responsive self-cleaving glmS ribozymes (Prommana et al., 2013). These RNA molecules 
displaying catalytic activity are commonly found in bacterial genomes. They reside in the 5′ UTRs of 
the genes implicated in production of glucosamine 6-phosphate (GlcN6P) (Lee & Lee, 2017). glmS 
ribozymes contain four domains (so called pseudoknots) of which P1 and P2 are involved in the 
recognition of GlcN6P, whereas P3 and P4 are required for structural stabilization (Roth et al., 2006). 
Glucosamine (GlcN)-induced self-cleavage of glmS ribozyme destabilizes the mRNA, in turn 
decreasing the produced protein levels. Therefore, by integrating the glmS ribozyme into the 3’ 
untranslated region (UTR) of the gene of interest, its expression can be regulated in GlcN-dependent 
manner (Prommana et al., 2013). 
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Conditional downregulation on the protein level could be achieved via the DD (FKBP-based 
destabilization domain) (Robbins et al., 2017) or the DDD (DHFR-based destabilization domain) 
approaches (Cobb et al., 2017). The fusion of the protein of interest with either of these two domains 
leads to its ubiquitination-mediated degradation, through the endoplasmic reticulum-associated 
degradation (ERAD) pathway. The presence of stabilizing ligands (Shield 1 and trimethoprim, for the 
DD and DDD system, respectively) can reverse the degradation (Cobb et al., 2017; Robbins et al., 
2017). Alternatively, the conditional aggregation domain (CAD)-based strategy could be employed as 
an inducible system for P. falciparum export proteins (Kuhn et al., 2010; Saridaki et al., 2008). Fusion 
of an export protein with CAD results in its aggregation inside the ER, and thereby inhibition of 
protein transport. The protein arrest can be reversed upon addition of an anti-aggregation ligand 
(AP21998) (Saridaki et al., 2008). 
Finally, the diversity of available inducible systems is of high relevance, as the success of the 
approach chosen for manipulation of a particular gene is often uncertain. Furthermore, a transgenic 
line generated using one of the above described methodologies requires robust functional assays for 
the phenotypic characterization of the parasite (de Koning-Ward et al., 2015).  
1.5. Aim of the study 
Posttranslational modifications (PTMs) control numerous processes with fundamental roles for the 
biology and pathogenesis of the human malaria parasite. Although alterations in the PTMs have been 
associated with the reduced drug susceptibility in several eukaryotes, such correlations have not yet 
been extensively investigated in Plasmodium.  
The purpose of this doctoral study was to gain a deeper insight into the role of specific PTMs in 
mediating P. falciparum events throughout its asexual life cycle. On the one hand, this thesis aimed 
to assess whether phosphorylation modulates the PfCRT-mediated resistance to chloroquine and 
quinine. The focus of the investigation was put on PfCRT’s serine 33. The involvement of 
phosphorylation in this phenomenon has been addressed through chemical and genetic methods. On 
the other hand, this work aimed at understanding the physiological function of PfUT during parasite’s 
intraerythrocytic development. Another objective was to validate the PfUT’s association with 
parasite’s altered responses to quinine and quinidine. To meet these goals a conditional 
downregulation as well as gene disruption have been attempted. 
As phosphorylation and ubiquitination regulate numerous pathways critical for P. falciparum 
proliferation and survival, the mediators of these PTMs are attractive targets for drug discovery 
against malaria. Moreover, understanding the mechanisms underlying the PTM-mediated drug 
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resistance could limit or even prevent the resistance spread by implementation of novel antimalarial 
combination therapies. Therefore, results of the current study could contribute not only to gaining a 
profound knowledge concerning implication of the PTMs in parasite’s biology, but also to 
identification of new targets for malaria therapy.   
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2. Materials and Methods 
2.1. Materials 
2.1.1. Equipments 
Equipment Company 
  
Analytical scales  
Autoclave ABT 120-5DM 
Autoclave 2540 EL 
Blot scanner C-DiGit 
Camera S6X11 
Centrifuge Biofuge fresco 
Centrifuge Biofuge pico 
Centrifuge J2-MC 
Centrifuge Megafuge 1.0 R 
Centrifuge Megafuge 2.0 R 
Centrifuge Sorvall RC5B Plus 
Electrophoresis power supply Power Pac 300 
Electrophoresis power supply Power Pac 200 
Electrophoresis power supply EPS 1001 
Electrophoresis power supply EPS 3501 
Electroporator Gene Pulser II 
Flow cytometer BD FACSCanto 
Freezer -20°C LGex 3410 MediLine 
Freezer -80°C HERAfreeze 
Fridge LKexv 3910 MediLine 
Gas burner gasprofi 1 micro 
Heating block NeoBlock Mono I 
Ice machine 
Incubator Heraeus B12/UB12 
Light optical microscope Axio Lab.A1 
Liquid nitrogen tank MVE Cryosystem 6000 
Liquid nitrogen tank LS 6000 
Liquid nitrogen tank RS Series 
Magnetic sorter VarioMACS 
Magnetic stirrer RCT 
Magnetic stirrer COMBIMAG RCH 
Magnetic stirrer HR 3001 
Microwave oven R940/94ST 
MiliQ water system Purist  ultrapure 
Particle counter 
pH meter pH 7110 
Pipetman Gilson P2, P20, P200, P1000 
Pipetus Forty / Standard 
Plate reader FLUOstar OPTIMA 
Printer hp LaserJet 1300 
Rotors JA20.2, JA20.1 
Rotors SS-34; GS-3 , SM24 
Sartorius, Göttingen 
Kern & Sohn, Balingen, Germany 
Tuttnauer, Breda, The Netherlands 
Li-cor, Bad Homburg, Germany 
Rainbow CCTV, Irvine, CA, USA 
Thermo Fisher Scientific, Dreieich, Germany 
Thermo Fisher Scientific, Dreieich, Germany 
Beckman Coulter, Krefeld, Germany 
Heraeus, Hanau, Germany 
Heraeus, Hanau, Germany 
Thermo Fisher Scientific, Dreieich, Germany 
Bio-Rad, München, Germany 
Bio-Rad, München, Germany 
Amersham (GE Healthcare), München, Germany  
Amersham (GE Healthcare), München, Germany 
Bio-Rad, München, Germany 
BD Biosciences, San Jose, CA, USA 
Liebherr, Biberach, Germany 
Thermo Fisher Scientific, Dreieich, Germany 
Liebherr, Biberach, Germany 
WLD-TEC 
NeoLab, Heidelberg, Germany 
Ziegra, Isernhagen, Germany 
Thermo Fisher Scientific, Dreieich, Germany 
Zeiss, Jena, Germany 
Thermo Fisher Scientific, Dreieich, Germany 
Taylor-Wharton, Husum, Germany 
Taylor-Wharton, Husum, Germany 
Miltenyi Biotec, Bergisch Gladbach, Germany 
IKA, Staufen, Germany 
IKA, Staufen, Germany 
Heidolph, Schwabach, Germany 
Sharp, Hamburg, Germany 
Rephile, Germany 
Beckman Coulter, Krefeld, Germany 
WTW, Weilheim, Germany 
Gilson,  Limburg an der Lahn, Germany 
Hirschmann, Eberstadt, Germany 
BMG Labtech, Ortenberg, Germany 
Hewlett Packard, Heidelberg, Germany 
Beckman instruments, Palo Alto, CA, USA 
DuPont Instruments, Bad Homburg, Germany 
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2.1.2. Consumables 
Consumable  Company 
96-well plates, black / clear Greiner Bio-One, Frickenhausen, Germany 
96-well plates for qPCR, MicroAmp Fast (0.1 ml) Applied Biosystems, Foster City, CA, USA 
Acetate sealing foil for 96-well plate Sarstedt, Nümbrecht, Germany 
Aluminium foil Roth, Karlsruhe, Germany 
Cell culture plater Greiner Bio-One, Kremsmünster, Germany 
Cellstar tubes Greiner bio one, Frickenhausen, Germany 
Cover slips Roth, Karlsruhe, Germany 
Cryovials Nalgene®, Wiesbaden, Germany 
Cuvettes Sarstedt, Nümbrecht, Germany 
Electroporation cuvettes Gene Pulser Bio-Rad, München, Germany 
Eppendorf tubes Sarstedt, Nümbrecht, Germanx 
Eppendorf LoBind tubes Sigma-Aldrich, Darmstadt, Germany 
Falcon polypropylene round-bottom tubes BD Biosciences, Bedford, MA, USA 
Filter systems 500 ml Corning, Kaiserslautern, Germany 
Filters Millex GS (0.2 µm) Merck Millipore, Darmstadt, Germany 
Filter tips P20, P200, P1000 Greiner Bio-One, Frickenhausen, Germany 
Gloves TouchNTuff Ansell, München, Germany 
Immersion oil Zeiss, Jena, Germany 
MACS CS column Miltenyi Biotec, Bergisch Gladbach, Germany 
Object slides Marienfeld, Lauda-Königshofen, Germany 
Parafilm Bemis, Londonerry, UK 
PCR softtubes 0.25 ml Biozym Scientific, Hessisch Oldendorf, Germany 
PCR strip tubes & domed caps    BioMedical Instruments, Zoellnitz, Germany 
Petri dishes (10 ml diameter) Greiner Bio-one, Frickenhausen, Germany 
Petri-dishes (25 ml diameter) Greiner Bio-one, Frickenhausen, Germany 
Pipette tips Corning incorporation, Bodenheim, Germany 
Plastic pipettes (1 ml; 2 ml; 5 ml; 10 ml; 25 ml; 50ml) Corning incorporation, Bodenheim, Germany 
Scanner Epson Perfection 2400 
SDS PAGE XCell SureLock Mini-Cell 
Semi-dry transfer cell Trans-blot SD 
Shaker KS 501 digital 
Shaker incubator Innova 4000 
Shaker incubator Innova 4300 
Sonicator Sonoplus HD 2070 
Spectrophotometer UVIKON 923 
Sterile work bench Herasafe 
Sterile work bench SterilGard Class II 
Stop watch 
Thermocycler Labcycler 
Thermal cycler ABI 7500 Real-Time PCR System 
UV chamber GS Gene linker 
UV table TFX-35M 
Vortex Genie 2 
Waterbath 7A 
Widefield fluorescent microscope Axiovert 200M 
Epson America, Long Beach, CA, USA 
Thermo Fisher Scientific, MA, USA 
Bio-Rad, München, Germany 
IKA, Staufen, Germany 
New Brunswick, Wesseling-Berzdorf, Germany  
New Brunswick, Wesseling-Berzdorf, Germany 
Bandelin, Berlin, Germany 
Kontron instruments, Munich, Germany 
Thermo Fisher Scientific, Dreieich, Germany 
The Baker company, Sanford, ME, USA  
Roth, Karlsruhe, Germany  
Sensoquest, Göttingen, Germany 
Applied Biosystems, Foster City, CA, USA 
Bio-Rad, München, Germany 
Vilber Lourmat, Eberhardzell, Germany  
Scientific Industries, Bohemia, NY, USA  
Julabo, Seelbach, Germany 
Carl Zeiss, Oberkochen 
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PVDF membrane Bio-Rad, München, Germany 
Sterile filtration devices Corning incorporation, Bodenheim, Germany 
Thermo well PCR Corning incorporation, Bodenheim, Germany 
Transfer pipettes Sarstedt, Nümbrecht, Germany 
  
2.1.3. Chemicals 
Chemicals Company 
  
2-Mercaptoethanol Sigma-Aldrich, Darmstadt, Germany 
2-Propanol Sigma-Aldrich, Darmstadt, Germany 
Acetic acid Honeywell Fluka, Schwerte, Germany 
Acrylamid (30%) Mix 29:1 AppliChem, Darmstadt, Germany 
Agar-Agar Roth, Karlsruhe, Germany 
Agarose Molecular Biology Grade BIORON, Ludwigshafen, Germany 
Albumin Fraction V (BSA) AppliChem, Darmstadt, Germany 
Ammonium peroxodisulfate (APS) Roth, Karlsruhe, Germany 
Ampicilin sodium salt Roth, Karlsruhe, Germany 
Brilliant blue R250 Roth, Karlsruhe, Germany 
Bromophenol Blue sodium salt SERVA, Heidelberg, Germany 
Calcium chloride dihydrate Sigma-Aldrich, Darmstadt, Germany 
Chlorophorm VWR International, Darmstadt, Germany 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt, Germany 
Dithiotreitol (DTT) Sigma-Aldrich, Darmstadt, Germany 
Dry ice Zentrallager UniKlinikum Heidelberg 
EDTA AppliChem, Darmstadt 
Ethanol (99%) Zentrallager UniKlinikum Heidelberg 
Ethidium bromide Sigma-Aldrich, Darmstadt, Germany 
Formaldehyde Sigma-Aldrich, Darmstadt, Germany 
G418 disulfate salt Sigma-Aldrich, Darmstadt, Germany 
Gelatin from cold water fish skin (40-50%) Sigma-Aldrich, Darmstadt, Germany 
Gentamicin c.c.pro, Oberdorla, Germany 
Giemsa staining solution Roth, Karlsruhe, Germany 
Glucosamine hydrochloride Sigma-Aldrich, Darmstadt, Germany 
Glucose Roth, Karlsruhe, Germany 
Glycerol Sigma-Aldrich, Darmstadt, Germany 
Glycine AppliChem, Darmstadt, Germany 
Glutaraldehyde (25%) Merck, Darmstadt, Germany 
H2O2 (30%) Honeywell  Fluka, Schwerte, Germany 
Heparin sodium salt Sigma-Aldrich, Darmstadt, Germany 
Hoechst 33342 Life technologies, CA, USA 
Hypoxanthine c.c.pro, Oberdorla, Germany 
IC50 drugs: 
       Chloroquine diphospahte salt 
       Quinine hydrochloride 
       Quinidine sulfate salt dihydrate 
       Pyrimethamine 
 
Sigma-Aldrich, Darmstadt, Germany  
Sigma-Aldrich, Darmstadt, Germany 
Sigma-Aldrich, Darmstadt, Germany 
Sigma-Aldrich, Darmstadt, Germany 
Immersion oil Waldeck, Münster, Germany 
Methanol VWR International, Darmstadt, Germany 
Paraformaldehyde (16%), EM Grade Electron Microscopy Sciences, Hatfield, PA, USA 
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PBS tablets Sigma-Aldrich, Darmstadt, Germany 
Protease inhibitor Roche, Basel, Switzerland 
Potassium chloride Sigma-Aldrich, Darmstadt, Germany 
RPMI 1640 Gibco, Darmstadt, Germany 
Saponin SERVA, Heidelberg, Germany 
SeaKem LE agarose  Biozym Scientific, Hessisch Oldendorf, Germany 
Skim milk powder Honeywell  Fluka, Schwerte, Germany 
Sodium chloride Sigma-Aldrich, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS) AppliChem, Darmstadt, Germany 
Sodium deoxycholate Sigma-Aldrich, Darmstadt, Germany 
Sodium fluoride Sigma-Aldrich, Darmstadt, Germany 
Sodium hydroxide Sigma-Aldrich, Darmstadt, Germany 
Sorbitol Sigma-Aldrich, Darmstadt, Germany 
Sucrose AppliChem, Darmstadt, Germany 
TEMED Roth, Karlsruhe, Germany 
Tris Roth, Karlsruhe, Germany 
Triton X-100 Merck, Darmstadt, Germany 
TRIzol reagent Ambion - Thermo Fisher Scientific, Dreieich,Germany 
Tryptone/Peptone Roth, Karlsruhe, Germany 
Tween 20  Roth, Karlsruhe, Germany 
Verapamil hydrochloride Sigma-Aldrich, Darmstadt, Germany 
WR99210 Jacobus Pharmaceuticals, Princeton, NJ, USA 
Yeast extract Roth, Karlsruhe, Germany 
  
2.1.4. KITs 
2.1.5. Biological material 
2.1.5.1. Antibodies 
KIT  Company 
BM chemiluminescence blotting substrate POD Roche, Mannheim, Germany 
CloneJET PCR Cloning Kit Thermo Fisher Scientific, Dreieich, Germany 
DNeasy Blood & Tissue Kit Qiagen, Hilden, Germany 
FastStart Universal SYBR Green Master (Rox) Roche, Mannheim, Germany 
Gel Extraction/PCR Purification Kit Qiagen, Hilden, Germany 
High Pure Plasmid Isolation Kit Roche, Mannheim, Germany 
In-Fusion® HD Cloning Kit Clontech Laboratories, USA 
Plasmid MaxiPrep Kit Qiagen, Hilden, Germany 
SuperScript® III First-Strand Synthesis Supermix Thermo Fisher Scientific, Dreieich, Germany 
DNA-free Kit – DNase Treatment and Removal Thermo Fisher Scientific, Dreieich, Germany 
  
Antibody Source Company 
Anti-α-tubulin, monoclonal Mouse Sigma Aldrich, München, Germany 
Anti-HA (12CA5), monoclonal  Mouse Roche, Mannheim, Germany 
Anti-PfUT (SAB 654), C-terminal Rabbit Signalway Antibody, College Park, MD, USA 
Anti-PfUT (Thermo 1-2a), N-terminal Rabbit Thermo Fisher Scientific, Dreieich, Germany 
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2.1.5.2. Enzymes 
2.1.5.3. Fluorescent dyes 
2.1.5.4. Size markers and loading dyes 
 
 
Anti-BiP, polyclonal Rabbit Kindly provided by J. Przyborski (Pesce et al., 2008) 
Anti-PfERC, polyclonal Rabbit Kindly provided by J. Przyborski (Adisa et al., 2001) 
Anti-PfERD2,  polyclonal Rabbit Kindly provided by J. Przyborski 
Anti-Ub (FL-76), polyclonal  Rabbit Santa Cruz Biotech., Heidelberg, Germany 
Anti-PfCRT, polyclonal Guinea Pig Eurogentec, Köln, Germany 
Anti-mouse-POD  Goat Jackson ImmunoResearch, Suffolk, UK 
Anti-rabbit-POD  Goat Jackson ImmunoResearch, Suffolk, UK 
Anti-guine pig-POD  Donkey Jackson ImmunoResearch, Suffolk, UK 
Alexa Fluor 488 anti-mouse IgG Goat Invitrogen - Thermo Fisher Scientific, Dreieich, 
Germany Alexa Fluor 546 anti-mouse IgG Goat 
Alexa Fluor 488 anti-rabbit IgG Goat Invitrogen - Thermo Fisher Scientific, Dreieich, 
Germany Alexa Fluor 546 anti-rabbit IgG Goat 
Anti-mouse IgG, 10 nm colloidal gold 
conjugate (GA1004) 
Goat 
Boster Biological Technology,  Pleasanton, CA, USA 
Anti-rabbit protein A 10nm gold Goat CMC UMC, Utrecht, The Netherlands 
   
Enzyme Company 
EuroTaq Polymerase BioCat, Heidelberg, Germany 
Phusion Polymerase Fermentas, Germany 
Restriction Enzymes New England Biolabs, Frankfurt am Main, Germany 
Shrimp Alkaline Phosphatase New England Biolabs, Frankfurt am Main, Germany 
T4 Ligase Thermo Fisher Scientific, Dreieich, Germany 
  
Fluorescent Dye Company 
Hoechst 33342 Thermo Fisher Scientific, Dreieich, Germany 
SYBR Green I Sigma Aldrich, München, Germany 
  
Marker Company 
GeneRuler 1 Kb plus DNA ladder Ambion - Thermo Fisher Scientific,Dreieich, Germany 
PageRuler Plus Prestained protein ladder Ambion - Thermo Fisher Scientific, Dreieich,Germany 
HiMark Pre-Stained HMW Protein Standard Invitrogen -  Thermo Fisher Scientific,Dreieich, Germany 
RNA Gel Loading Dye (2x) Ambion - Thermo Fisher Scientific, Dreieich,Germany 
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2.1.5.5. Plasmids 
All the plasmids used in this study are described in Appendix II. 
2.1.5.6. Oligonucleotides 
The oligonucleotides used in this study were purchased from Thermo Fisher Scientific or Eurofins. They 
were designed and tested for Tm, predicted dimers formation and 3’-end stability using IDT OligoAnalyzer 
3.1 Tool (https://eu.idtdna.com/calc/analyzer) 
Primers used for cloning, colony PCR and sequencing: 
 (blue: enzyme restriction sites; green: homology regions for In Fusion cloning; red: desired mutations) 
Plasmid Origin 
pUF1-Cas9 Provided by Dr. Jose-Juan Lopez-Rubio, Montpellier, France 
pL6-HA-glmS Generated by Dr. Cecilia Sanchez,  Heidelberg, Germany 
pL6-B Provided by Dr.  Jose-Juan Lopez-Rubio, Montpellier, France 
pSLI-TGD Provided by Dr.  Tobias Spielmann, Hamburg, Germany 
pSLI-APEX2 Provided by Dr.  Markus Ganter, Heidelberg, Germany 
pL6-PfUT-HA-glmS-UTguide1 Generated by Monika Jankowska-Döllken in this study 
pL6-HECT-C2S-HA-glmS-UTguide1 Generated by Monika Jankowska-Döllken in this study 
pSLI-TGD-PfUT Generated by Monika Jankowska-Döllken in this study 
pL6-B-AlEx-UTguide2 Generated by Monika Jankowska-Döllken in this study 
pL6-B-AlEx-UTguide3 Generated by Monika Jankowska-Döllken in this study 
pL6-PfUT-BirA-myc-UTguide1 Generated by Monika Jankowska-Döllken in this study 
pL6-BirA-myc-PfUT-UTguide4 Generated by Alicia Miranda Moraga (Lehramtsstudentin) in this study 
pSLI-PfUT-APEX2 Generated by Alicia Miranda Moraga (Lehramtsstudentin) in this study  
  
No. Name Sequence 
1 UT-12580- SpeI-for GGACTAGTTTAATGAAAGTTGTTAAGAAGGAG 
2 UT-13040-BssHII-rev TTGGCGCGCCAGAAAGGGAAAAATTCTTTTGGC 
3 UT-3'UTR-NarI-for ATGCGGCGCCTTTTTGTTTGCGACCCGATG 
4 UT-3'UTR-AflII-rev CAGTCTTAAGTCTTTAATGTATATGTCCTTGAC 
5 UT-guide1-for TAAGTATATAATATTAAGAAAGTGAAAAGTTCTTTGTTTTAGAGCTAGAA 
6 UT-guide1-rev TTCTAGCTCTAAAACAAAGAACTTTTCACTTTCTTAATATTATATACTTA 
7 UT-guide1-rev-short TAAAACAAAGAACTTTTCACTTTC 
8 UT-12367-for ATCTGCCCTACCTAATAATGG 
9 UT-3’UTR-rev AACATTTGGGGGAATCTCTC 
10 UT-3'UTR-rev-2 AAATACTCTTAGGAACTTAAACC 
11 UT-12265-SpeI-for ACTAGTTAGATATACGAACGATTCAATTAC 
12 UT-12614-C2S-for TACCAAGTGTGATGACTTCTAC 
13 UT-12614-C2S-rev GTAGAAGTCATCACACTTGGTA 
14 BirA-myc-BssHII-for GATGCGCGCCTATGAAAGATAATACAGTACC 
15 BirA-myc-linker-BssHII-for GCGCGCATGGAGCCGCTATGAAAG 
16 BirA-myc-NarI-rev CAACGGCGCCTAGATTATTAATAAGCTTTCA 
17 UT-61-NotI-for GCGGCCGCTAAAATGGAGATGAATCTGAAATGG 
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Primers used for qPCR: 
 
 
 
18 UT-498-MluI-rev ACGCGTCTACCTACAACCTCATTTATCC 
19 UT-548-rev GCATAAACTCCCATATGCTCTTG 
20 UT-5’UTR-for TCTTTATTTCTACATCATGCTTTAAG 
21 UT-3893-ext-SacII-for TCCGCGGTCTAAATACTATACGCAAGATATG    
22 UT-4759-ext-AflII-rev AGAGCTTAAGACTACCAGATTCATCATCCTC C          
23 UT-shield-for ATAAACGT AATGACCCGAA 
24 UT-shield-rev TTCGGGTCATTCACGTTTAT 
25 UT-guide3-for TAAGTATATAATATTATAAATGTGAACGACCCGAAGTTTTAGAGCTAGAA 
26 UT-guide3-rev TTCTAGCTCTAAAACTTCGGGTCGTTCACATTTATAATATTATATACTTA 
27 UT-guide3-rev-short TAAAACTTCGGGTCGTTCACA 
28 UT-3863-for GTAATAACATGAAGGAATATAATATG 
29 UT-5’UTR-SpeI-for ACTAGTTTTTGCAGTTCATACATATATCTGTG 
30 UT-5’UTR-AflII-rev CTTAAGTTATTCTTTAACTAAAATTATATATATATATTATACTTAAAGC 
31 UT-2-NotI-for GCGGCCGCTTGAAGAAATACTTGCTCTTTGAA 
32 UT-2-SacII-rev CCGCGGACTACCTACAACCTCATTTATCC 
33 BirA-myc-AflII-for CTTAAG CT ATG AAA GAT AAT ACA GTA CC 
34 BirA-NotI-4Nf-rev GCGGCCGCTAGATGATGAAATAAGCTTTCCCAG 
35 UT-guide4-for TAAGTATATAATATTTGAAGAAATACTTGCTTTTTGTTTTAGAGCTAGAA 
36 UT-guide4-rev TTCTAGCTCTAAAACAAAAAGCAAGTATTTCTTCAAATATTATATACTTA 
37 UT-guide4-rev-short TAAAACAAAAAGCAAGTATTTCTTC 
38 UT-12580-NotI-for GCGGCCGCCTTAATGAAAGTTGTTAAGAAGG 
39 UT-13040-MluI-rev ACGCGTAGAAAGTGAAAAGTTCTTTTGGC 
40 APEX2-BssHII-for GCGCGCGGAAAGTCTTACCCAACTGTGAG 
41 APEX2-NarI-rev GGCGCCGGCATCAGCAAACCCAAGC 
42 pJET-for CGACTCACTATAGGGAGAGCGGC 
43 pJET-rev AAGAACATCGATTTTCCATGGCAG 
44 pL6-guide-for GTAACCAAAATGCATAATTTTTCC 
45 pL6-guide-rev TAGGAAATAATAAAAAAGCACC 
46 pL6- HA-glmS-5’-for ATTTAACTATATACTATGGAATAC 
47 pL6- HA-glmS-5’rev TATTGAGAAAATAAGAACAAGAC 
48 pL6-HA-glmS-3’-for ATCACATGATCTTCCAAAAAACATG 
49 pL6-HA-glmS-3’-rev TAAACCAATAGATAAAATTTGTAGAG 
50 pSLI-4seq-for TCGTATGTTGTGTGGAATTGTG 
51 pSLI-GFP-rev CACTGACAGAAAATTTGTGCCC 
   
No. Name Sequence 
52 UT-10-for TACTTGCTTTTTGAGAATTCCCAG 
53 UT-309-rev ATTGCTCAAACCTCCGTCAG 
54 β-tubulin-for TGATGTGCGCAAGTGATCC 
55 β-tubulin-rev TCCTTTGTGGACATTCTTCCTC 
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2.1.5.7. E. coli  strains 
2.1.5.8. P. falciparum  strains 
2.1.6. Buffers, media and solutions 
Strain Origin 
  
E. coli PMC 103 Provided by Prof. Alan Cowman (Doherty et al., 1993) 
E. coli XL10 Gold Agilent Technologies, Böblingen, Germany 
  
Strain Origin 
P. falciparum 3D7 The Netherlands (D Walliker et al., 1987) 
P. falciparum 3D7 PfUT-HA-glmS Generated by Monika Jankowska-Döllken in this study 
P. falciparum 3D7 SLI-TGD-PfUT Generated by Monika Jankowska-Döllken in this study 
P. falciparum Dd2  Indochina  
P. falciparum Dd2 PfCRT S33A/D/E Generated by Dr. Sonia Moliner Cubel (PhD thesis 2016) 
and Dr. Cecilia Sanchez 
P. falciparum HB3 Honduras (Bhasin & Trager, 1984) 
  
Buffer/medium/solution Composition 
Albumax I 5% (w/v) Albumax I 
in RPMI 1640 with 25 mM HEPES and L-Glutamine (Gibco) 
filter sterilized 
Ampicillin Stock, 1000x  100 mg/ml in ddH2O 
Blocking Solution  5% (w/v) skimmed milk in PBS 
Cell Culture Media 
     Complete Medium 
      
 
 
     Transfectants Medium 
 
10% Human A Serum 
0.2 µg/ml Gentamycin 
0.1 mM Hypoxanthine 
in RPMI 1640 with 25 mM HEPES and L-Glutamine (Gibco) 
5% Human A Serum 
0.25% Albumax I 
0.2 µg/ml Gentamycin 
0.2 mM Hypoxanthine  
in RPMI 1640 with 25 mM HEPES and L-Glutamine (Gibco) 
Coomassie Destaining Solution  20% Methanol 
7% Acetic Acid 
Coomassie Staining Solution  50% Methanol 
10% Acetic Acid 
0.5% Coomassie Blue R-250 
Cytomix 120 mM KCl 
0.15 mM CaCl2 
10 mM K2HPO4/KH2PO4, pH 7.6 
25 mM HEPES/2 mM EGTA, pH 7.6 
5 mM MgCl2 in ddH2O 
Adjusted to pH 7.6 with KOH 
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Filter sterilized 
DNA Loading Buffer (6x) 60% Glycerol 
60 mM EDTA 
0.25% Bromophenol Blue 
DSM1 10 mM  in 20% DMSO (v/v) 
Fixation Solution 1x PBS 
4% Paraformaldehyde (PFA) 
0.0075% Glutaraldehyde (GA) 
Freezing Solution 6.2 M Glycerol 
0.14 M Na-Lactate 
0.5 mM KCl 
in ddH2O, adjusted to pH 7.2 with 0.5 M NaHCO3 
Filter sterilized 
G418 50 mg/ml in RPMI 
IC50 Lysis Buffer 20 mM Tris base  
Adjusted to pH 7.4 with concentrated HCl 
5 mM EDTA 
0.008% (w/v) Saponin 
0.08% (w/v) Triton X-100 
Vacuum filtered, stored at RT 
LB Medium  1% (w/v) tryptone/peptone 
0.5% (w/v) yeast extract 
0.5% (w/v) NaCl 
Autoclaved 
LB Agar 10 g tryptone/peptone 
5 g yeast extract 
5 g NaCl 
15 g agar 
in 1 L ddH2O, autoclaved 
MACS Buffer  
 
2 mM EDTA in 1x PBS, autoclaved 
0.5% (w/v) BSA added prior to use 
NZY+ Broth  
 
1% (w/v) NZ amine (casein hydrolysate) 
0.5% (w/v) yeast extract 
0.5% (w/v) NaCl 
pH adjusted to 7.5 with NaOH, autoclaved 
Prior to use the following filter-sterilized supplements were 
added: 
12.5 mM MgCl2 
12.5 mM MgSO4 
0.4% (w/v) Glucose 
PBS 1 tablet (Sigma-Aldrich) per 200 ml ddH2O 
Permeabilization Solution 0.1% Triton-100 in 1x PBS  
Permeabilization/Quenching Buffer 0.1% Triton-100  and 125 mM Glycine in 1x PBS 
Protease Inhibitors (PI)  
 
0.002% (w/v) Leupeptin 
0.005% (w/v) Aprotinin 
100 μM PMSF 
Protein Loading Buffer (2x) 
 
3% (w/v) SDS 
250 mM Tris pH 6.8 
20% Glycerol 
0.1% Bromophenol blue 
Protein Lysis Buffer  0.07% (w/v) Saponin in PBS 
  
32 
 Protease inhibitors 
RIPA Buffer 
 
50 mM Tris pH 7.5  
150 mM NaCl 
5 mM EDTA  
50 mM NaF (sodium fluoride) 
0.5% NaDOC (sodium deoxycholate) 
0.1% SDS  
1% Triton X-100 
Prior to use: 2 mM DTT, 100 mM PMSF, Protease Inhibitors 
RNA Running Buffer (20x) 41.86 g MOPS 
6.8 g NaOAc 
3.8 g EDTA 
In 500 ml ddH2O 
RNase Solution 0.3 mg/ml RNase A in 1x PBS 
SDS-PAGE Running Buffer 
 
25 mM Tris 
250 mM Glycine 
0.1% (w/v) SDS 
SDS-PAGE Transfer Buffer  
 
39 mM Tris 
48 mM Glycine 
0.038% (w/v) SDS 
SOB Medium 20 g Tryptone/Peptone 
5 g Yeast Extract 
0.5 g NaCl 
5 g MgSO4 x 7 H2O 
In 1 L ddH2O, autoclaved 
SOC Medium SOB + 20 mM D-Glucose, filter sterilized 
Stored at -20°C 
Sorbitol Lysis Solution 5% (w/v) D-sorbitol in ddH2O, filter sterilized 
Stripping Buffer  
 
1x PBS 
2% SDS 
100 mM β-Mercaptoethanol 
Super Broth (SB) 35 g Tryptone/Peptone 
30 g Yeast Extract 
5 g NaCl 
In 1 L ddH2O, autoclaved 
TAE Buffer, 1x 4 mM Tris-Acetate 
1 mM EDTA, pH 8 
TE Buffer 10 mM Tris/HCl, pH 8 
1 mM EDTA 
In ddH2O 
Filter sterilized 
Thawing Solution I 12% NaCl in ddH2O, filter sterilized/autoclaved 
Thawing Solution II 1.6% NaCl in ddH2O, filter sterilized/autoclaved 
Thawing Solution III 0.9% NaCl 
0.2% Glucose 
In ddH2O 
Filter sterilized 
WR99210 Stock 10 mM in 20% DMSO (v/v) 
WR99210 Working Solution 20 µM in RPMI 1640 with 25 mM HEPES and L-Glutamine 
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2.1.7. Computer software and databases 
 
2.2. Methods 
2.2.1. Parasitology 
2.2.1.1. In vitro  cultivation of P. falciparum 
Intraerythrocytic stages of P. falciparum were maintained in continuous blood culture according to 
standard protocols (Trager & Jensen, 1976). Parasites were cultured in complete RPMI medium at 
37°C under an atmosphere of 5% O2, 3% CO2, 92% N2 and 95% humidity. Human A+ erythrocytes 
were diluted to 2-4% hematocrit. Transfected parasites kept under selective drug pressure were fed 
with Transfectants Medium, supplemented with Albumax and containing high Hypoxantine 
concentrations.  Medium was changed at least every second day or more often if needed. Cultures 
were monitored regularly by methanol-fixed Giemsa-stained thin blood smears. Parasitemia, defined 
as a percentage of parasite-infected erythrocytes was kept between 0.1% to 5%, unless specified 
otherwise for particular experiments.  
2.2.1.2. Parasites freezing and thawing 
Parasite culture selected for cryopreservation was adjusted to 3-5% ring stage parasitemia. The 
culture was centrifuged at 900 x g for 2 min and supernatant was discarded. The pellet was 
resuspended in 1/3 volume of freezing solution added dropwise and incubated for 5 min at RT. 
Software Origin 
7500 Software v2.0.6. Applied Biosystems, Foster City, CA, USA 
BD FACSDiva Software BD Biosciences, San Jose, CA, USA 
BioEdit http://www.mbio.ncsu.edu/BioEdit/bioedit 
FIJI Image Analysis http://fiji.sc/Fiji 
Flowing Software 2.5.1 Cell Imaging Core, Turku Centre for Biotechnology, Finland 
GATCViewer GATC Biotech, Konstanz, Germany 
ImageJ https://imagej.nih.gov/ij/ 
Image Studio Digits 4.0 LI-COR Biosciences – GmbH,  Bad Homburg, Germany 
KERN Microscope VIS Software KERN & SOHN GmbH, Balingen, Germany 
MS Office Microsoft Corporation, CA USA 
Mendeley  Mendeley Ltd. 
OPTIMA BMG Labtech, Offenburg, Germany 
PlasmoDB http://plasmodb.org/plasmo/ 
Protospacer Workbench http://www.protospacer.com/ 
Serial Cloner 2.6 http://serialbasics.free.fr/Serial_Cloner.html 
Sigma Plot 13.0 Systat Software Inc. 
SnapGene Viewer 2.8.2 GSL Biotech LLC, Chicago, IL, USA 
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Subsequently, another 4/3 volume of freezing solution was added slowly, then mixed carefully. The 
suspension was transferred to cryogenic vials and frozen at -80°C. For long term storage, samples 
were kept in liquid nitrogen. 
For thawing of the cryopreserved parasites, the frozen cryovial was warmed up in a 37°C water bath 
for 30 sec. 200 µl of Thawing Solution I were added, mixed and the suspension was transferred to a 
15 ml falcon tube. Then, 9 ml of Thawing Solution II were added slowly, the sample was centrifuged 
at 900 x g for 2min and the supernatant was discarded. Finally, 7 ml of Thawing Solution III were 
slowly added, the sample was centrifuged again and the supernatant was discarded. The pellet was 
resuspended in 14 ml of pre-warmed complete RPMI medium and transferred to a culture dish 
containing 500 µl of fresh erythrocytes. 
2.2.1.3. Parasites synchronization 
Sorbitol: 
Ring stage parasites were synchronized by sorbitol treatment (Lambros & Vanderberg, 1979),  based 
on the differential permeability of parasite-infected erythrocytes membrane. Due to the structural 
modifications induced by the parasite, the erythrocyte membrane of mature parasite stages (late 
trophozoites and schizonts) is permeable to sorbitol, resulting in parasite death caused by osmotic 
shock. Since uninfected RBC and ring stage-infected RBC lack the new permeation pathways they 
survive sorbitol treatment. 
Briefly, parasite culture was collected and centrifuged at 900 x g for 2 min. The pellet was 
resuspended in 10 ml of pre-warmed 5% D-sorbitol solution and incubated for 5 min at 37°C. Cells 
were then centrifuged and the supernatant discarded. The pellet was resuspended in 14 ml of pre-
warmed complete RPMI medium and transferred to a culture dish. 
Heparin: 
For a tight synchronization of parasite cultures, a combination of sorbitol and heparin treatments has 
been applied. Heparin reversibly inhibits invasion of merozoites into the erythrocyte (Boyle et al., 
2010; Kobayashi & Kato, 2016). This property allows to manipulate the window during which 
merozoites can invade erythrocytes by adding and washing heparin out. 
Parasites were synchronized with sorbitol to narrow down the synchronization window. Afterwards, 
parasites were cultured in the presence of 50U/ml heparin until the majority of parasites were at the 
schizont stage. Heparin was then removed from cultures for approximately 4 h to allow schizont 
rupture followed by erythrocytes invasion by released merozoites. After that, heparin was re-added 
to cultures for a couple of hours in order to block any further invasion events. 
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2.2.1.4. Magnetic purification of late stage parasites 
P. falciparum trophozoite and schizont stages were purified from ring stages and uninfected RBC 
using the magnetic activated cell sorting (MACS) system. This approach is based on the paramagnetic 
properties of hemozoin present in late parasite stages facilitating their purification by magnetic cell 
sorting (Paul et al., 1981). The MACS column was washed twice with MACS buffer pre-warmed to 
37°C and inserted into the VarioMACS separator. The parasite cultures were resuspended and 
applied to the top of the column. The flow was adjusted to 1 drop every 3 sec. Afterwards, the 
column was washed with MACS buffer until the flow-through was clear. The column was then 
removed from the magnetic field and the late-stage infected erythrocytes were eluted with 12 ml of 
MACS buffer. The cells were centrifuged at 900 x g for 2 min and the pellet was resuspended in the 
appropriate buffer according to the experiment the cells were going to be used for. 
2.2.1.5. Transfection of P. falciparum 
Preparation of DNA: 
Approx. 100 µg of each transfection plasmid DNA were precipitated with 1/10 volume of 3M sodium 
acetate and 2.5 volumes of 100% ethanol and incubated at -20°C for at least 30 min. Samples were 
centrifuged at 17000 x g at 4°C for 30 min, washed with 0.5 ml 70% and centrifuged again for 10 min. 
Pellet was air-dried, resuspended in 30 µl of sterile TE-Buffer and stored at -20°C until needed. Prior 
to transfection, 370 µl of sterile cytomix were mixed with the 30 µl of plasmid.   
Preparation of parasite culture: 
P. falciparum ring stage parasites at 3-5% parasitemia were transfected by electroporation, as 
previously described (Wu et al., 1995). Parasites were synchronized using sorbitol treatment one 
cycle before transfection.  
Transfection: 
Parasite culture was centrifuged at 900 x g for 2 min and the supernatant was discarded. 200 µl of 
pellet were mixed by pipetting with the previously prepared 400 µl of plasmid DNA/cytomix mixture. 
The sample was then transferred to an electroporation cuvette and electroporated using the Gene 
Pulser II Electroporator (Bio-Rad) at 0.310 kV and 950 µF for 7-12 msec. Afterwards, the 
electroporated sample was immediately transferred to a culture dish containing 14 ml of transfection 
medium and 500 µl of fresh erythrocytes.  
Drug selection: 
Starting one day after transfection the positive drug selection was applied for the next seven days, 
where both, transfection medium and respective drugs were exchanged daily. Afterwards, medium 
was changed every 2-3 days and once per week culture was supplemented with 100 µl of fresh 
erythrocytes. Selection took 3 to 5 weeks until the parasites were visible again on the blood smears. 
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Part of the transfectant culture was cryopreserved (chapter 2.2.1.2) and the rest used for further 
characterization. The concentrations of the drugs used for the selection are listed below: 
Drug Stock conc.  Final conc. System 
DSM1 10mM 1.5μM CRISPR-Cas9 
WR99210 20μM 5nM CRISPR-Cas9 / SLI 
G418 50mg/ml 400µg/ml SLI 
CRISPR-Cas9: 
DMS1 and WR99210 were used simultaneously to select for the parasites carrying the pUF1-Cas9 and 
pL6 vector, respectively. 
SLI: 
WR99210 was used to select for the parasites carrying the pSLI plasmid. Transfectants obtained after 
3 to 5 weeks of selection were first cryopreserved and then adjusted to three independent cultures 
of 1-4% parasitemia and 5% hematocrit in 5 ml of transfection medium. These cultures were then 
pressured for 2 weeks with neomycin (G418) to select for the parasites having integrated the 
construct (integrants). Proper integration leads to disruption of the targeted gene. Therefore, only 
the parasites that have integrated the neomycin phosphotransferase marker are able to grow in the 
presence of G418 (Birnbaum et al., 2017). For the first 10 days of selection medium and G418 were 
changed daily, afterwards every 2 days. After 14-16 days of selection, cultures were cultivated 
without G418 until parasites reappeared. Cultures were then cryopreserved. WR99210 was re-added 
to the culture medium for 2 more cycles. Parasites were then used for further characterization. In 
case of failure of recovering parasites after G418 selection in 6 independent attempts, the gene can 
be assumed to be essential (Birnbaum et al., 2017). 
2.2.1.6. Cloning by limiting dilution 
Once the desired mutation or integration has been detected in transfectant culture, clones from the 
corresponding parasite line representing homogenous populations can be obtained by limiting 
dilution. Clonal parasite populations were cultivated in 96-well plate at 2% hematocrit, with an initial 
inoculum of 0.25 to 0.5 parasites per well. Individual clones in single wells were detected by 
microscopic examination of blood smears after 2 to 4 weeks of cultivation.  
Parasitemia of the parental line was carefully determined as a prerequisite for successful preparation 
of dilution series. The total number of parasites in the starting culture was calculated from the 
parasitemia, taking into account that 0.5 ml of packed blood (100% hematocrit) is considered to 
contain roughly 5x109 erythrocytes.  
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On this basis, a starting solution of 106 parasites per ml was prepared. It was subsequently diluted via 
1:10 dilution series until 101 parasites per ml. This was further diluted via 1:2 dilution steps to two 
final working solutions of 5 and 2.5 parasites per ml (with final volume of 10 ml for each dilution). 
200 μl uninfected fresh erythrocytes were added to those two solutions (final hematocrit of 2%). The 
samples were repeatedly inverted to ensure proper mixing. 100 μl of these suspensions were seeded 
into 96-well plates (V-shape bottom), resulting in 0.5 or 0.25 parasite per well. Parasites were 
cultured without drug selection in transfection medium exchanged every 2-3 days until parasite 
appearance, taking between 2 to 5 weeks. A dark color of the blood and yellowish medium were 
usually indicative of parasitized wells and this observation was further confirmed by microscopic 
analysis. Subsequently, the contents of parasitized wells were transferred to small culture plates to 
increase parasite numbers for freeze-downs and further investigations. 
2.2.1.7. Growth inhibition assay and IC50 determination 
In vitro parasite susceptibility to various compounds was assessed using SYBR Green-based growth 
inhibition assay (Smilkstein et al., 2004). To compare drug sensitivity profiles of different P. 
falciparum strains, the 50% inhibitory concentrations (IC50) were determined in SigmaPlot by fitting 
the dose-response curve to the four parameter Hill equation. All assays were performed in black 96-
well plates using synchronous ring stage parasite culture at 0.5% parasitemia and 1.5% hematocrit in 
final volume of 100 µl per well, in duplicates for each drug concentration. The uninfected RBC and 
untreated infected RBC, both at 1.5% final hematocrit, served in each plate as negative and positive 
control, respectively. Drugs tested in assay were prepared as 4x concentrated working solutions in 
RPMI 1640 medium and stored at -20°C for no longer than two months. 50 µl of a respective drug 
was added to the top well containing 50 µl of culture medium and mixed thoroughly. The 1:3 serial 
dilutions were performed using multichannel pipette by transferring 25 µl of the solution from each 
well to next rows containing 50 µl of culture medium (Fig. 2.1). 
 
Figure 2.1. Experimental plate scheme and concentrations of substances used in the growth 
inhibition assay. 50 µl of stock solution were added to the first row, containing culture medium. 
After mixing, drug solution was transferred in 1:3 dilution (25 µl) to the next rows. 25 µl of drug 
solution were discarded from the first and last row. 50 µl of parasite or erythrocyte culture were 
Drug / 
substance 
Stock  
conc. 
Final conc. in 
the first well 
CQ 6 µM 1.5 μM 
QN 11 µM 2.75 μM 
QD 6 µM 1.5  μM 
PYR 1 mM 166 µM 
ML-7 500 µM 83 µM 
GlcN 1.6 M 400 mM 
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added per well and plate was incubated for 72h. RBC – infected red blood cells, niRBC – non-infected 
red blood cells, CQ – chloroquine, QN – quinine, QD – quinidine, PYR – pyrimethamine, ML-7 – kinase 
inhibitor, GlcN –  glucosamine. 
 
The 25 µl drug solution from the final row was discarded, as well as 25 µl of the drug solution from 
the first row, resulting in a volume of 50 µl in each well of the plate. Finally, 50 µl of the parasite 
culture adjusted to 0.5% parasitemia and 3% hematocrit was added to each well resulting in final 
volume of 100 µl of parasite culture at 0.5% parasitemia and 1.5% hematocrit. Plates were incubated 
for 72h in the standard incubation conditions. Plates were then wrapped in aluminium foil and frozen 
at -80°C overnight. Afterwards, plates were thawed at RT for at least 2h and incubated with 100 
µl/well of Lysis Buffer containing SYBR Green I (1x) for 1h in the darkness. SYBR Green binds to DNA 
resulting in emission of green light at 520 nm after excitation with blue light at 485 nm. Fluorescence 
intensities correlate with increases in parasitic DNA contents. Parasites content in respective wells of 
the 96-well plate was measured using the FLUOstar OPTIMA fluorescence plate reader operated 
under following parameters: excitation 485 nm, emission 520 nm, gain 1380, 10 flashes/well, top 
optic.  
2.2.2. Microbiology and molecular biology 
2.2.2.1. Preparation of electrocompetent E. coli  
10 ml of Super Broth (SB) medium were inoculated with the electro-competent PMC 103 E. coli cells 
by scratching the frozen glycerol stock of bacterial culture and incubated overnight at 37°C with 
shaking at 200 rpm. The next day, 600 ml of SB medium were inoculated with 6 ml of overnight 
culture and incubated for 3.5 h at 37°C under shaking conditions (200 rpm). The culture was then 
centrifuged at 6000 x g for 10 min at 4°C. All the following steps were carried out on ice using pre-
chilled solution. The pellet was resuspended in an equal volume of sterile water and centrifuged at 
4000 rpm for 15 min at 4°C. This washing step was repeated twice. The pellet was then resuspended 
in an equal volume of 10% glycerol and centrifuged at 4000 rpm for 15 min at 4°C. The supernatant 
was discarded and the remaining pellet was resuspended in 1.2 ml of 10% glycerol. 50 µl of cell 
suspensions were aliquoted into pre-chilled Eppendorf tubes and stored at -80°C.  
2.2.2.2. Transformation of E. coli  
Transformation of PMC 103 electrocompetent cells by electroporation 
The 50 µl aliquots of PMC 103 cells were thawed on ice and gently mixed with 150 µl of 10% glycerol. 
10 µl of DNA were added to cells and transferred to pre-chilled electroporation cuvette. 
Electroporation was performed at 2500 V. 1 ml of pre-warmed SOC medium was immediately added 
to the cuvette. The mixture was then transferred to 15 ml falcon tube and incubated for 1 h at 37°C 
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with shaking at 200 rpm. Finally, the bacterial suspension was pelleted or directly plated onto 
selective LB agar plates and incubated overnight at 37°C.  
Transformation of XL10 Gold ultracompetent cells by heat shock 
The 40 µl aliquot of chemocompetent XL-10-Gold ultracompetent cells (Agilent Technologies) were 
thawed on ice and gently mixed with 1.6 µl of β-mercaptoethanol. The cell suspension was incubated 
for 10 min on ice and gently swirled every 2 min. 10 µl of DNA were added and the mixture was 
incubated for another 30 min on ice. Sample was then subjected to a heat shock for 30 sec at 42°C, 
followed by 2 min cooling down on ice. Afterwards, 0.9 ml of pre-warmed NZY+ medium was mixed 
with transformed cells, transferred to 15 ml falcon tube and incubated for 1 h at 37°C with shaking at 
200 rpm. Finally, the bacterial suspension was plated onto selective LB agar plates and incubated 
overnight at 37°C. 
2.2.2.3. Genomic DNA isolation from P. falciparum 
To release P. falciparum parasites from erythrocytes, 14 ml of trophozoite- and schizont-stage 
culture at 3-5% parasitemia were centrifuged at 900 x g for 2 min. The supernatant was discarded, 
whereas the pellet was washed in PBS and centrifuged again. The pellet was then lysed in freshly 
prepared 0.1% saponin for 3 min on ice, followed by centrifugation at 2600 x g for 8 min. The pellet 
was washed 2-3 times in PBS until the supernatant was clear, then resuspended in 200 µl of PBS and 
transferred to 1.5 ml Eppendorf tube. 
The genomic DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen). Briefly, the parasites 
were lysed with 200 µl AL buffer in presence of 20 µl of proteinase K, vortexed and incubated at 56°C 
for 10 min. Then, 200 µl of ethanol (99%) were added and the mixture was vortexed thoroughly. The 
mixture was then transferred to a DNeasy spin column and centrifuged at 6000 x g for 1 min. The 
flow-through was discarded and 500 µl of AW1 buffer were added, followed by a centrifugation at 
6000 x g for 1 min. Again, the flow-through was discarded and 500 µl of AW2 buffer were added, 
followed by a centrifugation at 17000 x g for 3 min. The column was then transferred to a fresh 1.5 
ml Eppendorf tube. To elute the DNA, 30 µl of ddH2O were loaded onto the membrane and 
incubated for 1 min at RT, followed by a centrifugation 6000 x g for 1 min. The genomic DNA was 
stored at -20°C. 
2.2.2.4. Polymerase Chain Reaction (PCR) 
The amplification of the DNA fragments used for cloning was performed using the Phusion High-
Fidelity DNA Polymerase. The PCR reaction mix and thermocycling conditions were as follows: 
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Master Mix 1   Thermocycling conditions 
Buffer 5x 10 µl  Initial denaturation 94°C 10 min 
dNTPs 2mM 5 µl  
 
 
 
Forward primer 50µM 0.5 µl  Denaturation 94°C 45 sec 
Reverse primer 50µM 0.5 µl  Annealing X °C 45 sec 
DNA template 1 µl  Elongation 68°C 1 min/kb 
Phusion 0.5 µl  
 
 
 
H2O MilliQ 32.5 µl  Final elongation 68°C 10 min 
Final volume 50 µl  X =  Tm of primers - 5°C 
The amplification of the DNA fragments for colony screening was performed using the Taq DNA 
Polymerase. The PCR reaction mix and thermocycling conditions were as follows: 
Master Mix 2   Thermocycling conditions 
Buffer 10x 2.5 µl  Initial denaturation 94°C 10 min 
dNTPs 2mM 2.5 µl  
 
 
 
MgCl2 50 mM 1.25 µl  Denaturation 94°C 45 sec 
Forward primer* 50µM 0.5 µl  Annealing X °C 45 sec 
Reverse primer*  50µM 0.5 µl  Elongation 68°C 1 min/kb 
DNA template** variable  
 
 
 
Taq 0.25 µl  Final elongation 68°C 10 min 
H2O MilliQ 17.5 µl  Hold 4°C ∞ 
Final volume 25 µl  X =  Tm of primers - 5°C 
* Colony PCR screening was performed using a vector flanking primer and a gene specific primer or 
both vector flanking primers.  
** A single colony was picked with a yellow tip, streaked onto a replica plate (selective agar plate) 
and shortly dipped in Eppendorf PCR tube containing 25 µl of Master Mix 2. The yellow tip was 
removed and the PCR tube was directly used for amplification in a thermal cycler. The replicate agar 
plate was incubated at 37°C overnight. 
2.2.2.5. Agarose gel electrophoresis 
Agarose is widely used for the separation of DNA and RNA molecules according to their size and 
charge. The resolution of the nucleic acid bands is dependent on the concentration of the agarose 
gel. 
DNA 
0.8 to 2 % agarose gels were prepared by dissolving appropriate amounts of agarose in 1x Tris-
acetate-EDTA (TAE) buffer by boiling in a microwave. Gel was subsequently cooled down to 55°C, 
supplemented with ethidium bromide (EtBr) and poured into a gel cast. A comb was inserted to 
create wells and the gel was left to solidify. The completely solidified gel was transferred to an 
electrophoresis chamber filled with 1x TAE buffer. DNA samples were mixed with 6x DNA loading dye 
and loaded into the wells of the gel. A 1 kb Plus DNA Ladder was run alongside the samples as a size 
marker. Electrophoresis was carried out at RT at constant voltage of 90 to 140 V, depending on size 
x 30  
x 30  
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of the gel. DNA was visualized under UV light and captured using a DC120 Zoom Digital camera 
(Kodak). 
RNA 
0.28 g of Biozym SeaKem LE Agarose were dissolved in 2 ml of 20x RNA running buffer and 30 ml of 
ddH2O, by boiling in a microwave, resulting in 0.7% gel. Gel was cooled down to 55°C, supplemented 
with 8 ml of formaldehyde (to maintain the denaturated form of RNA) and 0.5 µl of EtBr and poured 
into a gel cast. RNA samples were mixed with RNA loading buffer (Ambion - Thermo Fisher Scientific), 
heated for 3 min at 65°C and loaded into the wells of the gel. Electrophoresis was carried out at 
constant voltage of 60 V in RNA running buffer. RNA was visualized under UV light and captured 
using a DC120 Zoom Digital camera (Kodak). 
2.2.2.6. DNA extraction from agarose gel 
The extraction and purification of DNA fragments from the agarose gel was performed using the 
QIAquick Gel Extraction Kit (Qiagen) according to manufacturer’s instructions. Briefly, the DNA 
fragments were excised from the agarose gel and dissolved in QG buffer (1:3 w/v ratio) at 50°C. 
Isopropanol was then added to precipitate the DNA and the sample was loaded onto a QIAquick spin 
column and centrifuged at 17000 x g. DNA bound to the membrane was washed with PE buffer and 
subsequently eluted with 30 µl of ddH2O and stored at -20°C. 
2.2.2.7. Determination of nucleic acid concentration and purity 
The concentration of nucleic acids was analyzed using the spectrophotometer UVIKON 923 (Kontron 
Instruments). The absorbance spectrum from 230 to 300 nm was measured for 1:100 diluted sample 
with ddH2O used as a blank. The nucleic acid concentration was determined taking into account that 
absorbance at 260 nm (A260) of 1.0 equals 50 ng/µl of pure dsDNA or 40 ng/µl of pure RNA: 
DNA conc. [ng/µl] = A260 x 50 ng/µl x dilution factor 
RNA conc. [ng/µl] = A260 x 40 ng/µl x dilution factor 
To evaluate nucleic acid purity, the A260/A280 ratio was calculated: 
Pure DNA:  A260/A280 = 1.8 
Pure RNA:  A260/A280 = 2.0 
2.2.2.8. Restriction enzymes digestion 
PCR products and vectors were digested using respective restriction enzymes and buffers (NEB). 
When the digestion was performed with two enzymes in the same reaction, buffers and enzyme 
concentrations were used according to the recommendations generated by NEB Double Digest 
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Finder at https://nebcloner.neb.com. The restriction digestion reactions of plasmid DNA and PCR 
products were set up as follows: 
Control digestion   Digestion of vector/insert for cloning 
DNA  1 µg  DNA   20 µg 
NEB buffer 1 µl  NEB buffer 5 µl 
Enzyme 1 0.4 µl  Enzyme 1 1 µl 
Enzyme 2 0.4 µl  Enzyme 2 1 µl 
ddH2O x µl  ddH2O x µl 
Final volume 10 µl  Final volume 30 µl 
Control digestions were incubated for 1.5 h, whereas digestion of vectors and inserts for cloning for 4 
h at temperature optimal for each restriction enzyme.  
2.2.2.9. Dephosphorylation of DNA ends 
Thermosensitive Alkaline Phosphatase (TSAP) catalyses the removal of 5’ phosphate groups from 
DNA ends, preventing the recicularization of linearized plasmid DNA during ligation. All linearized 
vectors used for cloning were dephosphorylated prior to their use in ligation reactions. After 4 h of 
plasmid DNA digestion, 1 µl of TSAP (Promega) was added directly to the reaction mix and incubated 
for 1 h at 37°C, followed by inactivation for 15 min at 74°C. The sample was then loaded on 0.8% 
agarose gel, followed by plasmid DNA extraction using QIAquick Gel Extraction Kit (Qiagen).  
2.2.2.10. Ligation of DNA fragments 
Ligation into pJET1.2/blunt 
As an intermediate cloning step, some of the inserts used in this work were cloned into the 
pJET1.2/blunt plasmid. Ligation was peformed using CloneJET PCR Cloning Kit (Fermentas) following 
the manufacturer’s instructions:  
Components  
Reaction Buffer 2X 5 µl 
Insert 3.5 µl 
DNA blunting enzyme 0.5 µl 
→ Incubate 5 min at 70°C, then chill on ice 
pJET1.2/blunt cloning vector 0.5 µl 
T4 DNA Ligase 0.5 µl 
Final volume 10 µl 
The final ligation mixture (10 µl) was incubated at RT for 30 min. The reaction was directly 
transformed into E. coli PMC 103 electrocompetent cells. 
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T4 DNA ligase 
The vectors and DNA fragments ligated using the T4 DNA ligase were previously digested with the 
adequate restriction enzymes and purified using the QIAquick gel extraction kit (Qiagen). The ligation 
reaction was set as follows: 
Components  
T4 DNA Ligase Buffer 10x  1 µl 
Linear vector DNA 30-150 ng (0.5  µl) 
Insert DNA 5:1 molar ratio over vector  
T4 DNA Ligase 1 µl 
ddH2O x µl 
Final volume 10 µl 
The ligation reaction was incubated at 16°C overnight and transformed into E. coli PMC 103 
electrocompetent cells on the following day. 
In Fusion cloning of guide RNA 
The In Fusion Cloning technology has been used to insert the guide RNA into the pL6 plasmids. The 
pL6 vector of interest was digested with the BtgZI enzyme for 3-4 h at 60°C, dephosphorylated and 
purified with the QIAquick gel extraction kit. The primers consisting of the guide RNA sequences 
flanked by the homologous to the vector sequences necessary for In Fusion recombination were 
diluted to 100 µM. 4.5 µl of each primer (forward and reverse) were mixed together with 1 µl of NEB 
buffer #2. The mixture was heated for 5 min at 95°C, cooled down to 25°C in a step-wise manner and 
kept on ice until use for the ligation reaction. The ligation reaction was set as follows: 
Components  
Vector (200 ng) 0.5 µl 
Hybridized primers (1:5 dilution) 3.5 µl 
In Fusion Enzyme Mix 1 µl 
Final volume 5 µl 
The reaction mixture was incubated 15 min at 50°C and then kept on ice until its transformation into 
XL-10 Gold cells. 
2.2.2.11. Plasmid DNA isolation 
Small-scale isolation (Miniprep) 
The small-scale DNA plasmid isolation from bacteria was performed using the High Pure Plasmid 
Isolation Kit (Roche) according to the manufacturer's instructions. A single colony was inoculated into 
10 ml of LB medium with 100 µg/ml ampicillin and incubated overnight at 37°C with shaking at 200 
rpm. The overnight cultures were centrifuged at 2600 x g for 5 min at RT. Pellets were resuspended 
in suspension buffer, followed by incubation with lysis buffer for 5 min at RT. The lysed solution was 
  
44 
treated with chilled binding buffer for 5 min on ice, followed by centrifugation at 17000 x g for 10 
min at 4°C. The supernatant was loaded onto the High Pure filter tube and centrifuged at 17000 x g 
for 1 min at RT. After two washing steps, the DNA was eluted with 50 µl of ddH2O and stored at -
20°C. 
Big-scale isolation (Maxiprep) 
The big-scale DNA plasmid isolation from bacteria was performed using the Plasmid Maxi Kit (Qiagen) 
according to the manufacturer's instructions. A single colony was inoculated into 3 ml of SB medium 
with 100 µg/ml ampicillin and incubated for 6-8 h at 37°C with shaking at 200 rpm. The starter 
culture was then diluted 1:1000 in SB (i.e. 400 µl in 400 ml) containing 100 µg/ml ampicillin and 
incubated overnight at 37°C under 200 rpm shaking. The overnight bacterial culture was pelleted by 
centrifugation at 6000 x g for 15 min at 4°C, mixed with resuspension buffer and lysed by 5 min 
incubation at RT with lysis buffer. Lysis was stopped by addition of chilled neutralization buffer 
followed by 20 min incubation on ice. Samples were centrifuged at 15000 x g for 30 min at 4°C and 
the supernatant was loaded onto the pre-equilibrated column and run through the resin by gravity 
flow. After washing, DNA was eluted, precipitated with isopropanol and centrifuged at 15000 x g for 
30 min at 4°C. The pellet was washed with chilled 70% ethanol and centrifuged at 15000 x g for 20 
min at 4°C. The DNA pellet was then air-dried, resuspended in an appropriated amount of ddH2O and 
stored at -20°C. 
2.2.2.12. DNA sequencing 
The sequencing of the DNA samples was performed by GATC Biotech (Konstanz, Germany), later 
acquired by Eurofins Genomics (Ebersberg, Germany). The samples were prepared as follows: 
Plasmids:     20 µl, 30-100 ng/µl 
PCR products:      20 µl, 10-50 ng/µl 
Primers:     20 µl, 10 pmol/µl 
The GATC Viewer and Serial Cloner softwares were used to analyze the obtained sequences. 
2.2.2.13. Total RNA extraction from P. falciparum 
To release P. falciparum parasites from erythrocytes, 36 ml of trophozoite- and schizont-stage 
culture at 3-5% parasitemia were centrifuged at 4°C for 2 min at 900 x g with brake-off at 130 x g. 
The supernatant was discarded, whereas the pellet was resuspended in 5 ml of freshly prepared ice 
cold 0.2% saponin and incubated for 3 min on ice. PBS was added up to 25 ml and the tubes were 
centrifuged for 8 min at 3000 x g at 4°C. The supernatant was discarded and the pellet was washed 
with ice cold PBS and centrifuged again. The supernatant was discarded and 1-2 ml of Trizol were 
added to the pellet, mixed thoroughly by vortexing, and directly frozen at -80°C overnight. The 
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samples were then thawed at 37°C and transferred to 1.5 ml Eppendorf tubes. 200 µl of chloroform 
were added per 1 ml of Trizol, the mixture was vigorously hand-shaken, incubated for 3 min at RT 
and centrifuged at 10500 x g for 30 min at 4°C. The upper aqueous phase containing mostly RNA was 
carefully collected and transferred to a fresh 1.5 ml Eppendorf LoBind tube. 500 µl of isopropanol 
were added per 1 ml of Trizol to the aqueous phase, the mixture was incubated at -80°C for at least 
30 min and subsequently centrifuged at 10500 x g for 10 min at 4°C. The pellet was washed with cold 
70% ethanol and centrifuged at 10500 x g for 10 min at 4°C. The RNA pellet was then air-dried at RT 
to eliminate any trace of ethanol, and dissolved in 30 µl of ribonuclease-free water. The 
concentration was measured by spectrophotometry and the RNA was stored at -80°C. The integrity 
of the extracted RNA was assessed on a denaturing agarose gel (0.7% agarose). 
2.2.2.14. DNase treatment 
The possible genomic DNA contamination was removed from the freshly isolated RNA samples using 
the DNA-free Kit – DNase Treatment and Removal (Invitrogen). Briefly, 5 µg of RNA were mixed with 
1.5 µl of 10X DNase I Buffer and 1 μl DNase I, adjusted to a total volume of 15 µl with nuclease-free 
water. The mixture was gently shaken by hand and incubated at 37°C for 30 min. 2 µl of DNase 
Inactivation Reagent were added and incubated for 5 min at RT. The mixture was centrifuged at 
10000 rpm for 2 min at 4°C, the supernatant was transferred to a fresh Eppendorf LoBind tube and 
stored at -80°C if not used directly for cDNA synthesis. 
2.2.2.15. Reverse transcription 
The cDNA was synthesized using the SuperScript III First-Strand Synthesis SuperMix (Invitrogen). 
Briefly, 6 µl (~2 µg) of DNase-treated RNA were mixed with 1 µl of 50 µM oligo(dT)20 and 1 µl of 
annealing buffer, incubated for 5 min at 65°C, followed by 2 min chilling on ice. Subsequently, 10 µl 
of 2x First-Strand Reaction Mix and 2 µl of the SuperScript III/RNaseOUT Enzyme Mix were added to 
the RNA mixture and incubated for 50 min at 50°C. The reaction was terminated by 5 min incubation 
at 85°C, followed by 1 min cooling on ice. The cDNA concentration was measured by 
spectrophotometry and adjusted to 50 ng/µl. The cDNA was stored at -20°C. 
2.2.2.16. Quantitative real-time PCR 
Quantitative real-time PCR was performed using an ABI 7500 Real-Time PCR detection system and 
the FastStart Universal SYBR Green Master (Rox). Samples were analyzed in a MicroAmp Fast 96-well 
plate, in technical triplicates (each containing 200 ng of cDNA), using primer pairs for target (PfUT) 
and reference genes (β-tubulin) and including H2O as a negative control. The qPCR reaction mix and 
thermocycling conditions were as follows: 
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Master Mix    Thermocycling conditions 
SYBR Green Master (Rox) 10 µl  Uracyl N-Glycosylase activity 50°C 2 min 
Forward primer 50µM 0.2 µl  Polymerase activation 95°C 10 min 
Reverse primer 50µM 0.2 µl  
Primer-dependent amplifi-
cation and real-time analysis 
95°C 15 sec 
cDNA (50ng/ µl) 4 µl  55°C 15 sec 
H2O  5.6 µl  60°C 45 sec 
Final volume 20 µl  + melting curve 
Data were analyzed using delta-delta Ct method taking into account primers efficiencies.  
Determination of primer efficiency 
A validation experiment consisting of five points of cDNA dilution (400 ng, 200 ng, 100 ng, 50 ng and 
25 ng) was run for target and reference gene in triplicates, with H2O as a negative control. For each 
primer pair (target or reference gene) Ct values were plotted on a standard curve against the log of 
the cDNA concentrations. The linear regression was fitted to calculate the slope. Primer efficiency 
was then determined as 10^(-1/slope) and used for comparative Ct calculations. A slope of -3.32 
gives a primer efficiency value of 2, indicating a 100% efficiency. This means that in every PCR cycle, 
the amount of DNA will be doubled. Good primer efficiency is assumed to be between 1.95 and 2.05, 
with 95% and 105% efficiency, respectively (Bio-Rad Laboratories, 2006; Eurogentec, 2008). 
2.2.3. Biochemistry and cell biology 
2.2.3.1. Preparation P. falciparum protein extracts 
P. falciparum trophozoite stages at parasitemia of 5-10% were purified using the MACS system. After 
elution of infected erythrocytes from the column, samples were centrifuged for 2 min at 900 x g and 
pellets were washed once with PBS. Infected erythrocytes were then resuspended in 1 ml of Protein 
Lysis Buffer to remove red blood cell material. After 3 min incubation on ice, samples were 
centrifuged for 1 min at 17000 x g at 4°C and washed 3 times in ice cold PBS containing protease 
inhibitors. Parasites were then lysed in 4 pellet volumes of RIPA buffer containing 10 µg/ml DNase I 
for 30 min on ice, vortexed in between incubation time, and centrifuged for 20 min at 17000 x g at 
4°C. Protein lysates (supernatant) were transferred to a fresh Eppendorf tube, resuspended in 1:1 
ratio with 2x Protein Loading Buffer containing β-mercaptoethanol and stored at -20°C. 
2.2.3.2. SDS-PAGE electrophoresis 
Protein samples were analyzed by SDS-PAGE electrophoresis. Before being loaded on the SDS-PAGE 
gel, samples were heated at 37°C for 5-10 min. The PageRuler Plus Prestained (10 to 250 kDa) or 
HiMark Pre-Stained HMW Protein Standard (31 to 460 kDa) were used as protein ladders. Samples 
were loaded on NuPAGE Tris-Acetate 3-8% gradient gels or self-made gels. Gels were run at 150 V 
x 40 x 
30  
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and 40 mA for approx. 1.5 h in Tris-Acetate SDS running buffer (NuPAGE) or Tris-Glycine SDS running 
buffer. Self-made SDS-PAGE gels were prepared as follows: 
Resolving gel 8% 10% 12%  Stacking gel 4% 
ddH20 4.68 ml 3.96 ml 3.35 ml  ddH20 3.45 ml 
1.5M Tris pH 8.6 2.50 ml 2.50 ml 2.50 ml  1M Tris pH 6.8  630 µl 
10% SDS 100 µl 100 µl 100 µl  10% SDS 50 µl 
30% Acrylamid 2.66 ml 3.33 ml 4.00 ml  30% Acrylamid 830 µl 
10% APS (fresh) 100 µl 100 µl 100 µl  10% APS (fresh) 50 µl 
TEMED 6 µl 6 µl 6 µl  TEMED  5 µl 
Final volume 10 ml 10 ml 10 ml  Final volume 5 ml 
 
2.2.3.3. Coomassie staining 
To visualize proteins after SDS-PAGE electrophoresis gels were soaked in Coomassie Staining Solution 
for 10 min with shaking, followed by washing in Coomassie Destaining Solution with regular solvent 
changes until the background was clear and protein bands could be easily distinguished.  
2.2.3.4. Western blot 
After SDS-PAGE electrophoresis was completed, proteins were transferred from the gel onto an 
Immun-Blot PVDF membrane (Bio-Rad) using XCell II Blot Module. The gel was transferred onto 2 
sponges and 2 Whatman papers pre-soaked in Transfer Buffer. The PVDF membrane was activated 
with methanol for at least 30 sec, briefly rinsed in ddH2O and transferred onto the gel. Another 2 
Whatman papers and 3 sponges pre-soaked in Transfer Buffer were transferred on top of the 
membrane. The assembled “blotting sandwich” was then placed in a blotting chamber. The upper 
chamber was filled with transfer buffer, completely covering the blotting sandwich, whereas the 
lower chamber was filled with ddH2O to dissipate heat during the transfer. Wet transfer was run for 
1h at 230 mA and 30 V. Afterwards, the membrane was blocked in 5% milk overnight at 4°C with 
gentle agitation. The following day, the membrane was incubated with the respective primary 
antibody diluted in 1% BSA for 1h at RT on roller, followed by 3 washes (3 x 10 min) with PBST (0.1% 
Tween in PBS) and 30 min blocking in 5% milk. Incubation with a secondary antibody diluted in 1% 
BSA was carried out for 30 min at RT on roller, followed by 3 washes (3 x 10 min) with PBST. The 
protein ladder was marked on the membrane using LICOR WesternSure Pen, followed by 5 min 
incubation with freshly prepared Developing Solution (BM chemiluminescence blotting substrate 
POD, Roche; 2 ml of solution A mixed with 20 μl of solution B). Signal was captured using the LiCor C-
DiGit Blot Scanner and images were processed using Image Studio software. The dilutions of the 
antibodies used for Western blot were as follows: 
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Antibody Dilution 
Anti-α-tubulin (mouse) 1:1000 
Anti-HA (mouse) 1:1000 
Anti-PfUT, C-terminal, SAB 654 (rabbit) 1:1000 
Anti-PfUT, N-terminal, Thermo 1-2a (rabbit) 1:1000 
Anti-PfCRT (guine pig) 1:1000 
Anti-Ub (rabbit) 1:2000 
Anti-mouse-POD 1:10000 
Anti-rabbit-POD 1:10000 
Anti-guinea pig-POD 1:5000 
 
2.2.3.5. Western blot membrane stripping 
In order to remove antibodies from the western blot membrane for its reprobing, the membrane was 
incubated with Stripping Buffer for 30 min at RT on roller, followed by 3 washes (3 x 10 min) with 
PBST (0.1% Tween in PBS).  
2.2.3.6. Immunofluorecence assay (IFA) 
Parasites at trophozoite stage were either purified using the MACS system or collected unpurified 
from erythrocytes at parasitemia of 5-10%. Samples were centrifuged at 900 x g for 2 min. 
Erythrocytes were washed in PBS, followed by fixation in 4% PFA and 0.0075% GA for 30 min at RT 
with rotation. Samples were then washed twice with PBS and kept at 4°C or directly incubated with 
0.1% Triton X-100 and 125 mM Glycine for 15 min at RT with rotation. All the following treatments 
were conducted at RT with rotation. 3% BSA in PBS was used as blocking buffer and as antibodies 
dilution buffer. Samples were blocked for at least 2 h, followed by primary antibody staining for 1.5 h 
(or at 4°C overnight). Cells were then washed in 3% BSA in PBS 3 times for 15 min, followed by 
secondary antibody staining for 45 min in the dark. Samples were then washed with PBS 3 times for 
15 min, including addition of 5 µM Hoechst to the final wash. Cells were resuspended in PBS and 
stored at 4°C until imaging. Samples were imaged using Carl Zeiss Axiovert 25 widefield miscroscope 
using objective with 63x magnification. Images were acquired and processed in FIJI. The dilutions of 
the antibodies used for IFAs were as follows: 
Antibody Dilution 
Anti-HA (mouse) 1:1000 
Anti-PfUT, C-terminal, SAB 654 (rabbit) 1:1000 
Anti-PfUT, N-terminal, Thermo 1-2a (rabbit) 1:1000 
Anti-BiP (rabbit) 1:1000 
Anti-PfERC (rabbit) 1:500 
Anti-PfERD2 (rabbit) 1:500 
Alexa Fluor 488 anti-mouse IgGs 1:1000 
Alexa Fluor 546 anti-rabbit IgGs 1:500 
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2.2.3.7. Transmission electron microscopy (TEM) 
Immunogold-labelled samples for transmission electron microscopy (TEM) were prepared according 
to the Tokuyasu method (Cyrklaff et al., 2011). For this purpose, erythrocytes infected with the P. 
falciparum at trophozoite stage (36 ml culture, 2% hematocrit, 5% parasitemia) were purified from 
uninfected red blood cells using MACS system. After elution from the column, parasitized 
erythrocytes were centrifuged for 2 min at 900 x g and the pellet was washed twice with 1x PHEM. 
PHEM buffer contains Pipes, Hepes, EGTA and MgSO4 and is commonly used to preserve cell 
structure for immuno-labelling. The sample was fixed in 4% PFA and 0.016% GA in 1x PHEM buffer 
for 1h at RT under agitation and subsequently washed twice in 1x PHEM. Pellet was resuspended in 
1:1 ratio in 1x PHEM followed by embedding in 10-12% gelatine. Sample was incubated for 5 min at 
37°C, shortly pelleted and solidified on ice. Gelatinized sample was cut into small cubes (around 
1 mm3) and infused with 2.3 M sucrose solution for cryo-protection (at 4°C with light agitation 
overnight). The cubes were mounted on metal pins with excess of sucrose solution and frozen in 
liquid nitrogen. Subsequently, the frozen cubes were sectioned using the cryo-ultramicrotome (Leica, 
UCT6), melted on a drop of sucrose/methyl cellulose solution (2.3 M / 1.5%) and mounted onto TEM 
grids coated with Formvar film. Immuno-labelling was preceded by incubation in 50 mM glycine in 
PBS for 30 min to quench the remains of free aldehyde fixatives, followed by soaking in blocking 
buffer containing 1.5% BSA and 0.1% fish skin gelatine in 1x PBS for 30 min. This blocking buffer was 
also used as a dilution buffer for antibodies. Tokuyasu cryo-sections were labelled with primary 
mouse anti-HA antibody (dilution 1:1) for 1 h at RT and washed 5 times 3 min in the quenching 
buffer. Subsequent labelling with secondary goat anti-mouse antibody coupled to 10 nm colloidal 
gold (dilution 1:20) was carried out for 1 h at RT followed by washing 3 times in quenching buffer and 
3 times in ddH2O, for 3 min each. Cryo-sections were then fixed in 1% glutaraldehyde for 5 min at RT, 
followed by washing 5 times for 3 min in ddH2O. To enhance the contrast and to embed the sample, 
the sections were washed in a mixture of uranyl acetate and methyl cellulose (1.8% / 0.8 %) and air 
dried. Specimens were examined and images recorded using Jeol JEM-1400 transmission electron 
microscope. 
ER/Golgi complex was determined as membranous compartments adjacent to nuclei, including the 
margin of 50 nm at each side of a membrane for the accuracy of labelling that takes into 
consideration the cumulative length of the primary and secondary antibodies and the size of the 
protein A gold marker. 
The distribution of gold particles was analyzed stereologically (Lucocq, 1994) according to their 
subcellular localization in the infected red blood cell on several micrographs. For this purpose, a 
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square grid with known spacing was placed over each of the micrographs to facilitate the 
quantification of gold hits and the number of line intersections which define the area of a 
compartment. For each compartment, gold counts were determined and depicted as percentage of 
the total number of gold particles in the analyzed area, as well as was the compartment area 
presented as percentage of the total analyzed area. Subsequently, the ratios of gold counts per 
compartment area were generated for each subcellular region to obtain the number of gold hits per 
unit area. These values were then depicted as a proportion of total gold signal measured across all 
analyzed compartments of several micrographs.   
2.2.3.8. Flow cytometry based analysis 
Flow cytometry measurement of parasite DNA stained with SYBR Green offers the opportunity to 
study intraerythrocytic development of malaria parasites. It takes advantage of the fact that 
erythrocytes lack DNA, showing clear separation between P. falciparum infected and uninfected red 
blood cells. Therefore, based on the DNA content of parasite it is possible to quantify parasitemia 
and distinguish parasites at different stages (Grimberg, 2011). 
The staining procedure was performed as described by Ganter et al. (2017). Parasites were fixed in 
4% PFA and 0.0075% GA at 4°C overnight. Samples were then washed several times with PBS and 
stored in PBS at 4°C. 200 µl of each sample were transferred to a 96-well V-bottom plate, centrifuged 
for 2 min at 900 x g and permeabilized with 200 µl of 0.1% Triton X-100 for 8 min at RT. Cells were 
washed twice with PBS, and subsequently treated with 200 µl of 0.3 mg/ml RNase A for 30 min at 
37°C. Samples were then washed twice with PBS and kept at 4°C until staining. Cells were incubated 
with 200 µl of SYBR Green I (1:2000 in PBS) for 20 min at RT in the dark. Stained samples were then 
washed twice with PBS, transferred to FACS tubes containing 1 ml of cold PBS and run on a BD 
FACSCanto flow cytometer. SYBR Green fluorescence was detected in the fluorescein isothiocyanate 
(FITC) channel. For each sample 50 000 events were recorded and analyzed using Flowing Software. 
The FSC-H versus FSC-A plot was first used to discriminate doublets from single cells. Singlets gate 
was further used for analysis of FITC positive events. The unstained sample served as a negative 
control used for gating of uninfected erythrocytes. 
2.2.3.8.1. Determination of parasitemia and multiple-infections 
Parasitemia was quantified as a ratio of FITC positive cells representing infected erythrocytes to the 
total number of red blood cells analyzed per one flow cytometry measurement. 
SYBR Green staining allows not only to determine the total number of infected red blood cells in 
population (parasitemia), but also to distinguish between single, double, and triple P. falciparum 
infections (Bei et al., 2010). The flow cytometer is however unable to differentiate between the 
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signal emitted by a red blood cell infected with two ring stage parasites versus the signal of a single 
di-nucleated trophozoite (already after the first round of nuclear division). Therefore, for analysis of 
multiple infections it is crucial to use highly synchronized ring stage parasite cultures. The 
populations of singly-, doubly- and triply-infected erythrocytes were determined via a defined gating 
on dot plot and histogram (Fig 2.2). 
 
Figure 2.2. Flow cytometry gating. FITC channel was used to gate populations of uninfected red  
blood cells (uRBC), ring/trophozoite-stage parasites (R/T) and schizonts (S) on dot plot (A) and 
histogram (B). Parasitemia is expressed as a percentage of parasites (S + R/T) in all analyzed events (S 
+ R/T + uRBC). Ring-stage parasites can be used for analysis of single, double and triple infections. 
2.2.3.8.2. Quantification of parasite multiplication rates (PMR) 
The parasite multiplication rate (PMR) is the fold increase in parasitemia observed each new cycle of 
asexual growth (Chotivanich et al., 2000; Duncan et al., 2011). In order to determine the PMR, 
parasite cultures were synchronized using sorbitol and heparin treatments and diluted to 0.1% 
parasitemia at the trophozoite stage. 200 µl of each of three independent biological replicates were 
collected every 48 h over 4 cycles, fixed, stained with SYBR Green (chapter 2.2.3.8) and run on a BD 
FACSCanto flow cytometer. Data were analyzed using Flowing Software, Excel and Sigma Plot 13. 
Data points were plotted in a scatter plot depicting parasitemia expressed as the natural logarithm 
over the time of 4 replicative cycles. The linear regression was then fitted and the PMR was 
quantified as: 
       , 
where a corresponds to the slope of the linear regression.   
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2.2.3.8.3. Determination of merozoites number  
The number of merozoites generated per schizont was determined via flow cytometric analysis of the 
DNA content in rupturing schizonts. Parasites were synchronized using sorbitol and heparin 
treatments. Samples were collected, fixed, stained with SYBR Green (chapter 2.2.3.8) and run on a 
BD FACSCanto flow cytometer. Data were analyzed using Flowing Software and Sigma Plot 13. The 
merozoites number was expressed as a mean fluorescence emitted by a population of schizonts 
containing multiple DNA copy numbers, divided by a mean intensity obtained for a population of 
singly-infected red blood cells, with a single DNA copy number.  
                   
                                        
                                                           
 
The populations of schizonts and singly-infected erythrocytes were determined via a defined gating 
strategies (Fig 2.2). 
2.2.3.8.4. Determination of asexual life cycle duration 
Cell cycle progression of P. falciparum can be tracked using flow cytometry, by quantification of the 
increase in DNA content over time. Parasite cultures were synchronized to a 4 h window using 
sorbitol and heparin treatments, and adjusted to 0.5% ring stage parasitemia. The cell cycle length 
was analyzed as previously described (Ganter et al., 2017), by measuring the parasite DNA content 
(C-value) at 4 h intervals over the 66h post invasion. At each time point, 200 µl of each of three 
independent biological replicates were collected, fixed, stained (chapter 2.2.3.8) and run on a BD 
FACSCanto. Data were analyzed using Flowing Software, Excel and Sigma Plot 13. The C-value was 
quantified by dividing the total parasite mean fluorescence intensity at particular time point by the 
mean intensity of a single infection from the first time point.  
         
                                     
                                                              
 
The visible drop of the C-value after reaching the peak at schizont stage indicates the beginning of a 
new cycle. 
2.2.3.8.5. Egress and invasion assay 
Parasites were synchronized to the 4 h window using sorbitol and heparin treatments and adjusted 
to 0.3% parasitemia at schizont stage and 2% hematocrit. The experiment was carried out in 96-well 
flat bottom plates with 200 µl-sample volume in triplicates. The first time point was collected 2-4 h 
prior to schizont rupture. At each time point (every 2-4 h), the whole plate was collected, washed 
twice with PBS and fixed in 4% PFA and 0.0075% GA at 4°C overnight. Samples were then washed 
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with PBS, stained with SYBR Green (chapter 2.2.3.8) and run on a BD FACSCanto flow cytometer. 
Data were analyzed using Flowing Software, Excel and Sigma Plot 13. Data points were plotted in a 
line and scatter plot of parasitemia versus the time post invasion. The efficiency of merozoites egress 
from mature schizonts (egress efficiency) was depicted as a percentage of schizont parasitemia (Fig. 
2.2, gate S) over the time post invasion. The efficiency of released merozoites to invade red blood 
cells (invasion efficiency) was shown as a percentage of ring parasitemia (Fig. 2.2, gate R) over the 
time post invasion (A. S. Paul et al., 2015b). 
2.2.3.8.6. Merozoites attachment assay 
Merozoites attachment assay was performed to determine whether the increased invasion efficiency 
was associated with a stronger attachment of merozoites to erythrocytes or if it occurred at a later 
stage of the invasion process. The merozoite entry to the host cell is an actin-dependent process. 
Therefore, an inhibitor of actin polymerization, cytochalasin D, has been used to separate the two 
events (attachment and invasion). Cytochalasin D (cyt. D) allows merozoites to attach to erythrocytes 
but it blocks their entry (Egan et al., 2015; Paul et al., 2015) 
Parasites were synchronized to the 4 h window using sorbitol and heparin treatments and adjusted 
to 0.3% parasitemia at schizont stage and 2% hematocrit. For each clone, three independent 
biological replicates were prepared in three different conditions: Ø cyt. D (invasion), 1 µM cyt. D 
(attachment), 50 U/ml heparin (negative control; no attachment or invasion). 200 µl per sample were 
transferred to 96-well flat bottom plates (1 plate per time point). Plates were collected at 0 h 
(schizont rupture), 1 h, 4 h, and 7 h post invasion. At each time point, the whole plate was collected, 
and fixed in 10 volumes of 2% GA and 0.116 M sucrose (e.g. 100 µl sample per 1 ml fixative) at 4°C 
overnight. All washing steps and staining solutions were supplemented with 0.116 M sucrose. 
Samples were then washed with PBS, stained with SYBR Green (chapter 2.2.3.8) and run on a BD 
FACS Canto flow cytometer. Data were analyzed using Flowing Software, Excel and Sigma Plot 13. 
Data were presented as a comparison of merozoites attachment to erythrocytes (+ cyt. D) and 
invasion to ring stage parasites (Ø cyt. D) at different time points post invasion. Heparin served as 
negative control for background subtraction. 
2.2.4. In vitro development of resistance to quinine 
In vitro development of drug resistance using laboratory strains enables the detection of its 
determinants, before resistance emerges in the field. The gradual increase of selective pressure 
induces potential adaptive mutations conferring resistance to the applied drug (Oduola et al., 1988; 
Witkowski et al., 2010). Once the drug pressured strain reaches the desired level of resistance, the 
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parasite’s genome is sequenced. This procedure aims to identify new mutations potentially involved 
in the acquired resistance to quinine and/or other unrelated antimalarials (Rathod et al., 1997). 
This approach was attempted in P. falciparum Dd2 strain, chosen as experimental line due to its high 
mutation rate, which increases the probability of obtaining the mutants (Bopp et al., 2013; Rathod et 
al., 1997). The ultimate goal was to develop the parasite line resistant at least to 2 µM quinine. This 
concentration represents ten times the IC50 value determined for quinine in Dd2 strain. Parasites 
were treated with quinine, which concentration was increased in a step-by-step fashion. The 
experiment was conducted in multiple 50 ml cell culture flasks containing a filter cap, with a starting 
inoculum of 5x109 parasitized red blood cells. The initial treatment dose amounted to 200 nM, 
corresponding to quinine’s IC50 in Dd2. Development of resistance was determined by measuring the 
increase in IC50 values for quinine (QN) and its stereoisomer quinidine (QD), along with chloroquine 
(CQ) serving as a control. Parasite samples were regularly cryopreserved, as so called “freeze-
downs”. When necessary (e.g. after culture contamination), the freeze-downs were brought back to 
the culture and immediately subjected to the selective drug pressure. The experiment was carried 
out over a period of over one year until reaching the quinine exposure dose of 2 µM. 
 
Figure 2.3. Schematic representation of in vitro development of strain resistant to high quinine 
concentrations. Parasites were exposed to gradually increasing concentrations of quinine (QN), 
starting from 200 nM until reaching at least 2 µM treatment dose. Progress of acquired resistance 
was monitored via IC50 measurements. FD – freeze-down. 
2.2.5. Data analysis 
The data analysis and display were performed using Excel 2010 and SigmaPlot 13.0. 
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3.  Results 
 
3.1. Analysis of the role of PfCRT phosphorylation at S33 in 
resistance to chloroquine and quinine 
Reversible protein phosphorylation plays a key role in regulation of many cellular processes, 
including, among others, modulation of the activity of a transporter (Foster et al., 2006; 
Ramamoorthy et al., 2011; Stolarczyk et al., 2011). The chloroquine resistance transporter PfCRT is 
phosphorylated at various sites, including S33, S411, T416 and S420 (Kuhn et al., 2010; Lasonder et 
al., 2012; Solyakov et al., 2011). Phosphorylation of threonine 416 has been shown to direct the 
trafficking of PfCRT from the ER to the digestive vacuolar membrane (Kuhn et al., 2010). However, 
the functional roles of the other modifications remain unclear. The purpose of this project was to 
investigate the role of phosphorylation of serine 33 in the drug resistance-mediating function of 
PfCRT. 
3.1.1. The kinase inhibitor ML-7 reduces chloroquine and quinine 
resistance 
In a previous study conducted by Dr. Cecilia Sanchez, a range of protein kinase and phosphatase 
inhibitors was screened for the activity on accumulation of chloroquine in the P. falciparum 
chloroquine resistant strain Dd2 (unpublished data). Among the tested inhibitors, only ML-7, W-7 
and H-89 showed a significant increase in the uptake of chloroquine by Dd2 strain, with p values of 
<0.001, 0.003 and 0.004, respectively (One Way ANOVA, Holm-Sidak test). ML-7 has been previously 
identified as an inhibitor of a serine/threonine protein kinase PfCK2α (casein kinase 2) (Graciotti et 
al., 2014; Holland et al., 2009). W-7, a calmodulin-dependent protein kinase inhibitor, was shown to 
block the activity of PfPKB (protein kinase B-like enzyme) (Vaid & Sharma, 2006). H-89 is a known 
inhibitor of the cyclic AMP-dependent protein kinase catalytic subunit PfPKA-C (Syin et al., 2001). 
Interestingly, all three compounds are structurally related derivatives of naphthalene- and 
isoquinoline-sulfonamides (Fig. 3.1). 
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Figure 3.1. Chemical structures of the 3 inhibitors with a significant impact on chloroquine 
accumulation in P. falciparum chloroquine resistant Dd2 strain. 
 
Of the three inhibitors with a statistically significant impact on the chloroquine accumulation in the 
Dd2 strain, ML-7 was selected for further analysis in the current study. The dose-response curves 
have been generated to evaluate the inhibitory effect of ML-7 on the parasite growth (Fig. 3.2.A). The 
IC50 values of 19 ± 3 µM and 37 ± 5 µM were determined for P. falciparum Dd2 and HB3 strains, 
respectively. A maximum ML-7 concentration not affecting the development of Dd2 parasites was 
estimated to be 1 µM and was subsequently used in the growth inhibition assay together with 
chloroquine (CQ) and quinine (QN). A ML-7 concentration of 2.5 µM, with a mildly toxic effect on the 
parasite growth, has also been tested along with the two mentioned quinoline drugs. Presence of 
ML-7 resulted in a significantly (p<0.001) increased susceptibility of a resistant Dd2 strain to these 
drugs, with IC50  values for CQ ranging from 129 ± 5 nM in the absence of inhibitor, to 82 ± 6 nM and 
83 ± 9 nM in the presence of 1 µM and 2.5 µM ML-7, respectively. As for QN, the IC50  values ranged 
from 305 ± 8 nM in the absence of inhibitor, to 140 ± 9 nM and 167 ± 24 nM in the presence of 1 µM 
and 2.5 µM ML-7, respectively (Fig. 3.2.B and C). Presence of ML-7 did not affect the CQ and QN 
response levels of a sensitive strain HB3. An antifolate drug, pyrimethamine (PYR) has been used as a 
control (Fig. 3.2.D). PYR targets the parasite’s dihydrofolate reductase (DHFR) and resistance to PYR 
is conferred by point mutations in the enzyme (Oguike et al., 2016). Treatment with ML-7 had no 
influence on the responsiveness of Dd2 and HB3 to PYR, with average IC50 values of 30 ± 2 µM and 11 
± 2 µM, respectively.  
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Figure 3.2. Characterization of kinase inhibitor ML-7. A. ML-7 dose-response curves. Inhibition of 
parasite growth in the presence of increasing ML-7 concentrations was measured for Dd2 and HB3 
strains and is depicted as mean ± SEM of four independent biological replicates. B–D. Responsiveness 
of Dd2 and HB3 to selected antimalarial drugs in the presence and absence of 1 µM and 2.5 µM ML-
7. Half-maximal inhibitory concentrations (IC50) were determined for B. chloroquine (CQ), C. quinine 
(QN) and D. pyrimethamine (PYR). Each symbol represents an independent biological replicate. A box 
plot analysis of each data set is shown in grey. A thick black line indicates the mean value. Statistical 
significance between the data sets was calculated using One Way ANOVA Holm-Sidak test; n.s. – not 
significant. 
 
3.1.2. Phosphorylation of PfCRT’s serine 33 modulates chloroquine 
and quinine responsiveness 
To assess the role of phosphorylation in PfCRT function, the CRISPR-Cas9 genome editing technology 
(Ghorbal et al., 2014) was applied to replace PfCRT serine 33 by alanine, glutamic acid or aspartic acid 
(Fig. 3.3.A). Serine (S) substitution by alanine (A) prevents potential phosphorylation. Mutation to 
glutamic acid (E) or aspartic acid (D), the negatively charged amino acids, mimics phosphorylation of 
a serine residue. S33 mutant lines have been generated by Dr. Sonia Moliner Cubel and Dr. Cecilia 
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Sanchez. Several clones were isolated for each mutant line, namely B5 and B6 for S33A mutant, F8, 
C8 and B10 for S33E mutant, and A11, F8 and G8 for S33D mutant. 
The growth inhibition assays were performed for Dd2 wild type and mutant lines to verify the drug 
resistance-mediating function of PfCRT. Drug responsiveness was measured for chloroquine (CQ) and 
quinine (QN), along with pyrimethamine (PYR) as a control (Fig. 3.3.B-D). A significant (p<0.001) 
increase in the susceptibility to chloroquine has been observed for S33A clones, B5 and B6, with IC50 
values of 80 ± 4 nM and 72 ± 5 nM, respectively, in comparison to Dd2 WT with IC50 values of 131 ± 5 
nM. S33E clones, F8, C8 and B10, revealed an intermediate phenotype between the Dd2 wild type 
and S33A mutants with chloroquine IC50 values of 102 ± 3 nM, 108 ± 4 nM and 105 ± 4 nM, and a 
significance of p=0.001, p=0.006 and p=0.027, respectively. S33D clones, A11, F8 and G8 displayed a 
chloroquine resistance phenotype not significantly different from the Dd2, with IC50 values of 137 ± 6 
nM, 134 ± 6 nM and 130 ± 4 nM, respectively. A chloroquine sensitive strain HB3 exhibited IC50 value 
of 14 ± 2 nM. Regarding the quinine resistance phenotype, similar trends in drug responsiveness as 
for chloroquine have been observed. S33A clones, B5 and B6, showed a significant reduction 
(p<0.001) in resistance to quinine, with IC50 values of 202 ± 7 nM and 193 ± 13 nM, respectively, in 
comparison to Dd2 WT with IC50 values of 311 ± 9 nM. S33E mutation resulted in an intermediate 
quinine resistance phenotype, with IC50 values of 234 ± 11 nM, 228 ± 10 nM and 220 ± 16 nM, for 
clones F8, C8 and B10, respectively, with a significance of p<0.001 for each of the clones. S33D 
mutants, A11, F8 and G8, showed again a phenotype not significantly different from Dd2, with 
quinine IC50 values of 310 ± 19 nM, 314 ± 13 nM and 299 ± 14 nM, respectively. The quinine IC50 
value of HB3 strain analyzed in parallel was 127 ± 11 nM. In contrast to varying responses to 
chloroquine and quinine, there was no significant difference in the responsiveness of Dd2 and 
mutants to pyrimethamine, with an average IC50 value of 27 ± 2 nM.  
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Figure 3.3. CRISPR-Cas9-mediated mutagenesis of PfCRT locus and responsiveness of the mutants 
to selected antimalarials. A. Schematic representation of the CRISPR-Cas9-based strategy to replace 
serine (S) at position 33 by alanine (A), glutamic acid (E) or aspartic acid (D) in the PfCRT locus. 
Mutant lines were generated by Dr. Sonia Moliner Cubel and Dr. Cecilia Sanchez. B-D. Drug 
responsiveness of the PfCRT S33 mutants, the parental strain Dd2 and HB3. Half-maximal inhibitory 
concentrations (IC50) were determined for B. chloroquine (CQ), C. quinine (QN) and D. 
pyrimethamine (PYR). Each symbol represents an independent biological replicate. A box plot 
analysis of each data set is shown in grey. A thick black line indicates the mean value. Statistical 
significance between the data sets was calculated using One Way ANOVA Holm-Sidak test; n.s. – not 
significant. Data in B and C were generated together with Marina Müller. 
3.1.3. Multiplication rate variation in the PfCRT S33 mutants 
Acquiring resistance against a drug is often associated with fitness cost (Felger & Beck, 2008; 
Schneider & Escalante, 2013). Different pfcrt alleles have been previously shown to confer various 
impact on the parasite fitness (Mita et al., 2004; Petersen et al., 2015). To assess whether PfCRT S33 
mutations carry a fitness cost for the parasite, growth of the respective mutants in a co-culture with 
Dd2 wild type was examined in a fitness assay (Fig. 3.4.A). S33A and S33E mutants revealed a fitness 
advantage in relation to Dd2 wild type parasites, as a proportion of these PfCRT mutants increased 
over time, with slopes of linear regression determined to be 1.057 and 1.025, respectively. The 
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fitness of the S33D clones analyzed over 20 cycles was comparable with the Dd2 wild type, with a 
slope of the regression line of -0.171. 
To better understand the differences in fitness between Dd2 wild type and PfCRT S33 mutants, the 
parasite multiplication rates (PMRs) were determined for each clone (Fig. 3.4.B). For this purpose, 
pre-synchronized parasites were cultured for 4 replicative cycles during which samples were 
collected every 48 h at the trophozoite stage. PMR of each clone was expressed as a fold increase in 
parasitemia measured over time. The PMR for Dd2 and HB3 of 11 ± 1 and 7 ± 1, respectively, were 
consistent with the results of previous studies (Murray et al., 2017; Reilly et al., 2007). S33A clones, 
B5 and B6, exhibited a significant increase (p<0.001) in PMR, with values of 18 ± 1 and 19 ± 1, 
respectively. Similar results were observed for S33E clones, F8, C8 and B10, with PMR of 19 ± 1, 17 ± 
1 and 19 ± 1, respectively, with a significance of p<0.001 for each clone. The multiplication rates 
obtained for S33D clones, A11, F8 and G8, with values of 12 ± 1, 12 ± 1 and 12 ± 1, respectively, were 
not significantly different from the Dd2 wild type. 
 
Figure 3.4. Characterization of the growth of PfCRT S33 mutants. A. Effect of PfCRT S33 mutations 
on the parasite fitness. Dd2 WT and S33 mutants were mixed at   1:1 ratio and cultivated for 20 
cycles. The allelic proportions of serine (S) over alanine (A), glutamic acid (E) or aspartic acid (D) were 
measured by pyrosequencing. The proportion of S33 mutants co-cultured with Dd2 WT over time is 
presented at the Y axis. Results were fit to a linear regression model of the relative proportion of the 
wild type over the mutated S33 alleles over time. For each clonal line data is shown as the mean ± 
SEM of three independent mixed cultures. Fitness assays for S33A, S33E and S33D mutants were 
performed by Dr. Sonia Moliner Cubel, Chinhda Xoumpholphakdy and Dr. Britta Nyboer, respectively. 
B. Parasite multiplication rates (PMR) of Dd2 wild type and PfCRT S33 mutant lines. PMR of each 
clone represented by three independent biological replicates was determined as a fold increase in 
parasitemia per 48h, measured over 4 cycles. A box plot analysis of each data set is shown in grey. 
Statistical significance between the data sets was calculated using One Way ANOVA Holm-Sidak test. 
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3.1.4. Fitness advantage of PfCRT S33 mutants results from an 
increased numbers of merozoites  
Different factors of parasite intraerythrocytic development can affect parasite multiplication rates, 
one of the measures of parasite fitness. These include the cell cycle duration, numbers of merozoites 
generated per schizont, or efficiency of red blood cell invasion (Chotivanich et al., 2000; Ganter et al., 
2017; Garg et al., 2015). The above-mentioned aspects were taken into account to address the 
observed differences in the multiplication rates between the Dd2 wild type and PfCRT S33 mutants. 
Since the different clones of a particular PfCRT S33 mutant displayed comparable results, as 
presented in previous sections, in some of the following experiments, a representative clone of each 
mutant has been selected for further investigations. To begin with, the length of the cell cycle has 
been investigated. For this purpose, the parasite DNA content, referred to as the “C-value”, was 
measured in samples collected in 4 h intervals throughout the replicative cycle. The intraerythrocytic 
cycle duration of both Dd2 wild type and S33 mutants was determined to be 44h, as estimated from 
the peak of mitotic activity (Fig. 3.5.A). Interestingly, C-values obtained at 44 h post invasion differed 
for each clone, indicating that different numbers of merozoites have developed in mature schizonts. 
Therefore, numbers of merozoites generated per schizont were further analyzed, as a potential 
reason of differences in multiplication rates observed for the clones (Fig. 3.5.B). Numbers of 
merozoites per schizont quantified for Dd2 and HB3, with values of 15 ± 1 and 11 ± 1, respectively, 
were consistent with previous reports (Reilly et al., 2007). S33A clones, B5 and B6, showed a 
significant increase (p<0.001) in merozoites numbers, with values of 19 ± 1 and 20 ± 1, respectively. 
Similar results have been observed for S33E clones, F8, C8 and B10, with merozoites numbers of 18 ± 
1, 17 ± 1 and 18 ± 1, respectively, and with a significance of p<0.001. The numbers of merozoites 
obtained for S33D clones, A11, F8 and G8, of 16 ± 1, 16 ± 1 and 16 ± 1, respectively, were not 
significantly different from Dd2 wild type. 
 
  
62 
Figure 3.5. Comparison of cell cycle length and merozoites numbers in Dd2 wild type and PfCRT S33 
mutant lines. A. The cell cycle length expressed as an increase in the parasite DNA copy number (C-
value) measured over time. The drop in the C-value after reaching the peak indicates the beginning 
of a new cycle. For each clone, each time point represents a mean ± SEM of three independent 
biological replicates. B. Number of merozoites generated per schizont determined using flow 
cytometry. Each symbol represents an independent biological replicate. A box plot analysis of each 
data set is shown in grey. A thick black line indicates the mean value. Statistical significance between 
the data sets was calculated using One Way ANOVA Holm-Sidak test. 
Furthermore, the differences in multiplication rates may also derive from an altered parasite egress 
or invasion. Release, also known as egress, of daughter merozoites from a mature schizont and the 
subsequent invasion of new red blood cells are two tightly coordinated processes, essential for 
parasite replication (Collins et al., 2017; Koch & Baum, 2016). To assess whether alterations in 
multiplication rates of PfCRT S33 mutants are associated with egress or invasion events, mature 
schizonts at initially identical parasitemia were allowed to rupture and re-invade fresh erythrocytes 
and were monitored in 2 h intervals. Egress efficiency is depicted as parasitemia of schizonts 
decreasing over time with the gradual release of merozoites from rupturing mature schizonts as a 
new cycle begins (Fig. 3.6.A). Invasion efficiency is presented as parasitemia of ring stage parasites 
increasing over time with the merozoites invading new red blood cells (Fig. 3.6.B). While no 
difference in egress efficiency has been observed between Dd2 wild type and PfCRT S33 mutants, 
clone S33A B6 displayed a significant increase in invasion efficiency in relation to other clones, for up 
to 49 h post invasion (p.i.), with p≤0.001 (according to One Way ANOVA Holm-Sidak test). Since the 
cell cycle length of Dd2 and PfCRT mutants was estimated to be 44 h (Fig. 3.5.A), a time point of 49 h 
p.i. corresponds to the first 5 h of a new replicative cycle. Although the difference in ring parasitemia 
between S33A B6 mutant and Dd2 wild type was slightly reduced at subsequent time points, it 
remained significant, ranging between p=0.003 and p=0.019. In contrast, after 49 h p.i. the 
differences in invasion efficiencies of S33A B6 and S33E F8 clones were statistically non-significant. 
Invasion efficiency of S33A B6 was significantly higher in comparison to S33D A11 mutant during all 
analyzed time points, with p≤0.001. 
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Figure 3.6. Egress and invasion efficiencies of Dd2 parental line and PfCRT S33 mutants. A. Egress 
efficiency presented as a parasitemia of schizonts decreasing over time. B. Invasion efficiency 
depicted as a parasitemia of ring stage parasites increasing over time. The mean ± SD of three 
independent biological replicates are shown. *** indicates a significant difference in parasitemia of 
clone S33A B6 in relation to Dd2 WT, S33E F8 and S33D A11, with p≤0.001, according to One Way 
ANOVA Holm-Sidak test. 
Prior to invasion, the merozoite attaches to the erythrocytes surface. Subsequently, it reorientates 
and forms a tight junction with the erythrocyte membrane, enabling its actin-based entry into the 
host cell (Field et al., 1993; Koch & Baum, 2016). To determine whether the increase in invasion 
efficiency observed for PfCRT S33A mutant already occurred during merozoite attachment to the red 
blood cell surface or later in the invasion process, a merozoites attachment assay was performed. To 
distinguish between the two events (attachment or invasion) an inhibitor of actin polymerization, 
cytochalasin D (cyt. D), has been used (Egan et al., 2015; Paul et al., 2015). In the absence of cyt. D, 
the parasites are able to invade erythrocytes, whereas addition of cyt. D results in only attachment of 
merozoites to the red blood cell surface, as their entry is blocked. Parasites were synchronized to a 4 
h window at mature schizont stage. Following schizont rupture (time point: 0 h), parasitemias of 
released merozoites attaching to (+ cyt. D) or invading (- cyt. D) new red blood cells were monitored 
at 1, 4 or 7 h post invasion (p.i.). As shown in Figure 3.7, no significant differences were observed in 
both attachment and invasion between the analyzed clones at 0 h p.i. At the subsequent time points, 
merozoites of PfCRT S33A B6 mutant seemed to have higher attachment in comparison to other 
clones, but only at 4 h p.i. the difference was statistically significant (Fig. 3.7.A). Regarding invasion, 
S33A B6 displayed significant increase (p<0.001) in invasion at 1 and 4 h p.i. in relation to all other 
clones (Fig. 3.7.B), confirming results depicted in Figure 3.6.B. At 7 h p.i. S33A B6 showed significantly 
higher invasion than Dd2 WT and S33D A11 (p=0.006 and p=0.001, respectively), but no more than 
S33E F8, what is also consistent with previous findings. 
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Figure 3.7. Flow cytometry-based analysis of merozoites attachment and invasion events in Dd2 
parental line and PfCRT S33 mutants. A. Merozoites attachment to the RBC surface measured in the 
presence of 1 µM cytochalasin D. B. Merozoites invasion into RBC measured in the absence of 
cytochalasin D. Results are presented as parasitemia over respective time points: 0, 1, 4 and 7 h post 
invasion (p.i.), corresponding to parasites age of 41-1 h p.i., 43-3 h p.i., 2-6 h p.i. and 5-9 h p.i., 
respectively. Data were normalized at each time point to the Dd2 WT. Each symbol represents an 
independent biological replicate. A box plot analysis of each data set is shown in grey. A thick black 
line indicates the mean value. Statistical significance between the data sets was calculated using One 
Way ANOVA Holm-Sidak test; n.s. – not significant. 
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3.2. Functional characterization of PfUT in parasite’s asexual 
life cycle 
Ubiquitination is a crucial posttranslational modification regulating numerous cellular processes via 
labelling of substrate proteins with mono-, multi- and polyubiquitin chains (Suryadinata et al., 2014). 
A HECT E3 ubiquitin ligase, termed Plasmodium falciparum ubiquitin transferase (PfUT), has been 
suggested as a novel candidate gene for multifactorial resistance to quinine (Sanchez et al., 2014). 
However, both PfUT’s role in the reduced quinine responsiveness and its physiological function in the 
parasite remain unclear. Therefore, this chapter aims to provide an insight into a better 
understanding of a biological role of PfUT in the asexual life cycle of P. falciparum. 
3.2.1. Conditional knockdown of PfUT using glmS ribozyme system 
Multiple genetic tools are available to study the function of Plasmodium genes (Prommana et al., 
2013; Ghorbal et al., 2014; Jones et al., 2016; Kirchner et al., 2016; Birnbaum et al., 2017; 
Balabaskaran-Nina & Desai, 2018). Since ubiquitination is a key regulator of many cellular processes, 
the components of the ubiquitination pathway, including PfUT, are likely critical for the parasite’s 
survival. Interestingly, an ortholog of PfUT in a murine malaria model Plasmodium berghei was 
annotated as indispensable for parasite asexual blood stages, as determined in the large pool of 
barcoded gene-deletion mutants (Bushell et al., 2017). Taking the above into account, a knockout 
attempt of a likely essential gene would have had a lethal effect for haploid blood stage Plasmodium 
parasites. Therefore, in order to link the parasite phenotype to a controlled PfUT abundance, a 
conditional knockdown approach has been chosen over a conventional knockout strategy. 
3.2.1.1.  Generation of PfUT-HA-glmS parasite line 
To assess the role of PfUT in the asexual life cycle of P. falciparum, a conditional gene knockdown 
using the glucosamine inducible glmS ribozyme system was attempted (Elsworth et al., 2014; 
Prommana et al., 2013). The CRISPR-Cas9 genome editing technology (Ghorbal et al., 2014) has been 
applied to incorporate the triple hemagglutinin (HA) tag and the glmS ribozyme within the 3’ 
untranslated region of PfUT (Fig. 3.8.A). PfUT-HA-glmS line has been generated in P. falciparum 3D7 
quinine-sensitive strain via a double-crossover homologous recombination between the transfection 
vector pL6-PfUT-HA-glmS-UTR bearing two homology regions and the pfut locus. Three clones 
termed 5G, 6E and 11B were isolated from the parental line via limiting dilution and used for further 
characterization. Correct integration of 3xHA and glmS ribozyme into the endogenous PfUT locus was 
confirmed by PCR amplification and Sanger sequencing (Fig. 3.8.B and C). Multiple attempts to obtain 
a transgenic parasite line in P. falciparum Dd2 quinine-resistant strain were unsuccessful. 
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Figure 3.8. CRISPR-Cas9-mediated integration of HA-glmS into PfUT locus. A. Schematic 
representation of the CRISPR-Cas9-based strategy used to incorporate sequences of HA and glmS 
ribozyme at the 3’ end of the endogenous PfUT gene. Glucosamine (GlcN) added to the culture 
medium is taken up by the parasite and converted to the glucosamine-6-phosphate (GlcN6P). Binding 
of GlcN6P stimulates self-cleavage of glmS ribozyme, leading to mRNA destabilization and 
downregulation of the target protein. B. Results of PCR amplification for wild type and the three 
PfUT-HA-glmS clones (5G, 6E and 11B). The expected sizes of PCR products (primer pairs: 8/4, 1 /10 
and 8/47) are indicated. Primers 8 and 10 are located, respectively, upstream and downstream of the 
homology regions (PfUT and 3’ UTR). C. Representative DNA sequence chromatogram of one of the 
PfUT-HA-glmS clones showing a correct integration of triple HA and glmS ribozyme sequences 
between the two homology regions. 
3.2.1.2.  Determination of optimal glucosamine concentrations 
Prior to validation of the glmS ribozyme system in the PfUT-HA-glmS parasites, dose dependent 
growth curves were performed for the P. falciparum 3D7 wild type line in order to determine the 
optimal conditions of GlcN treatment (Fig. 3.9). Several GlcN concentrations were tested, ranging 
from 1.25 to 10 mM. The maximal concentration at which parasites still retained normal growth and 
morphology was 5 mM GlcN. Therefore, it has been chosen for further characterization of the PfUT-
HA-glmS mutants. 
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Figure 3.9. Effect of GlcN treatment on the growth and morphology of P. falciparum 3D7 wild type. 
A. Growth of the 3D7 wild type parasites in the presence of various GlcN concentrations measured 
over 72h in two independent experiments (top and bottom panel). Parasitemia was estimated from 
Giemsa-stained thin blood smears. B. Morphology of the 3D7 wild type parasites in the Giemsa-
stained thin blood smears analyzed at various GlcN concentrations over 72h of treatment. Scale bar: 
5 µm. 
3.2.1.3.  PfUT is overexpressed in the HA-glmS mutant line 
Glucosamine-induced downregulation of PfUT levels was assessed on both transcript and protein 
levels, as the glmS ribozyme is a RNA-based gene regulatory system, mediating glucosamine 
dependent reduction of protein expression (Prommana et al., 2013). 
First, the pfut mRNA levels were analyzed via a reverse transcription quantitative PCR (RT-qPCR) 
using primer pairs specific to the N-terminal part of PfUT gene and an internal reference gene, β-
tubulin. A validation experiment in which a dilution series of cDNA was amplified using primers 
targeting PfUT and β-tubulin determined their respective efficiencies to 1.95 and 2.01, indicating 
qPCR amplification efficiencies of 98% and 100%, respectively (Fig. 3.10.A). According to its 
transcription profile (Bozdech et al., 2003; Llinás et al., 2006), PfUT is relatively equally expressed 
throughout the intraerythrocytic cycle, with a slight decrease in late schizonts and merozoites. Taking 
that into account, total RNA was then extracted from the trophozoite stage parasites cultured in the 
presence or absence of 5 mM glucosamine (GlcN) and subjected to RT-qPCR analysis. The levels of 
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pfut mRNA in untreated PfUT-HA-glmS line were found to be significantly increased by approx. 2-fold 
in relation to the wild type parasites, with p<0.001 according to One Way ANOVA Holm-Sidak test 
(Fig. 3.10.B). Exposure of mutant parasites to 5 mM GlcN resulted in a significant reduction of pfut 
transcripts in relation to untreated PfUT-HA-glmS parasites, with p<0.001. Glucosamine treatment 
did not affect the pfut mRNA levels in 3D7 wild type strain. 
 
Figure 3.10. RT-qPCR analysis of the pfut transcript levels in 3D7 WT and PfUT-HA-glmS line. A. 
Determination of RT-qPCR primer pairs efficiencies. A series of cDNA 2-fold dilutions was amplified 
using primer pairs specific for the target (PfUT) and the housekeeping gene (β-tubulin). Results were 
plotted as mean Ct values of triplicates (each dot) against the log of cDNA input and fitted to the 
linear regression model. Primers efficiencies of 1.95 for PfUT and 2.01 for β-tubulin were quantified 
from the slope, indicating the qPCR amplification efficiency of 98% and 100%, respectively. B. RT-
qPCR measurement of pfut mRNA levels in trophozoite stage 3D7 WT and PfUT-HA-glmS parasites in 
the presence and absence of 5 mM glucosamine (GlcN). GlcN treatment for 120 h, corresponding to 
the 3rd replicative cycle, is indicated as circles, whereas the 48 h exposure is marked with rhombus 
shape. RT-qPCR data were analyzed using the delta-delta Ct method normalized to β-tubulin and 
relative to untreated 3D7 WT. Results for the three clones of PfUT-HA-glmS line (5G, 6E and 11B) are 
pooled together and shown as “HA-glmS”, yet depicting values for individual clones with a blue scale 
colour code. Each symbol represents an independent biological replicate. A box plot analysis of each 
data set is shown in grey. A thick black line indicates the mean value. Statistical significance between 
the data sets was calculated using One Way ANOVA Holm-Sidak test; n.s. – not significant. 
To determine whether changes observed for PfUT on the transcript level correlate with the protein 
levels, a western blot analysis was performed. For this purpose, protein extracts of trophozoite stage 
parasites cultured in the presence or absence of 5 mM glucosamine (GlcN) were immunoblotted with 
antibodies against HA-tag, as well as C- and N-terminal ends of PfUT. Anti-α-tubulin was used in 
parallel as a loading control. Western blot analysis displayed bands of approx. 460 kDa and 50 kDa 
corresponding to the predicted size of PfUT and α-tubulin, respectively (Fig. 3.11.A). Densitometric 
     
69 
quantification of signal intensity using anti-HA antibody revealed around 40% reduction in PfUT-HA 
protein abundance in the mutant line exposed to GlcN, with a significance of p<0.001 as estimated 
by t-test (Fig. 3.11.B). Interestingly, the PfUT protein levels detected in PfUT-HA-glmS line using 
antibodies raised against its C-terminal and N-terminal domains were found to be increased by 
approx. 2-fold in relation to 3D7 WT parasites, with a significance of p<0.001 in case of N-terminal 
labelling (Fig. 3.11.C and D). Since the use of C-terminal antibody resulted in unspecific binding (Fig. 
3.11.A, middle panel), the immunoblots stained with anti-C-terminal PfUT have been aligned to the 
ones labelled with anti-HA to verify which of the two bands corresponds to the PfUT (data not 
shown). As a result, the lower band has been chosen for quantification of signal intensity. Exposure 
to GlcN led to a significant decrease of PfUT protein levels with p values of 0.02 and p<0.001, as 
determined by probing with C-terminal and N-terminal PfUT, respectively (Fig. 3.11.C and D). 
Glucosamine treatment did not influence the PfUT protein levels in 3D7 WT strain. 
 
Figure 3.11. Western blot analysis of PfUT expression levels in 3D7 WT and PfUT-HA-glmS 
parasites. A. Protein lysates were prepared from late trophozoites cultured for 120 h in the presence 
or absence of 5 mM GlcN. Proteins were resolved in 3-8% Tris-Acetate SDS-PAGE and immunoblotted 
with antibodies against HA-tag (mouse, 1:1000; top panel), residues 3654 to 3875 of the C-terminal 
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domain of PfUT (rabbit, 1:1000; middle panel) and residues 473 to 712 of the N-terminal PfUT 
(rabbit, 1:1000; bottom panel) along with α-tubulin (mouse, 1:1000) as a loading control. 
Representative western blots are shown. An uncropped view of the western blot membranes can be 
found in Appendix I, Fig. I.3. B.-D. The intensities of the bands in the western blots in part A were 
analyzed using LI-COR Image Studio Digits 4.0 software and normalized to α-tubulin. Data for the 
three clones of PfUT-HA-glmS line (5G, 6E and 11B) is pooled together and shown as “HA-glmS”, yet 
depicting values for individual clones with a blue scale colour code. The downregulation levels of 
PfUT-HA in mutant line upon GlcN treatment in relation to HA-glmS untreated were quantified using 
anti-HA (B). The PfUT expression levels relative to untreated 3D7 WT (“WT”, grey dots) were 
determined for immunoblots labelled with C-terminal PfUT (lower band indicated with a black 
arrowhead) (C) and N-terminal PfUT (D). Exposure of parasites to 5 mM GlcN for 48 h revealed 
results comparable to 120 h treatment (data not shown). Each symbol represents an independent 
biological replicate. A box plot analysis of each data set is shown in grey. A thick black line indicates 
the mean value. Statistical significance between the data sets was calculated using t-test (B) or One 
Way ANOVA Holm-Sidak test (C and D); n.s. – not significant. 
3.2.1.4.  PfUT-HA localizes to the ER/Golgi complex 
PfUT has previously been shown to localize to the parasite’s ER/Golgi complex in wild type parasites 
(Sanchez et al., 2014). To verify whether the localization of PfUT in the mutant line was affected by a 
C-terminal integration of HA-glmS, immunofluorescence assays (IFA) were performed. To assure the 
specificity of the commercially available anti-HA antibody, which was intended to be tested in 
colocalization with respective ER/Golgi markers, it was first colocalized with N- and C-terminal PfUT 
antibodies used in the above mentioned study of Sanchez et al. As shown in Figure 3.12, staining of 
HA was absent in the 3D7 WT, but it overlapped with a signal for both, N- and C-terminal PfUT in the 
HA-glmS transgenic line, thus proving the specificity of the tested antibodies.  
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Figure 3.12. Colocalization of HA and PfUT primary antibodies by indirect immunofluorescence 
assay (IFA). Late stage P. falciparum-infected erythrocytes were fixed and labelled with anti-HA 
(mouse, 1:1000) along with N-terminal PfUT (rabbit, 1:1000) or C-terminal PfUT (rabbit, 1:1000). 
Secondary antibody staining was carried out using anti-mouse Alexa Fluor 488 (green) and anti-rabbit 
Alexa Fluor 546 (red). The nuclei were visualized with Hoechst (blue). Overlay of the green, red and 
blue channels, as well as the differential interference contrast (DIC) are shown. Additional merge of 
green and red channels together with DIC and plot profiles are included for a better presentation of 
signals colocalization. 3D7 WT (top panel) lacking a HA-tag served as a control for specificity of anti-
HA staining in PfUT-HA-glmS line. Scale bar: 5 µm. 
Subsequently, localization of PfUT-HA in the mutant line was analyzed via IFA by a colocalization with 
ER markers, BiP and ERC, as well as with a Golgi marker, ERD2. The results of the colocalization 
studies confirmed the previously demonstrated partial colocalization of PfUT with indicated ER/Golgi 
markers (Fig. 3.13). 
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Figure 3.13. Colocalization of PfUT-HA with ER and Golgi markers by indirect immunofluorescence 
assay (IFA). Late stage P. falciparum-infected erythrocytes were fixed and labelled with anti-HA 
(mouse, 1:1000) along with one of the ER markers, BiP (rabbit, 1:1000) or ERC (rabbit, 1:500), or with 
a Golgi marker ERD2 (rabbit, 1:500). Secondary antibody staining was carried out using anti-mouse 
Alexa Fluor 488 (green) and anti-rabbit Alexa Fluor 546 (red). The nuclei were visualized with Hoechst 
(blue). Overlay of the green, red and blue channels, as well as the differential interference contrast 
(DIC) are shown. Additional merge of green and red channels together with DIC and plot profiles are 
included for a better presentation of signals colocalization. Scale bar: 5 µm. 
The sub-cellular localization of PfUT-HA was further attempted by immuno-electron microscopy. 
Cryo-preserved Tokuyasu sections of erythrocytes infected with late trophozoite stage PfUT-HA-glmS 
parasites were consecutively labelled with anti-HA and gold conjugated secondary antibody and 
examined via transmission electron microscopy (TEM). No abnormalities in the morphology of the 
parasites were observed in the HA-glmS line with a reference to the published TEM images of wild 
type P. falciparum parasites (Muregi et al., 2011; Sanchez et al., 2014; Sherling et al., 2017). Although 
a minor unspecific labelling was detectable in some areas of the cell, the vast majority of the gold 
particles accumulated in the region of the ER/Golgi complex, membranous compartments adjacent 
to nuclei (Fig. 3.14.A). The gold labelling was quantified by estimating the distribution of gold 
particles across the area of their subcellular localization in several recorded micrographs. This 
analysis exposed the specificity of gold counts in ER/Golgi complex over the other subcellular 
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compartments (Fig. 3.14.B), with a significance of p<0.001 assessed by One Way ANOVA Holm-Sidak 
test. 
 
Figure 3.14. Immunogold subcellular localization of PfUT-HA by transmission electron microscopy 
(TEM). A. A representative electron micrograph depicting the localization of PfUT-HA in the parasite’s 
ER/Golgi complex (ER) as indicated by accumulation of the vast majority of gold particles (black 
arrowheads). Infected erythrocytes samples prepared according to the Tokuyasu approach were 
labelled with anti-HA (mouse, 1:1), followed by staining with anti-mouse antibody coupled to 10 nm 
colloidal gold (goat, 1:20). n - nucleus. Scale bar: 200 nm. B. Quantification of EM immunogold 
labelling. The distribution of gold in particular regions of the infected erythrocyte to the total 
analyzed area was determined in 5 micrographs. Gold particles were significantly more present in 
areas of ER/Golgi complex (ER) than in other subcellular compartments, including the parasite’s 
cytoplasm (Cyt.), nucleus (Nuc.), digestive vacuole (DV), red blood cell cytosol (RBC) and non cellular 
background (BG). Data is shown as the mean ± SEM. Statistical significance between the data sets 
was calculated using One Way ANOVA Holm-Sidak test.  
These results confirm the localization of PfUT-HA indicated earlier via IFA (Fig. 3.14.A) and are 
consistent with previously reported immuno-electron microscopic localization of PfUT in the wild 
type parasites (Sanchez et al., 2014). 
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3.2.1.5.  PfUT-HA-glmS line displays a reduced growth phenotype 
Growth curves analysis was performed to assess whether integration of HA-glmS, resulting in PfUT 
overexpression, impacted the parasite proliferation. Parasite growth expressed as an increase in 
parasitemia was measured for 3D7 WT and PfUT-HA-glmS line in the presence and absence of 5 mM 
GlcN over 168 h, corresponding to 4 replicative cycles (Fig. 3.15.A). Interestingly, growth of the HA-
glmS transgenic line, compared to 3D7 WT was significantly reduced in the absence of GlcN, with 
p<0.001 according to F-test statistics. The impaired growth of PfUT-HA-glmS parasites was partially 
rescued upon GlcN treatment, with a significance of p=0.02, in relation to untreated mutants. The 
presence of GlcN had no effect on the growth of the 3D7 WT. Despite the differences observed in the 
growth of 3D7 WT and PfUT-HA-glmS line, the parasites appeared morphologically normal 
throughout the whole experiment (data not shown).  
To further verify these findings, the parasite multiplication rates (PMR) per 48 h were determined for 
each clone throughout the 168 h of experimental duration (Fig. 3.15.B). PMRs were expressed as a 
fold increase in parasitemia measured over time. The multiplication rate for 3D7 WT was estimated 
to be 8 ± 1 regardless the GlcN presence, consistent with previous reports (Murray et al., 2017). GlcN 
untreated PfUT-HA-glmS clones 5G, 6E and 11B displayed a significantly lower PMR (p<0.001), with 
values of 5 ± 1, 6 ± 1 and 5 ± 1, respectively. Exposure of the HA-glmS transgenic line to GlcN resulted 
in an increase in PMR of clones 5G, 6E and 11B, with values of 8 ± 1, 8 ± 1 and 8 ± 1, respectively, 
with  significance of p=0.02, p=0.01 and p=0.02, in relation to respective untreated clones. These 
results support the findings from the growth curve analysis. 
Figure 3.15. Growth and multiplication rates of P. falciparum 3D7 WT and PfUT-HA-glmS mutant 
lines. A. Growth of the 3D7 WT and PfUT-HA-glmS parasites (represented by three individual clones: 
5G, 6E and 11B) measured over 168h in the presence and absence of 5mM GlcN. Each symbol depicts 
a mean of three independent biological replicates. Statistical significance between the growth curves 
was assessed with F-test. B. Parasite multiplication rate (PMR) for each clone was determined as a 
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fold increase in parasitemia per 48h, measured over 4 cycles. Each symbol represents an 
independent biological replicate. A box plot analysis of each data set is shown in grey. A thick black 
line indicates the mean value. Statistical significance between the data sets was calculated using One 
Way ANOVA Holm-Sidak test. 
3.2.1.6.  The impaired growth of the PfUT-HA-glmS line results from    
 an extended cell cycle duration  
Several features of parasite intraerythrocytic development were taken into consideration to address 
the impaired growth and reduced PMR of PfUT-HA-glmS clones in the absence of GlcN. First, 
numbers of merozoites generated per schizont were determined, as a decreased merozoite number 
may lead to reduced invasion and consequently a decrease in parasitemia. Since the nuclear division 
in P. falciparum occurs asynchronously, the number of merozoites produced per schizont ranges 
between 8 and 24 (Reilly et al., 2007; Garg et al., 2015). No differences in the number of merozoites 
have been observed between the 3D7 WT and the PfUT-HA-glmS clones, with the average number of 
19 merozoites, irrespective of GlcN presence (Fig. 3.16.A).  
The impaired growth phenotype may also arise from the differences in multiple infections of 
erythrocytes. Multiply-infected erythrocyte refers to a red blood cell containing more than one 
parasite. Invasion of a single erythrocyte by up to seven merozoites is commonly observed in patient 
samples. However, only up to three parasites are capable of maturation until the schizont stage 
(Orjih, 2014). A triple infection of a single erythrocyte compared with three separate singly-infected 
red blood cells gives the impression of reduced overall parasitemia, although the number of parasites 
in both events is equal. Therefore, to assess whether multiply-infected erythrocytes were preferable 
to single infections, being a cause of the reduced growth, the proportions of single, double and triple 
infections were quantified for the 3D7 WT and the PfUT-HA-glmS parasites. The singly parasitized red 
blood cells were the majority among all the types of infections, however, no differences have been 
observed in quantities of singly-, doubly, and triply-infected erythrocytes between the 3D7 WT and 
the PfUT-HA-glmS line (Fig. 3.16.B). 
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Figure 3.16. Analysis of merozoites numbers and multiply-infected erythrocytes in 3D7 WT and 
PfUT-HA-glmS parasites. A. Number of merozoites generated per schizont determined using flow 
cytometry in the presence and absence of 5mM GlcN. B. Singly-, doubly- and triply-infected red 
blood cells expressed as percentage of ring-stage parasitemia measured by flow cytometry. Each 
symbol represents an independent biological replicate. A box plot analysis of each data set is shown 
in grey. A thick black line indicates the mean value. Statistical significance between the data sets was 
calculated using One Way ANOVA Holm-Sidak test; n.s. – not significant. 
Another possible factor that could have influenced the growth of the HA-glmS transgenic parasites is 
the length of intraerythrocytic cycle. To investigate whether there were differences in the duration of 
cell cycle of 3D7 WT and PfUT-HA-glmS line, the DNA content in these parasites was measured over 
time post invasion. For this purpose, samples of parasites synchronized to a 4 h window were 
collected in 4 h intervals. The DNA content was expressed as a DNA copy number (C-value). The wild 
type parasites C-value starts to increase around 28-32 h post invasion, with the beginning of parasite 
DNA replication in the S phase (Fig. 3.17.A). The length of 3D7 WT was estimated to be 48 h, 
identified by a sudden drop in C-value, in agreement with the previous studies (Bozdech et al., 2003; 
Van Biljon et al., 2018). The asexual life cycle of the PfUT-HA-glmS line, however, was extended for 
approximately 8 h in the absence of GlcN, due to an apparent elongation of S phase (Fig. 3.17.A). 
Exposure to GlcN in the 1st replication cycle had no influence on the cell cycle time of either 3D7 WT 
or PfUT-HA-glmS line, resulting still in 48 h and 56 h cycle, respectively (Fig. 3.17.B). Interestingly, 
parasites treatment with GlcN prolonged up to the 3rd cycle resulted in a 4 h shorter cycle length for 
mutants, comparative to the 1st cycle (Fig. 3.17.C and D). The duration of the 3D7 WT cycle was 
unaffected by 144 h GlcN exposure. The peak of C-value corresponds to the number of merozoites at 
the schizont stage parasites, reflecting the data depicted in Figure 3.16.A. There was no difference in 
the numbers of merozoites measured for 3D7 WT and PfUT-HA-glmS parasites, irrespective of the 
time of GlcN exposure (Fig. 3.17.A-C). 
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Figure 3.17. Analysis of cell cycle length and morphology of 3D7 WT and PfUT-HA-glmS parasites. 
The cell cycle length expressed as an increase in the parasite DNA copy number (C-value) over time 
was measured for tightly synchronized parasites (4 h window) in the absence of GlcN (A), as well as 
in the presence of 5 mM GlcN in the 1st (B) and 3rd (C) replicative cycle. The drop in the C-value after 
reaching the peak indicates the beginning of a new cycle. For each clone at each time point a mean ± 
SEM of three independent biological replicates is shown. G0/G1 and S/M phases of the 48 h intra-
erythrocytic cell cycle of 3D7 WT are also indicated, to better display the differences observed in the 
mutant line. D. Graph summarizing panels A, B and C, presented as a final cell cycle length of 3D7 WT 
and PfUT-HA-glmS parasites measured in the 1st (C1) and 3rd cycle (C3) in the presence or absence of 
GlcN. E. Morphology of the parasites in the Giemsa-stained thin blood smears analyzed in the 
absence of GlcN (“Ø”, top 2 panels), as well as in presence of 5 mM GlcN in the 1st (“+”, middle 2 
panels) and 3rd cycle (“+”, bottom 2 panels), depicted for selected time points. Scale bar: 2 µm. 
Giemsa-stained thin blood smears revealed morphologically normal appearance of transgenic and 
wild type parasites at all analyzed time points, regardless of GlcN presence, simultaneously exhibiting 
the elongated S phase of PfUT-HA-glmS parasites (Fig. 3.17.E). 
3.2.1.7.  Analysis of the ubiquitination patterns 
In order to understand the mechanism underpinning the phenotype of PfUT-HA-glmS parasites 
described in previous sections, the identification of PfUT’s biological substrates is crucial. To address 
this issue, the ubiquitination patterns of the 3D7 WT have been compared with those of the mutant 
line via a western blot analysis, both in presence and absence of 5 mM GlcN. Ubiquitinated proteins 
were detected by immunoblotting with a polyclonal anti-ubiquitin antibody. As shown in Figure 3.18, 
no obvious differences in the ubiquitination patterns were found between 3D7 WT and the three 
PfUT-HA-glmS clones, 5G, 6E and 11B, irrespective of GlcN presence. 
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Figure 3.18. Western blot analysis of ubiquitination patterns in 3D7 wild type and PfUT-HA-glmS 
parasites. Protein lysates were prepared from late trophozoite stage parasites pre-cultured for 120 h 
under standard conditions in the presence or absence of 5 mM GlcN. Proteins were resolved via 3-8% 
Tris-Acetate SDS-PAGE followed by immunoblotting with polyclonal anti-ubiquitin antibody (rabbit, 
1:1000). α-tubulin (50 kDa) was used as a loading control. 
 
3.2.1.8.  Investigating PfCRT as a substrate of PfUT 
A genetic linkage analysis conducted on the progeny of a genetic cross between a resistant Dd2 and a 
sensitive HB3 strain revealed an association between PfUT and a resistant PfCRT variant in altering 
the parasite responses to quinine (Sanchez et al., 2014). Moreover, it has been shown that PfCRT 
traffics to the digestive vacuolar membrane via ER/Golgi complex (Kuhn et al., 2010), prompting to 
hypothesize that PfCRT might be a substrate of PfUT. Therefore, a potential role of PfCRT as PfUT’s 
target has been investigated via a western blot analysis. In a number of studies, the molecular weight 
of PfCRT has ranged from 38 to 50 kDa, depending on the PfCRT variant and SDS-PAGE conditions 
(Cooper et al., 2002; Johnson et al., 2008; Valderramos et al., 2010; Shahinas et al., 2013; Sanchez et 
al., 2014). Most likely due to the specific SDS-PAGE conditions (Tris-Acetate, 3-8% gradient gel) 
applied in this experiment, the size of the detected PfCRT corresponded to   38 kDa (Fig. 3.19.A). 
Densitometry of western blot bands revealed that, regardless of GlcN presence, the levels of PfCRT 
abundance in the 3D7 WT were not significantly different from those in the HA-glmS transgenic line 
carrying the overexpressed PfUT variant (Fig 3.19.B).  
 
Figure 3.19. Western blot analysis of PfCRT expression levels in 3D7 wild type and PfUT-HA-glmS 
parasites. A. Protein lysates prepared from late trophozoites pre-cultured for 120 h in the presence 
or absence of 5 mM GlcN were resolved in 3-8% SDS-PAGE followed by immunoblotting with 
antibody raised against peptide MKFASKKNNQKNSSK of the N-terminal PfCRT (guinea pig, 1:1000). α-
tubulin with an expected size of 50 kDa served as a loading control. B. The intensities of the bands in 
the western blots were analyzed using LI-COR Image Studio Digits 4.0 software. Data was normalized 
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to α-tubulin. Results for the three clones of PfUT-HA-glmS line (5G, 6E and 11B) are pooled together 
and shown as “HA-glmS”, yet depicting values for individual clones with a blue scale colour code. The 
PfCRT expression levels were quantified in relation to the untreated 3D7 WT (“WT”, grey dots). Each 
symbol represents an independent biological replicate. A box plot analysis of each data set is shown 
in grey. A thick black line indicates the mean value. Statistical significance between the data sets was 
calculated using One Way ANOVA Holm-Sidak test; n.s. – not significant. 
 
3.2.1.9. PfUT-HA-glmS parasites are more susceptible to quinine  
and quinidine 
PfUT has been identified as a novel candidate gene that might contribute to multi-factorial resistance 
to quinine (Sanchez et al., 2014). To validate the association of PfUT with altered quinine 
responsiveness, growth inhibition assays were conducted for 3D7 WT and PfUT-HA-glmS line carrying 
the overexpressed PfUT variant. The half-maximal (50%) inhibitory concentrations (IC50) were 
determined for a comparison of drug resistance phenotypes for respective parasite lines. Drug 
responsiveness was measured for quinine, along with two other quinoline drugs, quinidine and 
chloroquine. Although quinidine is not an effective antimalarial drug, as a stereoisomer of quinine, it 
should, supposedly, show similar trend in results. Chloroquine was used as a control drug, since the 
main determinant of chloroquine resistance is a mutated PfCRT variant, whereas the 3D7 WT 
parasites are carrying the sensitive alleles (Valderramos et al., 2010). Therefore, parasites of the 3D7 
genetic background tested in this growth inhibition assay should display a comparable 
responsiveness to chloroquine. 
Genomic integration of the HA-glmS sequence to the PfUT locus resulted in a significantly increased 
(p<0.001) susceptibility of HA-glmS transgenic line to quinine in the absence of GlcN, with IC50 values 
of 74 ± 4 nM, 61 ± 2 nM and 64 ± 3 nM, for the three PfUT-HA-glmS clones, 5G, 6E and 11B, 
respectively, in comparison to 94 ± 4 nM determined for 3D7 WT (Fig. 3.20.A). Similarly, a significant 
reduction (p<0.001) in resistance to quinidine has been observed for clones 5G, 6E and 11B with IC50 
values of 25 ± 2 nM, 19 ± 1 nM and 22 ± 1 nM, respectively, in relation to 3D7 WT with a IC50 of 36 ± 2 
nM. However, the chloroquine sensitivity profile of PfUT-HA-glmS clones was not significantly 
different from 3D7 WT, with an average IC50 value of 11 ± 1 nM. Treatment with 5 mM GlcN further 
reduced the response levels of HA-glmS mutants to quinine. HA-glmS clones, 5G, 6E and 11B, 
displayed significantly lower (p<0.001) quinine IC50 values of 34 ± 4 nM, 35 ± 3 nM and 42 ± 1 nM, 
respectively, than 3D7 WT with 68 ± 6 nM (Fig. 3.20.B). Regarding quinidine response levels, clones 
5G, 6E and 11B were significantly (p<0.001) more sensitive to quinidine exposure, with IC50 values of 
15 ± 1 nM, 14 ± 1 nM and 17 ± 1 nM, respectively, in comparison to 3D7 WT with  IC50 value of 26 ± 2 
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nM. The chloroquine IC50 values with an average of 10 ± 1 nM, again, revealed no significant 
difference between 3D7 WT and PfUT-HA-glmS clones. 
 
Figure 3.20. Growth inhibition assays of 3D7 wild type and PfUT-HA-glmS parasites in the absence 
(A) and presence (B) of 5 mM GlcN. Half-maximal inhibitory concentrations (IC50) were determined 
for chloroquine (CQ, control drug), quinine (QN) and quinidine (QD, stereoisomer of QN). Each 
symbol represents an independent biological replicate. A box plot analysis of each data set is shown 
in grey. A thick black line indicates the mean value. Statistical significance between the data sets 
consisting of at least 6 independent measurements was calculated using One Way ANOVA Holm-
Sidak test; n.s. – not significant.  
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The outcome of the growth inhibition assay performed in the presence of 5 mM GlcN (Fig. 3.20.B) 
must be taken with caution, since GlcN could have a slightly toxic effect at the indicated 
concentration in this experiment. The set-up of an assay in a 96-well plate containing parasite culture 
and serial drug dilutions incubated for 72 h in 37°C may lead to medium evaporation, which would, in 
turn, increase the final GlcN concentration in each well to levels harmful for the parasite (as 
previously shown in Figure 3.9.A). The growth response curves conducted for GlcN in the P. 
falciparum 3D7 strain revealed an IC50 value of 9.1 ± 0.4 mM (data not shown). 5 mM GlcN was the 
highest concentration at which parasites displayed unaffected growth. It suggests that an increase in 
local GlcN concentration above 5 mM due to medium evaporation during the course of experiment   
might have negative effects on the parasite. For that reason, the drug responsiveness of the WT and 
HA-glmS transgenic parasites was also measured in the presence of 2.5 mM GlcN (Appendix I, Fig. 
I.4). The data showed a similar trend to the results obtained for untreated parasites depicted in 
Figure 3.20.A. However, due to the limited number of repetitions (n=3-4), the differences between 
the WT and HA-glmS line were not significant. Quinine IC50 values were estimated to be 60 ± 10 nM, 
48 ± 12 nM and 60 ± 8 nM for clones 5G, 6E and 11B, respectively, and 82 ± 11 nM for 3D7 WT. The 
responsiveness of the parasites to quinidine was represented by IC50 values of 22 ± 5 nM, 16 ± 3 nM 
and 21 ± 5 nM for clones 5G, 6E and 11B, respectively, in comparison to 32 ± 3 nM for 3D7 WT. All 
parasites displayed comparable responses to the chloroquine treatment, with an average IC50 value 
of 11 ± 1 nM. 
3.2.2. Inactivation of PfUT’s HECT catalytic domain 
The extended cell cycle length of the PfUT-HA-glmS line may have resulted from an overexpressed 
PfUT regulating the abundance, activity or trafficking of its substrates, any of which might be 
involved in control of parasite proliferation. Another possible explanation of the observed 
phenotype, assuming targeting proteins for degradation as the main function of PfUT, is that 
integration of HA-glmS could affect the stability and/or activity or HECT catalytic domain, resulting in 
a dominant negative phenotype, most likely due to accumulation of PfUT’s substrates which escaped 
degradation in the proteasome. Nonetheless, it cannot be ruled out that both overexpressed and 
catalytically inactive version of HECT domain could lead to a dominant negative PfUT effect.  
To investigate the hypothesis of PfUT’s negative dominance, an active cysteine site of its HECT 
catalytic domain has been replaced by a serine residue by means of the CRISPR-Cas9 genome editing 
technology, maintaining the presence of HA-glmS at the C-terminus of PfUT to allow for comparison 
between the two transgenic lines (Fig. 3.21.A). An active cysteine site is located 32-36 amino acids 
upstream of the C-terminal end of HECT domain (Huibregtse et al., 1995), which in case of PfUT 
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corresponds to the cysteine at position 3860. As already mentioned in the introduction part (chapter 
1.3.3), E3 type ubiquitin ligases belonging to the HECT family, including PfUT, form a thioester 
intermediate with a target protein via an active cysteine residue of their catalytic domains, before a 
final labelling of the substrate with a ubiquitin molecule. The cysteine active site is therefore critical 
for their ubiquitinating function. Replacement of cysteine to serine deactivates HECT domain by 
depriving it of redox activity, yet retaining the hydrophilic properties and structure of the residue 
(Fig. 3.21.B).  
 
Figure 3.21. CRISPR-Cas9-mediated replacement of an active cysteine site of the PfUT’s HECT 
catalytic domain. A. Schematic representation of the CRISPR-Cas9-based strategy to replace the 
active cysteine (Cys) at position 3860 by serine (Ser) in the PfUT locus. The homology region referred 
to as HECT*, carrying a Cys3860Ser mutation (black star) and a shield mutation (grey star) has been 
integrated via a double crossover homologous recombination at a PfUT locus. A guide RNA targeting 
the Cas9 endonuclease to a recognition and cleavage site was the one successfully used in generation 
of PfUT-HA-glmS line (chapter 3.2.1.1). B. Chemical structures of the cysteine and its amino acid 
replacement, serine.  
The P. falciparum 3D7 strain was transfected with pL6-HECT*-HA-glmS and pUF1-Cas9 vectors on 
three independent occasions. Following the two months of drug selection, no re-appearance of 
parasites has been observed in any of the three transfection events. This result might be an 
indication of a detrimental role of the inactivation of a HECT catalytic domain in the protein possibly 
essential for the parasite intraerythrocytic development.  
3.2.3. PfUT disruption using SLI-TGD system 
A conditional knockdown strategy using the glmS ribozyme system was not efficient enough to 
conclude whether PfUT is essential in P. falciparum blood stages. Therefore, to further investigate 
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the role of PfUT in parasite asexual life cycle, a recently developed approach, termed selection-linked 
integration mediated targeted gene disruption (SLI-TGD), was undertaken (Birnbaum et al., 2017). 
SLI-TGD generates a gene knockout by a single crossover homologous recombination between the 
construct and the N-terminal region of the gene of interest. Following the transfection and selection 
with WR99210, parasites carrying the plasmid were successfully recovered in P. falciparum 3D7 
strain, but not in Dd2 strain. Transfectants were then pressured with neomycin to select for parasites 
which had integrated the pSLI-TGD-PfUT construct. Since disruption of the targeted gene results in 
expression of GFP and neomycin phosphotransferase, only integrants are able to survive the 
neomycin selection. The failure in parasites recovery after neomycin selection is indicative of a 
potentially essential gene (Birnbaum et al., 2017). The six independent attempts to recover 
integrants after neomycin selection were unsuccessful, suggesting that PfUT might be essential for P. 
falciparum blood stage growth. 
 
Figure 3.22. Schematic of the SLI-TGD strategy. The pSLI-TGD-PfUT vector has been integrated via a 
single crossover homologous recombination at a N-terminal PfUT locus. A skip peptide (2A) included 
between GFP and Neo-R (neomycin phosphotransferase resistance gene) leads to expression of Neo-
R separately from GFP-tagged PfUT. A stop codon (*) was inserted at the beginning of homology 
region to prevent undesired expression of Neo-R from an episome and to ensure the gene knockout 
after recombination. hdhfr – human dihydrofolate reductase gene. 
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4. Discussion and Outlook 
4.1. Unravelling the role of PfCRT phosphorylation at position 
S33 in resistance to chloroquine and quinine 
The chloroquine resistant transporter PfCRT is a well characterized drug-metabolite carrier 
associated with conferring resistance to quinoline drugs (Bray et al., 2005; Juge et al., 2015). The 
natural function of PfCRT is, however, still not fully understood. Posttranslational modifications, 
including palmitoylation and phosphorylation, seem to be responsible for modulating the role of this 
transporter in the parasite (Jones et al., 2012; Kuhn et al., 2010). Out of the four phosphorylation 
sites in this phosphoprotein, namely S33, S411, T416 and S420, only the threonine at position 416 
has been linked to PfCRT’s trafficking to the digestive vacuole, whereas the relevance of the other 
three residues has so far remained unknown. The present study attempts to understand the role of 
serine 33 phosphorylation in context of drug resistance. 
4.1.1. Phosphorylation of PfCRT’s serine 33 modulates chloroquine    
      and quinine responsiveness 
The role of phosphorylation in the drug resistance mediating function of PfCRT has been evaluated 
from two perspectives. On the one hand, chemistry-based approach was used to block various 
protein kinases and phosphatases. On the other hand, genetic engineering has been implemented to 
modify the serine 33 phosphorylation site.  
First, a screen of a range of kinase and phosphatase inhibitors revealed three compounds, ML-7, W-7 
and H-89 (Fig. 3.1), which presence significantly increased accumulation of chloroquine in the P. 
falciparum Dd2 strain, carrying a resistant variant of PfCRT (Dr. Cecilia Sanchez, publication under 
review). A representative of the three inhibitors with a comparable influence on chloroquine 
accumulation, ML-7, was tested for an effect on the resistance profile of the Dd2 strain, and it 
significantly sensitized Dd2 parasites to chloroquine (CQ) and quinine (QN) (Fig. 3.2). These results 
provided the first evidence of phosphorylation being involved in modulating drug responsiveness in 
parasites bearing a mutant PfCRT background. However, the inhibitors of protein kinases used to 
regulate the levels of phosphorylation are often not specific and may cause various cellular effects, 
leading to misinterpretation of the observed phenotypes. For instance, although ML-7 is classified in 
humans as a selective mammalian myosin light chain kinase inhibitor (MLCK) (Isemura et al., 1991; 
Xiong et al., 2017), it also inhibits CK2α and PKA (Holland et al., 2009; McKenzie et al., 2018), whereas 
in P. falciparum it blocks PfCK2α (Graciotti et al., 2014; Holland et al., 2009). W-7 targets human 
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MLCK (Pinna & Cohen, 2005) and parasite PfPKB (Vaid & Sharma, 2006). H-89 blocks an activity of 
parasite and mammalian PKA (Syin et al., 2001; Warrier et al., 2007) as well as mammalian MSK1, 
PKBα, SGK, RSK1, RSK2, ROCK2, AMPK,  CHK1 and MLCK  (Limbutara et al., 2019; Raina et al., 2009). 
Noteworthy, although human MLCK, a target of all three inhibitors, lacks an ortholog in P. 
falciparum, it shares a high homology with parasite’s calcium-dependent protein kinase family, 
including PfCDPK5. 
Then, to link the drug resistance phenotype specifically with a PfCRT phosphorylation, a genetic 
manipulation has been undertaken. CRISPR-Cas9-mediated PfCRT serine 33 substitutions aiming to 
prevent or mimic phosphorylation in P. falciparum Dd2 strain, further supported the above 
observations, exposing the dependency of drug responsiveness on a variant of PfCRT 33 residue. As 
anticipated based on the outcome of the chemical approach, phosphorylation-defective alanine 
mutants (S33A) displayed significantly increased susceptibility to CQ and QN, in comparison to Dd2 
strain bearing a phosphorylated serine 33 (Fig. 3.3). Similar observations regarding regulatory 
influence of phosphorylation in context of drug resistance have been made in human ABC 
transporters, of which non-phosphorable alanine mutants displayed an increased sensitivity to drugs 
(Germann et al., 1996; Xie et al., 2008). Replacement of serine by a glutamic and aspartic acid, 
respectively, partially and fully mimicked the phosphorylation of serine 33. The differences in drug 
responses of these two negatively charged amino acids could be attributed to their chemical 
structure. A non-phosphorylated aspartic acid (D) appears chemically more similar to a phospho-
serine, than a glutamic acid (E) does; therefore the phosphorylation mimicry effect of S33D mutants 
was stronger than of S33E. Moreover, PfCRT’s localization and protein levels were comparable 
regardless of the variant of amino acid residue at position 33 (Dr. Cecilia Sanchez and Dr. Sonia 
Moliner Cubel, publication under review). Therefore, the differences observed in drug susceptibilities 
between the respective mutants are likely associated with the physiological function of PfCRT. 
To get an insight into the mechanism underlying the above findings, a substitution of serine by a non-
phosphorable alanine or one of the two amino acids mimicking phosphorylation, was reproduced in 
Xenopus laevis oocytes expressing the Dd2 variant of PfCRT (Dr. Britta Nyboer; publication under 
review). The oocyte heterologous expression system, commonly applied for characterisation of 
membrane transporters, allows to determine substrate affinity (Km) and maximum transport velocity 
(Vmax) (Krishna & Woodrow, 1999). While the pH of the digestive vacuole and cytoplasm of the 
parasite is approx. 5.2 and 7.2, respectively (Kuhn et al., 2007), it is inverse in the oocyte system, 
where the oocyte cytosol and extracellular medium exhibit a pH of 5.0-6.0 and 7.0-7.2, respectively 
(Martin et al., 2009). Therefore, oocyte uptake assays reflect parasite efflux of the compounds from 
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the digestive vacuole. Keeping that in mind, CQ uptake assays in oocytes revealed a comparable 
transport velocity of Dd2 WT and S33D mutant, in contrast to S33A and S33E mutants, with 
noticeably reduced and intermediate uptake velocities, respectively (Dr. Britta Nyboer, publication 
under review). The described results confirm the study performed in the parasite, additionally 
indicating a role of PfCRT serine 33 phosphorylation as a regulator of transport velocity in this drug 
and metabolite carrier. Nevertheless, to rely on the oocytes data, one would need to provide an 
evidence of PfCRT being phosphorylated in the oocyte system, e.g. via immunoblotting with a 
phospho-antibody or by phosphoproteomic analysis (work in progress). 
Taking these findings together, kinase inhibition as well as lack of a phosphorylation site, both 
resulted in increased CQ accumulation and enhanced susceptibility to CQ and QN. As the 
phosphorylation of PfCRT was directly linked to the drug resistance-mediating activity of this 
transporter, it motivated the identification of a responsible kinase. To investigate which of 
approximately 90 P. falciparum kinases (Doerig et al., 2008) is implicated in regulation of drug 
resistance mediating function of PfCRT, the protein-protein interaction methods such as Bio-ID, co-
immunoprecipitation or yeast-two-hybrid screen, could be applied to reveal potential kinase 
candidates. Then, to verify the ability of these kinases to phosphorylate PfCRT and in particular its 
S33, they could be subjected to an in vitro kinase assays using a synthetic peptide of the N-terminal 
PfCRT region as a substrate, and a mutant peptide containing alanine replacement to serine at 
position 33, as a control. The yeast two-hybrid assays (performed in the lab by Anne Christin Roth, 
Dr. Cecilia Sanchez and Dr. Sonia Moliner Cubel) revealed a serine/threonine protein kinase 
(PF11_0488 / PF3D7_1148000) as an interacting partner of a C-terminal domain of PfCRT, but none 
of kinases targeting the N-terminal PfCRT. On the other hand, one could potentially use 
bioinformatics tools, such as PKIS (Zou et al., 2013) or PhosphoPredict (Song et al., 2017), designed to 
identify the kinases responsible for experimentally verified phosphorylation sites. However, these are 
so far available only for human catalyzing phosphorylation enzymes, and their predictability of P. 
falciparum kinases should therefore be taken with caution. Ultimately, as Plasmodium kinases are 
interesting antimalarial drug targets and they show relatively low sequence homology with their 
mammalian orthologs (Doerig, 2004), the inhibitor of the identified kinase could potentially be 
administered in combination therapies with chloroquine and quinine, preserving the usage of these 
long appreciated antimalarials. 
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4.1.2. Fitness advantage of PfCRT S33 mutants results from the  
       increased numbers of merozoites 
As conferring resistance to drugs is often associated with fitness cost for the parasite (Walliker, 2005; 
Felger & Beck, 2008), the fitness of PfCRT S33 mutants was put under investigation. In the absence of 
drug pressure, alanine and glutamic acid mutants, with a sensitive and an intermediate resistance 
phenotype, respectively, were significantly fitter than Dd2 wild type and the aspartic acid mutant 
(Fig. 3.4.A). Fitness of the latter was comparable to Dd2 wild type. The fitness advantage of alanine 
and glutamic acid mutants was reflected by an increase in parasite multiplication rates (PMR) (Fig. 
3.4.B), arising from the corresponding changes in merozoite numbers and their invasion efficiencies 
(Fig. 3.5 - 3.7). 
Divergences in PMR arising from changes in cell cycle length, numbers of generated merozoites or 
erythrocyte invasion efficiency are commonly observed between the laboratory adapted P. 
falciparum strains differing in drug resistance background (Murray et al., 2017) as well as in field 
isolates causing distinct levels of malaria severity (Chotivanich et al., 2000). For example, a 
comparison of multidrug resistant (Dd2) and a sensitive wild type (HB3) strain revealed that the latter 
is characterized by longer cell cycle duration, a lower merozoite numbers and reduced invasion rates 
(Reilly et al., 2007).  
A causal link between altered resistance profile, fitness and altered merozoites viability has also been 
notified in another mediator of chloroquine and quinine resistance, encoded by mdr1 gene, a P-
glycoprotein homolog 1, which similarly to PfCRT localizes to the digestive vacuole membrane 
(Cowman et al., 1991). Resistance acquired by parasites bearing either mutated alleles or multiple 
mdr1 copy numbers incurred reduced fitness, associated with lower parasite multiplication rates and 
diminished merozoites viability (Hayward et al., 2005; Preechapornkul et al., 2009; Reed et al., 2000). 
These in vitro observations are consistent with results of several epidemiological studies reporting 
that after the selective pressure is removed, parasites conferring resistance may be put at a 
competitive disadvantage, as seen by drug sensitivity increasing over time (Thaithong et al., 1988; Liu 
et al., 1995; Kublin et al., 2003; Mita et al., 2004).  
As the physiological function of PfCRT has still to be established, it is not clear how PfCRT S33 
mutations might lead not only to the altered drug responses but also to such a pronounced effect on 
parasite overall fitness. Considering the differences in CQ transport velocity between the mutants, it 
cannot be ruled out that there are also variations in transport velocity of the natural substrates of 
this carrier. Assuming that the natural substrate of PfCRT is toxic for the parasite, its reduced 
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transport rate would result in lower levels of the toxic compound in the cytoplasm. Therefore, the 
parasite could direct its resources into enhanced proliferation, leading to increased merozoite 
numbers. Furthermore, if the natual substrate is a metal ion, its accumulation in the food vacuole 
could stimulate the activity of certain enzymes, such as aminopeptidases. It turn, this could result in 
higher levels of basic amino acids and peptides, derived from host haemoglobin digestion (Juge et al., 
2015; Martin et al., 2009; Patzewitz et al., 2012), which could be further utilized for synthesis of 
parasites’ own proteins. Metabolomic analysis conducted for PfCRT S33 mutants (Dr. Cecilia Sanchez, 
unpublished data) revealed a significant increase in levels of various tri- and tetrapeptides in S33A 
and S33E mutants in relation to S33D clone, and a significant reduction in content of some dipeptides 
in S33A mutant. Therefore, one of the possible mechanisms underlying the fitness variation in S33 
mutants might be associated with altering amino acid-generating pathways, present both in digestive 
vacuole and in cytoplasm (Dalal & Klemba, 2007). One of the cytoplasmic aminopeptidases localizing 
to the parasite’s apical organelles is P. falciparum dipeptidyl aminopeptidase 3 (DPAP3), the activity 
of which has been shown to be important for parasite proliferation and critical for merozoites 
attachment and invasion events (Lehmann et al., 2018). DPAP3 is most abundant in late schizont and 
merozoite stages and its knockout results in significantly decreased numbers of ring-infected 
erythrocytes (Lehmann et al., 2018). The expression of DPAP3 coincides with the transcription profile 
of PfCRT (Bozdech et al., 2003). Nevertheless, a lack of correlation between PfCRT’s RNA and protein 
levels cannot be ruled out, and should be validated experimentally. Interestingly, another member of 
this family essential for parasite proliferation, namely dipeptidyl aminopeptidase 1 (DPAP1), localizes 
to parasite’s digestive vacuole (Klemba et al., 2004). Moreover, before trafficking to its final 
destination, a proenzyme form of DPAP1 is found in the parasitophorous vacuole of mature schizonts 
(Klemba et al., 2004). Although at reduced levels, DPAP1 pro-form retains its activity (Wang et al., 
2011), suggesting that similarly to DPAP3, it might be involved in modulating parasite egress and the 
following red blood cell invasion.  
Secretion of different proteins from apical organelles prior to egress is known to be mediated by two 
signalling proteins, plant-like calcium-dependent protein kinase PfCDPK5 (Absalon et al., 2018; 
Dvorin et al., 2010) and cGMP-dependent protein kinase PfPKG (Collins et al., 2013), the knockouts of 
which block the egress. Attention should be paid to PfCDPK5, as it was mentioned before as an 
ortholog of mammalian MLCK targeted by all three kinase inhibitors tested in the present study. 
Other kinases with a potential role in phosphorylation of PfCRT S33 could include either a cyclin-
dependent PfCrk-5 or an orphan protein kinase PfPK7, as disruption of these important for 
schizogony kinases resulted in reduced growth rates, linked to decreased numbers of merozoites 
formed per schizont (Dorin-Semblat et al., 2008; Dorin-Semblat et al., 2013). Furthermore, several 
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studies draw attention to the role of calcium signalling pathways in merozoites development and 
invasion (Garcia, 1999; McCallum-Deighton & Holder, 1992). Noteworthy, a calcium-binding 
calmodulin, which is an activator among others of PfPKB (Silva-Neto et al., 2002; Vaid & Sharma, 
2006; Vaid et al., 2008), similarly to DPAP3 localizes to parasite’s apical region, and its inhibition was 
shown to block schizonts maturation and merozoites invasion (Garcia, 1999). Therefore, it would be 
rational to compare calcium levels in PfCRT S33 mutants. Potentially elevated calcium levels in S33A 
mutant could increase the activity of one of the kinases implicated in regulation of parasite 
proliferation, through a signalling cascade. This might theoretically explain the enhanced invasion 
rates of merozoites. Thus, it could be speculated that the same kinase which phosphorylates PfCRT’s 
S33 residue is also implicated in regulation of intraerythrocytic development and invasion of 
merozoites. In that case, the activity of this kinase in S33A mutant could potentially be reinforced 
into intensified mediation of schizont maturation, egress and invasion events. This in turn could 
possibly upregulate DPAPs and likely other proliferation-controlling enzymes, leading to increased 
numbers of viable merozoites.  
Another hypothesis may comprise the involvement of the lipid metabolism in the observed fitness 
variation, since the aforementioned metabolic profiling of S33 mutants revealed also differences in 
the abundance of certain lipids. Both alanine and glutamic acid mutants displayed significantly less 
phosphatidylcholines (PC) and lysophospholipids (LPL), than the aspartic acid mutant, which likely 
corresponds to Dd2 WT (not included in analysis), as could be assumed based on the similarities in 
fitness and drug resistance profile. Notably, none of these lipids was detectable in the case of PfCRT 
knockdown. During intraerythrocytic growth, parasite requires considerable amounts of lipids, 
among the others for the formation of membrane networks and development of daughter 
merozoites. P. falciparum, by synthesizing these lipids de novo or acquiring them from the host cell, 
shows a high adaptability of its lipids synthesis pathways in response to various disturbances (Gulati 
et al., 2015; Wein et al., 2018). Interestingly, analysis of serum lipid profiles in malaria-positive 
patients revealed lower levels of lipids and lipoproteins present in Plasmodium-infected group 
compared to healthy individuals (Visser et al., 2013) and more pronounced lipid alterations in severe 
than in uncomplicated malaria cases (Mfonkeu et al., 2010; Mohanty et al., 1992; Njoku et al., 2001). 
Although high-density lipoprotein cholesterol (HDL) is essential for P. falciparum survival in vitro, 
another study demonstrated that the parasite’s development is promoted at lower HDL 
concentrations (Imrie et al., 2004). These studies suggest that reduced levels of certain lipids may 
actually facilitate parasites’ proliferation, thus their potential correlation with increased merozoites 
numbers cannot be excluded.  
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Biological mechanisms influencing changes in lipid profiles during malaria infection may be both 
host- and parasite-related. A host-related decrease of plasma lipoproteins accompanying various 
acute diseases is likely caused by their migration into tissues due to increased capillary permeability 
(Visser et al., 2013); whereas, the parasite-related changes in lipid levels seem to be associated with 
heme detoxification into hemozoin, taking place in the parasite’s digestive vacuole (Fitch et al., 1999; 
Fong & Wright, 2013; Hänscheid et al., 2007; Pandey et al., 2003; Pisciotta et al., 2007). The role of 
neutral lipids in mediating the formation of hemozoin has been supported by transmission electron 
micrographs illustrating hemozoin crystals within lipid nanospheres (Pisciotta et al., 2007). These 
lipids, albeit, were not the ones found significantly affected in the metabolomic profiling of PfCRT 
S33 mutants. Most likely, since there is no correlation between levels of total hemozoin and P. 
falciparum sensitivity to CQ (Zhang et al., 1999), a demand for the neutral lipid bodies surrounding 
hemozoin crystals is then comparable in sensitive and resistant strains. On the other hand, the 
situation changes under drug pressure. Since CQ and QN are targeting the heme detoxification 
pathway, presence of these drugs results in accumulation of toxic heme and reduction of hemozoin 
levels in sensitive strains, in contrast to CQ resistant strains, which may even elevate hemozoin 
production (Orjih et al., 1994). Heme overload in drug susceptible strains in turn results in increased 
hemolysis (release of haemoglobin) of parasitized red blood cells. Prior to the hemolysis, osmotic 
fragility and passive permeability are increasing, whereas ATPase-dependent transport of sodium 
ions is decreasing. These changes are caused by esterification of fatty acids to membrane 
phospholipids, which alters the fluidity of the phospholipid bilayer, by changing its unsaturation 
degree (Holz, 1977). Noteworthy, S33A and S33E mutants exhibit significantly reduced levels of those 
esterified fatty acids, precisely of phosphatidylcholines (PCs). Moreover, some of the fatty acids are 
known to enhance the activity of adenylate cyclases generating cAMP, which further influence cAMP-
dependent protein kinases. Phosphorylating activity of these kinases was shown to modify the 
membrane proteins interacting with phospholipid bilayer, consequently changing membrane fluidity 
and barrier properties (Holz, 1977; Wang & Oram, 2007). One could therefore assume that altered 
lipid levels might be potentially related to the disturbed function of PfCRT, due to phosphorylation-
defective 33 residues in these mutants. A natural function of PfCRT as a lipid transporter could also 
be considered, since as shown on example of two human lipid transporters, ACBA1 and CD36, 
phosphorylation can influence the lipid changes mediated by these carriers (Glatz et al., 2010; Wang 
& Oram, 2007). This supposition, however, still does not explain the alterations of merozoite 
numbers observed in S33 mutants.  
Another assumption takes into consideration that PfCRT may interact with one of the enzymes 
hydrolysing phosphatidylcholine (PC) in the parasite. It happens that lysophospholipase A (LPLA; 
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PF14_0017 or PF3D7_1401500) implicated in PC hydrolysis, was found in the STRING functional 
protein association network (www.string-db.org) as one of the PfCRT’s interacting partners 
(Appendix I, Fig. I.1). This enzyme which has been shown as dispensable in P. berghei, facilitates a 
release of fatty acids (FA) from lysophospholipids (LPL), which also have been found at reduced levels 
in S33A and S33E mutants. LPL in turn are products of hydrolysis of PC and phospholipids (PL) 
catalyzed by a phospholipase A (PLA) (Flammersfeld et al., 2018). Noteworthy, the conversion of 
phosphatidylethanolamine (PE, precursor of PC) to PC by PE-methyltransferase (PEMT) requires 
serine, which can be taken up either from the host or from the haemoglobin degradation in digestive 
vacuole (Flammersfeld et al., 2018), linking the latter again to phospholipid synthesis pathway. 
Furthermore, it has been shown that phospholipases may both activate and be activated by kinases. 
On the one hand, phospholipases are regulated by some kinases, such as PKC (Exton, 1997). On the 
other hand, by hydrolysing phospholipids, activated phospholipase generates unsaturated fatty 
acids, the presence of which, as already mentioned earlier, stimulates the kinase which in turn again 
activates phospholipase, forming a positive feedback loop  (Exton, 1997; Holz, 1977; Wang & Oram, 
2007). A possibility of LPLA being regulated by phosphorylation is highlighted by a presence of serine 
active site in this enzyme (Flammersfeld et al., 2018). Interestingly, it has been shown that blocking 
the function of phospholipase C, which further activates PfPKB, resulted in impaired invasion (Vaid et 
al., 2008). Another study reports that the activity of P. falciparum phospholipase A2 has been 
inhibited by exposure to chloroquine, quinine, and the artemisinin derivative, arteether (Zidovetzki 
et al., 1993), suggesting that the phospholipid catabolism pathway may indeed be associated with 
PfCRT-mediated resistance to chloroquine and quinine.   
The results of this study showed that fitness advantage incurred by S33A and S33E mutants was due 
to increased numbers of merozoites, which displayed better invasion efficiencies (Fig. 3.5-3.7). 
Although the differences in merozoites attachment to the red blood cell membrane were not 
significant, a trend similar to the results of the invasion assay could be detected. The lack of 
significance is observed likely due to a spread of attachment results for each analyzed clone, in 
comparison to quite similar range of values within a clone in case of invasion assay. These differences 
may arise from the fact that attaching merozoites, whose invasion is blocked by the presence of 
cytochalasin D, may detach before fixation, causing a bigger data variation within replicates of the 
same clone. Taking this into consideration, one possible explanation of increased attachment and 
invasion rates could be again linked to changes in lipid profiles. While during the attachment of 
merozoites to the erythrocyte membrane the composition of phospholipids remains relatively 
unchanged, the ratio of unsaturated fatty acids chains to the saturated ones within these 
phospholipids rises significantly (Holz, 1977; Vial et al., 2003; Flammersfeld et al., 2018), changing the 
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membrane fluidity and further facilitating invasion. Interestingly, it has been reported that with 
progression through the parasite’s cell cycle, PC contents decreases, whereas the level of 
unsaturation of fatty acids remarkably increases (Wunderlich et al., 1991). It is therefore tempting to 
speculate that this process might be enhanced in S33A and S33E mutants. Although the differences 
in the lipid saturation state could not be distinguished in metabolomic profiling, one could attempt to 
resolve them via lipidom analysis. 
Taking into account all the observations regarding lipid metabolism in the parasite, a simplified 
model is being proposed towards unravelling the mechanism underlying fitness variation between 
PfCRT S33 mutants (Fig. 4.1). The present model draws attention to the possibility that a kinase 
which phosphorylates PfCRT S33 is also a regulator of a lipid pathway, where it regulates LPLA, either 
directly or by activating another enzyme in PC hydrolysis cascade. Since the S33A mutant lacks a 
phosphorylation site, the activity of the kinase regulating it might be intensified towards the 
phospholipid catabolism pathway. It could potentially lead to upregulation of some of the pathway 
components, ultimately resulting in enhanced hydrolysis of PC and its intermediate degradation 
product LPL to free fatty acids. To test this hypothesis one could compare the relative expression 
levels of LPLA via qPCR and Western Blot. Additionally, this enzyme could be overexpressed in P. 
falciparum Dd2 strain and the resulting transfectants examined for the fitness advantage and for an 
associated increase in merozoites numbers. Alternatively, LPLA could be also targeted with a specific 
inhibitor and tested whether or not it affects parasite invasion.  
 
Figure 4.1. A simplified model illustrating possible changes in parasite’s lipid profile depending on 
PfCRT S33 phosphorylation. Left panel: PfCRT S33 (WT). Right panel: PfCRT S33A. Kinase X – yet 
undefined kinase, PLA – phospholipase A, LPLA – lysophospholipase A, PC – phosphatidylcholine,  
FA – fatty acids, LPL – lysophospholipids, P – phospho-serine 33.  
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The model does not include the involvement of a kinase in generating increased merozoites 
numbers. It is possible that schizont maturation and merozoites invasion are either directly 
stimulated by an indicated kinase, or that responsibility lies on the side of FA hydrolysed from PC, 
which may further modulate the activity of other kinases implicated in control of these processes. 
As the here described phenotype of PfCRT S33 mutants was obtained in the absence of selective 
pressure, it would be interesting to see how these clones behave upon exposure to chloroquine and 
quinine, to develop a full picture of the effect of phosphorylation-defective substitutions on 
parasite’s drug resistance profile. 
To confirm that these findings are not a result of a technical issue, being either a random selection of 
clones exhibiting stronger phenotype among the whole pool of recombinant parasites or potential 
experimental errors, performing the complementation studies could be considered. This would 
comprise the replacement of alanine in S33A mutants back to serine, followed by a comparison of 
the phenotype of such a recombinant strain to Dd2 WT. Alternatively, all the S33 mutants could be 
generated in the chloroquine sensitive and quinine semi-resistant P. falciparum 3D7 strain. Although 
the resistance profile of these mutants might differ remarkably, the fitness variation would rather be 
expected to reflect the observations made in Dd2 strain. Furthermore, since a genetic cross between 
the resistant Dd2 strain and sensitive HB3 has been already performed obtaining a progeny varying 
with regard to resistance profile as well as growth patterns (Sanchez et al., 2014), the sensitive fast 
growers could be selected. A subsequent QTL analysis could potentially identify genes contributing to 
this phenotype.  
One may also wonder why various parasite strains carry a phosphorable serine at PfCRT’s position 33 
(PlasmoDB) if replacing it by alanine seems to be more advantageous. As commonly known, 
laboratory observations do not always reflect the field studies. It is important to bear in mind that by 
increasing invasion rates, the parasite may enhance its virulence, leading to the host death and 
thereby jeopardizing its own survival. 
Many studies have shown that mutations could be beneficial or that the presence of a protein 
critical, albeit, only within a particular parasite stage (Helm et al., 2010; Kenthirapalan et al., 2016; 
Rathnapala et al., 2017). It therefore would be interesting to investigate whether the S33A mutant, 
displaying increased invasion rates, would further increase gametogenesis, and in turn enhancing 
transmission to a mosquito vector, alter the sporogony and finally increase the efficiency of parasites 
in mammalian host. Although the S33A mutant has a fitness advantage in parasite’s blood stage, it 
might be only a stage-specific effect, and a transmission to the subsequent stages might be blocked, 
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as observed for the parasites resistant to atovaquone (Goodman et al., 2016). Such scenario would 
render the kinase phosphorylating PfCRT S33 even more attractive as a drug target.  
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4.2. Functional characterization of PfUT in the parasite’s 
asexual life cycle 
The HECT E3 ubiquitin ligase PfUT is one of the components of the ubiquitination pathway, crucial for 
P. falciparum intraerythrocytic development. It localizes to the membrane of the ER/Golgi complex 
with the N- and C-terminal ends presumably facing the parasite’s cytosol (Sanchez et al., 2014). 
Although several studies have suggested that PfUT might be post-translationally modified by 
phosphorylation (Pease et al., 2013) and acetylation (Cobbold et al., 2016), the functional significance 
of those modifications is so far unknown. The S. cerevisiae homolog, an ubiquitin fusion degradation 
protein 4 (UFD4), is involved in the proteasome-mediated proteolysis of its targets, a nucleotide 
excision repair protein RAD4 (Ju & Xie, 2006) and DNA repair helicase RAD25 (Bao et al., 2015). 
However, the role of PfUT in P. falciparum blood stages and the substrates of this ubiquitin ligase 
remain to be resolved. Furthermore, PfUT has been suggested to play a role in altered responses to 
quinine and quinidine in certain genetic backgrounds (Sanchez et al., 2014). Nevertheless, these 
findings require further validation. The present study was designed to gain a deeper insight into the 
physiological function of PfUT in the parasite’s development, as well as its association with resistance 
to quinine. 
4.2.1. Overexpression of PfUT results in cell cycle lengthening of  
      PfUT-HA-glmS parasites 
Aiming to verify the essentiality of PfUT in P. falciparum blood stages, the glmS ribozyme system was 
applied. Used to conditionally control the pfut expression, this method revealed on the one hand, the 
inefficiency of attempted pfut downregulation, and on the other hand, an increase in PfUT transcript 
correlated with protein levels (Fig. 3.10 and 3.11). An apparent 2-fold overexpression of PfUT 
resulted in an elongation of the cell cycle length of HA-glmS-tagged transgenic line (Fig. 3.17), which 
was further reflected in the impaired growth of these parasites. 
The altered cellular mRNA levels may result either from changes in their transcription efficiency or 
mRNA stability. Transcription factors, which bind to the promoter or enhancer regions of a gene, 
control the rates of mRNA synthesis by either promoting or suppressing the DNA transcription 
(Latchman, 1993). On the other hand, the mRNA stability could potentially be influenced by multiple 
factors, including 5’ mRNA capping (eukaryotes) or just 5’ phosphorylation state (prokaryotes), 
polyadenylation of the mRNA 3’ end, ribosome-mediated protection from RNases, formation of 
secondary structures proximal to the 5’ and 3’ ends or regulatory-protein factors (Liu et al., 1995; 
Grunberg-Manago, 1999; Condon, 2003; Sharp & Bechhofer, 2003; Collins et al., 2007; Schoenberg, 
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2007). As the glmS ribozyme used in the present study is a RNA molecule containing structure 
stabilization domains (chapter 1.4.2) (Lee & Lee, 2017), the herein observed increase of PfUT 
transcript levels could result from its C-terminal tagging with HA-glmS, enhancing mRNA stability of 
the mutant line. Moreover, the expression of GC-rich genes has been shown to be much more 
efficient than of GC-poor ones, containing identical promoters and UTR sequences, and resulted from 
an elevated steady-state mRNA levels of the first ones (Kudla et al., 2006). Therefore, as non-
Plasmodium derived sequences of HA and glmS have notably high GC content (Appendix III.2), their 
presence could likely increase the stability of pfut mRNA. Although due to several biological factors a 
relationship between mRNA and the corresponding cellular protein levels might be poor, in nearly 
80% of instances the variance in protein abundance correlates with underlying mRNA changes (Lee et 
al., 2011; Liu et al., 2016). This also seems to be the case for PfUT-HA-glmS, with a 2-fold increase in 
pfut transcripts reflected by a respective change in PfUT protein levels.  
Despite the fact that the glmS system did not facilitate the efficient downregulation of PfUT, it 
revealed an impaired growth phenotype, presumably due to PfUT’s overexpression. As shown in 
numerous reports, even though the efficiency of conditional systems does not always fulfil the 
expectations, they often display interesting phenotypes. For instance, previous studies revealed a 
phenotype resulting from a complete knockdown (Elsworth et al., 2014; Gabriel et al., 2018) or a 
partial downregulation (Bei et al., 2010; Beck et al., 2014). In contrast, less successful attempts have 
also been reported, including a gene knockout or full downregulation with no detrimental effect on 
the parasite (Cobb et al., 2017; Thériault & Richard, 2017; Wezena et al., 2018), no downregulation 
and no phenotype despite the presence of inducible system (Azevedo et al., 2012) and finally even a 
failure to integrate a tag (Azevedo et al., 2012). These divergent outcomes probably arise from the 
function affiliated to the gene product and its importance for the parasite’s survival or in the most 
unfortunate case, simply to a lack of success in obtaining recombined parasites.  
As discussed in the preceding chapter, an apparent slowed-down growth and reduction of parasite 
multiplication rates may result from the alteration of various aspects of parasitic development, 
including numbers of merozoite generated per schizont, multiple infections of a single erythrocyte or 
the duration of parasite’s replicative cycle. The current study linked the reduced growth of the PfUT-
HA-glmS line with its apparent prolongation of the intraerythrocytic cycle. The growth defect was 
partially rescued by glucosamine treatment, due to a shortening of the cell cycle length. This effect 
can probably be explained by an extension of the S phase in the mutant parasites. Nonetheless, the 
cause of the altered growth may possibly be also attributed to a delay in the transition from G1 to S 
phase. Considering that replication starts around 30 hours post invasion, and that at this stage of the 
cycle the DNA copy number equals one, a delayed duplication of a single nucleus may at first glance 
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escape one’s attention. However, although these differences in doubling time between wild type and 
mutant lines may appear to be non-significant, their relevance cannot be definitively excluded. 
Interestingly, a delayed transition to the mitotic division has been associated with a reduced 
multiplication rate and fitness of artemisinin resistant parasites (Bunditvorapoom et al., 2018). 
Notably, a main determinant of artemisinin resistance is a mutated variant of PfKelch13, a substrate 
adaptor for an E3 ubiquitin ligase (Ariey et al., 2014). PfKelch13 was suggested to play a role in 
regulating ubiquitination (Mbengue et al., 2015) and was recently shown to be implicated in the 
control of DNA replication and repair (Gibbons et al., 2018). Moreover, a comparison of multidrug 
resistant and sensitive strains, Dd2 and HB3, respectively, depicted longer cycle duration, caused by 
extension of ring stage phase, and a decline in merozoite invasion rates in the latter (Reilly et al., 
2007). While the DNA replication phase of PfUT-HA-glmS parasites seems to be extended in time 
leading to delayed egress and, hence, subsequent invasion, the attachment and invasion efficiencies 
were not yet particularly investigated. Nonetheless, the observed decrease in parasite multiplication 
rates might not only be due to cell cycle lengthening but also due to an altered efficiency of 
merozoite attachment or invasion into the red blood cell. Furthermore, in order to address the 
probable differences in timing of DNA replication between the wild type and mutant parasites, the 
bromodeoxyuridine (BrdU) cell proliferation assay could be attempted. This method, based on BrdU 
incorporation to the parasite’s DNA, allows to track undergoing DNA synthesis using an anti-BrdU 
antibody (Claessens et al., 2018; Merrick, 2015). However, since Plasmodium parasites lack an 
enzyme capable of integrating BrdU to the DNA, namely a thymidine kinase, its expression is a 
requirement preceding the assay performance. This approach would clearly indicate not only 
divergences in the DNA replication dynamics, but also a potentially delayed G1 to S phase transition. 
When it comes to phenotypic characterization of the PfUT-HA-glmS parasites, one has to account for 
the overexpressed PfUT variant. A brief screen of PlasmoDB database revealed that PfUT expression 
profiles are relatively low in comparison to other known P. falciparum genes (PlasmoDB), indicating 
that low levels might be sufficient to perform its functions in the asexual life cycle. Therefore, the 
abnormal expression of PfUT is likely to have deleterious effects on the parasite intraerythrocytic 
development, possibly resulting in a decelerated metabolism and in turn a prolongation of the cell 
cycle length, if not directly leading to the parasite’s death. Nevertheless, as shown in numerous 
studies, overexpression of a E3 ubiquitin ligase may have both a conducive or a detrimental effect for 
an organism (Adler et al., 2018; Chen et al., 2017; Ito et al., 2017; Lin et al., 2015; Lu & Legerski, 2007; 
Melgar-Lesmes et al., 2018; Totland et al., 2017). Noteworthy, the overexpression of PfUT’s minimal 
HECT domain (containing E2-binding site and catalytically active cysteine) conferred an increase in 
quinine resistance profile of strains with certain genetic backgrounds, not affecting susceptibility of 
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other ones (Sanchez et al., 2014). Although the growth patterns were not investigated, the results 
suggested that the expression of the HECT catalytic domain does not seem to be toxic for any of 
these parasite stains. Moreover, such an approach does not guarantee the specificity of 
ubiquitination, as a putative substrate binding region localizing to the N-terminus of PfUT is excluded 
from the experimental design. Therefore, to better understand the described here phenotype of the 
PfUT-HA-glmS line, an overexpression of a wild type and a dominant-negative mutant of PfUT should 
be considered, aiming a phenotypic comparison of the obtained transfectants with the HA-glmS 
transgenic parasites.  
The overexpression, ideally of untagged PfUT would help to see whether the effect observed herein 
is only due to PfUT overexpression or if HA-glmS tagging might have affected the conformation, 
structure and/or function of PfUT. To further support this investigation, it would be desirable to 
overexpress a dominant negative PfUT mutant, as by comparison with PfUT-HA-glmS, it would reveal 
whether the phenotype of the latter results only from an increase in PfUT abundance or also due to 
its altered catalytic activity. To verify the possibility of PfUT’s negative dominance, the CRISPR-Cas9 
system was applied to replace an active cysteine by a serine residue, thus inactivating the PfUT’s 
HECT catalytic domain. Failure to recover parasites in three independent trials after around two 
months of drug selection suggests that the cysteine active site might be critical for PfUT’s function 
and its substitution in a likely essential protein lethal to the parasites. However, a technical issue as a 
reason for unrecovered parasites, such as transfection inefficiency, cannot be entirely excluded.  
Due to its prominent size (   460 kDa), a fully functional PfUT cannot be expressed episomally. 
Nevertheless, overexpression of the endogenous PfUT could be achieved, for instance using a 
promoter swapping technique (Kaufmann & Knop, 2011; McCleary, 2009) to replace a native weak 
pfut promoter with another highly active during parasite blood stages. Another possibility includes 
the integration of a drug resistance cassette (such as human dihydrofolate reductase, conferring 
resistance to WR) downstream to the PfUT via a skip peptide. In a fashion analogous to the 
previously described SLI method (Birnbaum et al., 2017), both proteins would be under control of 
pfut’s promoter, albeit, due to the presence of a skip peptide, expressed apart from each other. This 
approach would allow the levels of PfUT expression to be regulated in a drug-dose dependent 
manner. 
Localisation studies using immunofluorescence and immuno-electron microscopy revealed that PfUT-
HA localizes to the ER/Golgi complex, consistent with the localization of this protein in the wild type 
parasites. Therefore, the differences in cell cycle duration are likely to arise from the overexpressed 
PfUT variant modulating the activity of its substrates, being it either degradation or regulatory role.  
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4.2.2. Investigating the biological substrates of PfUT 
Understanding the mechanisms underlying the increase in cell cycle duration requires the 
identification of the proteins targeted by PfUT in the parasite. Addressing this issue by an analysis of 
ubiquitination patterns did not show any obvious differences between the 3D7 WT and PfUT-HA-
glmS parasites. This approach, however, remains quite qualitative and should be addressed in a 
quantitative manner, i.e. by mass spectrometry analysis. Noteworthy, a polyclonal ubiquitin antibody 
(Ub FL-76 from Santa Cruz Biotechnology) used herein for immunoblotting has been discontinued by 
the supplier and replaced by a more specific monoclonal Ub P4D1, stated to provide a stronger 
signal. Therefore, as the antibody quality might have played a role in results obtained in this study, it 
would be worth repeating the experiment with the new recommended version. Moreover, the 
differences in abundance of ubiquitinated proteins may not be apparent under standard cell culture 
conditions, but might be revealed once the parasites are under stress. To test this hypothesis, one 
could conduct an analysis of protein ubiquitination elevated by heat shock or blocked activity of the 
proteasome. Increase of the cell culture temperature e.g. to 42°C or presence of the proteasome 
inhibitor, such as MG132, will surely augment accumulation of ubiquitinated proteins, possibly 
exposing PfUT’s substrates. 
The process of identifying substrates of a ubiquitin ligase encounters various challenging factors, 
including the dynamic nature of protein ubiquitination, weak and/or transient interactions between 
ligase and its substrate, multiplicity of substrates targeted by a single ligase (and vice versa) or the 
rapid degradation of many ubiquitinated proteins (Iconomou & Saunders, 2016). The possibility of 
low substrate abundance as well as a subcellular localization should also be taken into consideration 
before approaching identification of targets of a particular ubiquitin ligase, as they may respectively, 
hinder the identification or reveal false positive substrate-ligase interactions. 
Numerous strategies could be applied in order to identify substrates of PfUT. These include genetic 
screens like yeast two-hybrid (Y2H), protein microarrays or high-throughput quantitative microscopy 
(high-content analysis, HCA), mass spectrometry based-proteomics methods, such as stable isotope 
labelling by amino acids in cell culture (SILAC), various configurations of affinity purification strategies 
(e.g. co-immunoprecipitation, co-IP, or tandem ubiquitin-binding entities, TUBEs), ubiquitin ligase 
trapping and proximity labelling or Gly-Gly (di-Gly) remnant affinity purification, and finally 
integrated approaches combining several of the available techniques (Iconomou & Saunders, 2016). 
Some of these methods have already been attempted for PfUT, whereas others are not even yet 
established for Plasmodium. 
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A compilation of yeast two-hybrid assays conducted in different studies, accessible on PlasmoDB, 
revealed a handful of PfUT-interacting partners. These include proteins critical for egress and/or 
invasion, such as merozoite surface protein MSP-1 and rhoptry neck protein RON2, essential for 
protein export EXP2, several so far uncharacterized proteins associated with transcription or 
translation and a proteasome beta subunit. Interestingly, a recent study has shown that EXP2 
knockdown leads to a reduction of parasite growth and protein export (Charnaud et al., 2018), 
hence, an altered growth of PfUT-HA-glmS line may potentially result from EXP2 being regulated by 
overexpressed PfUT. The same might be true for MSP-1 and RON2, proteins associated with invasion 
and egress events. Although not listed among the hits presented on PlasmoDB, the chloroquine 
resistance marker protein PfCRMP, a putative chloroquine target in the nucleus, was found in a Y2H 
screen conducted by LaCount and colleagues (2005). Noteworthy, potential interacting partners of 
several HECT ubiquitin ligases indicated in various Y2H screens turned out to be their actual targets, 
thus supporting the usage of this method as a reasonable for identification of substrate proteins 
(Mitsui et al., 1999; Traweger et al., 2002). 
Proximity dependent biotin labelling (BioID) is based on the fusion of a protein of interest (POI) with 
a biotin ligase (BirA*) or ascorbate peroxidase (APEX2), which in the presence of biotin will label all 
the proteins directly interacting with or in close proximity to the POI. Biotinylated proteins can then 
be pulled down using streptavidin beads and identified by mass spectrometry. Multiple attempts to 
tag PfUT either with BirA or APEX2 were unsuccessful, possibly due to the size of the fusion proteins. 
Nevertheless, taking advantage of already generated HA-tagged PfUT, a co-immunoprecipitation 
coupled to mass spectrometry (co-IP-MS) analysis will be carried out in the near future. Moreover, 
the earlier mentioned diGly proteomics of ubiquitin-enriched proteins is also considered for future 
investigations. Conducting both methods will hopefully reveal targets of PfUT and, hence, unravel the 
mechanisms underpinning the herein described phenotype of PfUT-HA-glmS parasites. Alternatively, 
one could make use of an already overexpressed variant of PfUT in HA-glmS transgenic line, which is 
required for another affinity purification-based strategy, aiming to identify the E3 ubiquitin ligase 
substrates. This approach exploits the labelling of substrates with His-tagged ubiquitin followed by 
their pull down and a quantitative proteomic comparison of protein ubiquitination in wild type 
versus overexpressed ligase variants (Song et al., 2011). Proteins identified by mass spectrometry, in 
case of PfUT overexpression, would display enhanced incorporation of His-tagged ubiquitin in 
comparison to its WT variant, being likely substrates of this ubiquitin ligase.  
The majority of protein-protein interaction networks will generate a list of upstream and 
downstream candidates, either mediating PfUT’s function or being regulated by this ubiquitin ligase, 
respectively. Therefore, aiming to identify particularly the substrates of PfUT, enrichment of 
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ubiquitinated proteins, for example by means of TUBEs (Mata-Cantero et al., 2016) is desired and will 
be applied in future investigations. Furthermore, while identified in one of the above approaches 
interacting proteins will represent potential substrates of PfUT, their status as a “target protein” may 
require further validation, for example by co-IP followed by western blot analysis, 
immunofluorescence co-localization studies or in vitro ubiquitination assays. 
The chloroquine resistance transporter PfCRT has been previously indicated as a potential substrate 
of PfUT, since both, although in particular genetic backgrounds, were associated with altered quinine 
and quinidine responses (Sanchez et al., 2014). This observation was further supported by the finding 
that PfCRT traffics to the digestive vacuole membrane via ER/Golgi complex (Kuhn et al., 2010). 
Contrary to expectations, the western blot analysis conducted in the current study displayed no 
differences in PfCRT protein abundance between the wild type and the overexpressed PfUT variant, 
regardless of glucosamine presence (Fig. 3.19). Nevertheless, one cannot rule out the possibility that 
the overexpression of PfUT does not affect PfCRT, whereas its reduced levels would. Since 
resistances to chloroquine or quinine have multifactorial natures, a mutational change or altered 
abundance of any of the resistance mediators may imbalance the relevant gene combinations. This, 
however, does not necessarily mean that all the components directly interact with each other; they 
may instead form a cascade of dependencies or potentially even reflect a cumulative effect of 
independent pathways. Moreover, although PfCRT was shown to be ubiquitinated by PfUT’s HECT 
domain in an in vitro ubiquitination assay, so were the immunoglobulins present in the assay due to 
elution conditions (Sanchez et al., 2014). This indicates a potentially unspecific reaction, likely arising 
from usage of solely the overexpressed HECT domain lacking a putative substrate binding site, 
instead of the whole fully functional PfUT. On top of that, one need to keep in mind that in vitro 
ubiquitination does not account for a cellular context, such as subcellular localization, mediation of 
posttranslational modifications or feedback regulation by deubiquitinating enzymes. Therefore, 
although it is possible that PfCRT is specifically targeted by PfUT, the aforementioned results have to 
be taken with caution. Furthermore, the same study of Sanchez and colleagues (2014) showed 
somewhat contradictory results regarding requirement of mutated variants of PfCRT and PfUT in the 
resistance of respective strains. While overexpression of mutant PfCRT in selected strains, bearing 
PfUT resistance alleles led to their increased susceptibility to quinine and quinidine, the presence of 
mutated variants of both genes in a group of analyzed field isolates and laboratory strains was 
associated with an opposite effect, namely an increase of quinine IC50 values determined for these 
parasites (Sanchez et al., 2014). This might indicate that not only PfUT and PfCRT are required for 
quinine resistance and that interaction of one of these two with another resistance mediator, rather 
than their interaction with each other, influences the parasite’s sensitivity to quinine. A possible 
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cause of the observed differences in drug responsiveness of the analyzed strains has been related to 
a genetic variation found within a segment on chromosome 13 (Sanchez et al., 2014). The suggested 
region may contain one or more quinine resistance mediators, and although they are yet undefined a 
potential substrate of PfUT might be found among them. However, with so many uncertainties, at 
the moment the clear conclusions in this regard cannot be drawn. 
Given that the overexpression of PfUT affects the length of the cell cycle of HA-glmS transgenic line, 
it is likely that among the substrates of this ubiquitin ligase one will find proteins involved in the 
control of parasite proliferation and cell cycle progression. Among the known regulators of these 
processes are cyclins, encoded by pfcyc1-4 genes, as well as activated by them cyclin-dependent 
protein kinases (CDKs) and CKD-related kinases (CRKs) (Le Roch, 2003; Matthews et al., 2018). 
Interestingly, PfCYC1, an activator of a protein kinase 5 PfPK5 and a MO15-related kinase PfMRK, was 
shown to be critical for parasite proliferation (Robbins et al., 2017), whereas PfCYC3, another 
modulator of PfPK5 activity, was shown to be involved in the regulation of DNA replication initiation 
(Roques et al., 2015). Moreover, dormancy of artemisinin resistant parasites resulting from a 
prolongation of their ring phase through a delayed G1/S phase progression, was shown to be linked 
to a downregulation of PfCYC1 and PfCYC3, as well as of kinases activated by them, namely PfMRK 
and PfPK5 (Gray et al., 2016). Furthermore, it has been reported that PfPK5 is critical for both 
activation and maintenance of parasite’s S phase (Graeser et al., 1996). Other possibilities include 
cdc-2 related kinases PfCRK1, PfCRK3 and PfCRK4, as they were shown to have a crucial role for 
parasite growth and proliferation (Ganter et al., 2017; Halbert et al., 2010; Iwanaga et al., 2013). 
Among non-cyclin/CDK regulators of the cell cycle with a potential of being targeted by PfUT, one 
could consider plant-like calcium-dependent protein kinases (CDPKs), such as PfCDPK5 (Absalon et 
al., 2018) and PfCDPK7 (Kumar et al., 2014), the disruption of which has been associated with the 
blocked egress and altered proliferation, respectively. Another possible target could be a cyclic GMP-
dependent protein kinase PfPKG, as it has been proven to play a crucial role in parasite egress and 
invasion (Alam et al., 2015; Ganter et al., 2017). A eukaryotic elongation factor 1A (eEF1A) could also 
be considered, as its knockout in P. berghei blood stages revealed associated with the G1 phase 
increase of the parasite cycle length of up to 4 h (Janse et al., 2003). Another interesting PfUT’s 
substrate candidate might include the already mentioned in the preceding chapter dipeptidyl 
aminopeptidase DPAP3, shown to be important for parasite proliferation and merozoite invasion 
(Lehmann et al., 2018). The findings from other studies summarized here do not explain the 
mechanisms underlying the phenotype of PfUT-HA-glmS parasites, but highlight candidate proteins 
and biological processes which could be further examined using genetic manipulation methods. 
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Intriguingly, the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database 
containing known and predicted protein-protein interactions, depicted in the network of PfUT, apart 
from a few components of a ubiquitin proteasome system, a plasmodial homologue of cell division 
cycle 48 (CDC48) (PFF0940c/PF3D7_0619400) and a DNA repair protein RAD23 
(PF10_0114/PF3D7_1011700) (Appendix I, Fig. I.2), the alteration of which could potentially affect 
parasite proliferation. CDC48 is associated with the ERAD pathway AAA-type ATPase, suggested to 
play degradative and regulatory roles in many processes, as well as to maintain the cellular 
homoeostasis (Chung et al., 2012; Imamura et al., 2012; Ponts et al., 2008a; Wang et al., 2015). 
Notably, in yeasts, CDC48 has been shown to be involved in the degradation of critical cell cycle 
regulators (Ye, 2006). RAD23 has been characterized as a linker of DNA repair and the 
ubiquitin/proteasome pathways, as it belongs to a nucleotide excision repair (NER) pathway (Gupta 
et al., 2016), but is also known to shuttle polyubiquitinated proteins to the 19S regulatory subunit of 
the proteasome (Kirkpatrick et al., 2005; Wang et al., 2015). A validation of these two proteins as 
substrates of PfUT, for instance via Western Blot and IFA, might be worth considering. 
Another important finding might be a potential involvement of PfUT in tryptophan metabolism, with 
a special focus on biosynthesis of its derivative, indole-3-acetate, as suggested by MetaCyc Metabolic 
Pathway and KEGG (Kyoto Encyclopedia of Genes and Genomes) databases. It has been reported that 
various tryptophan-derived indolamines regulate the P. falciparum cell cycle by increasing the levels 
of cytosolic calcium (Beraldo & Garcia, 2005). Presence in the parasite culture medium of one of 
them, melatonin, as well as of its precursors, substantially increased maturation of young stages into 
schizonts followed by enhanced parasite invasion rates. Furthermore, melatonin was shown to 
activate phospholipase C (PLC), which generates inositol triphosphates (IP3) and in turn opens ER-
localized IP3-sensitive calcium channels (Alves et al., 2011). The localization nearby the ER and a high 
likelihood of the cell cycle progression being regulated by this process prompts to speculate, that 
overexpressed PfUT reduces the levels of some of the tryptophan derivatives, in turn leading to 
slowed-down parasite maturation and decreased invasion efficiencies. To test this hypothesis, the 
cytosolic levels of calcium could be compared in WT and HA-glmS parasites, which one would expect 
to be decreased in the mutant line. Alternatively, a metabolomic analysis could be conducted. 
Noteworthy, the process described here associates lipid metabolism with the observed phenotype of 
PfUT-HA-glmS, which as suggested earlier could also be involved in the increased fitness of PfCRT S33 
mutants. As in the case of an aforementioned phospholipid, namely phosphatidylcholine, a 
phospholipase A (PLA) facilitates the hydrolysis of phosphatidylinositol (PI) to 
lysophosphatidylinositol (LPI), which can be further processed to inositol and fatty acids (FA) by 
lysophospholipase A (LPLA) (Hurley & Mccormick, 2008), much like in the case of the aforementioned 
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phosphatidylcholine (compare with Fig. 4.1 found in chapter 4.1.2). Thus, PfUT and PfCRT might be 
linked through the lipids catabolism pathway. This might possibly explain the dependency of the 
quinine resistance profile on the presence of mutant versions of both these genes. It is also worth 
mentioning that IP3 is a hydrolysis product of phosphatidylinositol bisphosphate (PIP2), which when 
phosphorylated by a phosphatidylinositol-3-kinase (PI3K) appears as phosphatidylinositol 
trisphosphate (PIP3). In turn, in the artemisinin resistant P. falciparum increased levels of PfPI3K and, 
hence, its product PIP3 were associated with a mutated variant of Kelch13 (a substrate adapter for a 
yet unidentified Cullin-RING E3 ubiquitin ligase), which mediates a reduction of the degradative 
polyubiquitination of PfPI3K (Coppée et al., 2018; Mbengue et al., 2015; Ng et al., 2017). Taken 
together, the information referred to in this paragraph suggest that regulation of the phospholipids 
synthesis and turnover might have a critical role for the parasite susceptibility to various antimalarial 
drugs.  
Once the substrates of PfUT are identified, it will be of interest to determine the site of 
ubiquitination as well as the type and topology of ubiquitin chain linkages generated by PfUT. Some 
of the above exemplified methods may address this issue within the scope of the conducted 
approach (such as diGly proteomics), whereas the other ones will need additional effort. A variety of 
antibodies is available on the market, facilitating recognition of either diGly remnants (Lys-ε-Gly-Gly) 
produced by trypsin digestion (Kim et al., 2011; Wagner et al., 2011) or whole polyubiquitin chains 
(Matsumoto et al., 2010; Newton et al., 2008). Different polyubiquitin chain types are recognized by 
ubiquitin-binding-domains (UBDs) of distinct proteins and targeted to specific signalling pathways 
(chapter 1.3.3). For example, PfUT’s substrates displaying lysine 48-linked polyubiquitin chains would 
indicate the role of this ubiquitin ligase in the proteasomal degradation, whereas, polyubiquitination 
through lysine 63 would suggest its involvement in non-degradative cellular processes, such as kinase 
activation, DNA damage tolerance, signal transduction or endocytosis (Hamilton et al., 2014; 
Suryadinata et al., 2014). 
4.2.3. PfUT is likely essential for P. falciparum blood stages 
The efficiency of the conditional glmS ribozyme system applied in the current study turned out to be 
below the expectations resulting on average in 40% and 70% downregulation of PfUT upon 
glucosamine exposure, as evaluated via anti-HA and anti-N-terminal PfUT staining, respectively. 
Although for various proteins such incomplete knockdown might be already sufficient to conclude 
about its importance for the parasite, in case of overexpressed PfUT, it only brings us close to the 
abundance levels of its wild type variant. Addressing this issue an alternative gene disruption 
strategy called SLI-TGD revealed that pfut was refractory to truncation. Such finding, according to the 
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designers of the system, is an indication of PfUT being likely essential (Birnbaum et al., 2017). 
However, a definite proof of PfUT indispensability is still missing and could be approached either 
chemically or via genetic engineering. While a non-genetic method to inactivate PfUT using selective 
inhibitors may seem to be straight forward, finding specific inhibitors exclusively targeting PfUT could 
be challenging. An interesting alternative appears to be a selective chemical labelling using 
Fluorophore-Assisted Laser Inactivation (FALI) technique, though it is not yet established in 
Plasmodium (Marks et al., 2004). Despite the fact that genetic manipulations may uncontrollably 
alter protein localization or function, as seen on the example of HA-glmS transgenic line, an 
implementation of another available conditional knockdown strategy (chapter 1.4.2) seems to be 
reasonable for controllable downregulation of PfUT, permitting to link the phenotype to the protein 
abundance. Alternatively, improvement of the glmS ribozyme strategy could be attempted to achieve 
more pronounced downregulation levels. As shown in Fig. 3.9, glucosamine concentration could not 
be increased over 5 mM, because of its toxicity for the parasite. However, one could consider an 
exchange of the glmS ribozyme by another riboswitch from the inducible self-cleavage ribozymes 
class (Felletti et al., 2016; Lee & Lee, 2017). Moreover, incorporation of double- or triple-tandem 
riboswitches may substantially improve the regulation of gene expression, likewise it occurs naturally 
in such multiple form in Bacillus thuringiensis (Zhou et al., 2016). Furthermore, for all likely essential 
genes according to the SLI-TGD, authors of the selection-lined integration (SLI) approach suggest to 
conduct their further functional analysis using knock sideways (KS) strategy (Birnbaum et al., 2017). 
KS relies on mislocalization of native proteins to another subcellular compartment via rapalog-
induced dimerization of FRB* and FKBP fusion proteins (Birnbaum et al., 2017). 
A functional genomics study conducted by the research group of Dr. John Adams, based on the 
piggyBac transposon-mediated mutagenesis of the P. falciparum genome characterized PfUT as a 
gene dispensable for asexual blood-stage development (Zhang et al., 2018). The analysis was based 
on the mutagenesis index score (MIS) depending on the number of identified piggybac insertions 
relative to the possible target sites within a particular gene, and a mutagenesis fitness score (MFS) 
defining the mutant’s growth fitness. While high MIS and low MFS qualifies mutant PfUT as a 
“growth winner” in the additionally performed in vitro growth screen, the herein described alteration 
of PfUT expression clearly revealed a contrary effect. Furthermore, according to their analysis 
essential genes have significantly enhanced expression levels throughout the intraerythrocytic cycle 
and their gene ontology (GO) functions are associated among others with cell cycle control, DNA 
replication, ER-associated ubiquitin-dependent protein catabolism or response to drugs. This 
contrasts the aforementioned findings that PfUT has relatively low and homogenous expression 
levels, with the data presented herein suggesting that it might be involved in cell cycle regulation. At 
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the same time, another study performed in P. berghei annotated PfUT as likely essential for asexual 
blood stage growth, based on the growth rates measurement of barcoded knockout mutants (Bushell 
et al., 2017). Nevertheless, a rodent malaria model does not necessarily reflect the observations 
made in a human pathogen, as Plasmodium harbours species-related differences in the genome 
(Frech & Chen, 2011). Given that P. falciparum encodes three other HECT ubiquitin ligases 
(PF3D7_0628100, PF3D7_0826100, PF3D7_1119400) and approximately 50 E3-type or E3-like 
enzymes (Hamilton et al., 2014), they might potentially be capable of maintaining the ubiquitin-
mediated cellular homeostasis in case of PfUT’s absence. Hence, one cannot rule out the possibility 
that PfUT might not be essential for parasite’s survival, yet still playing a crucial role in its 
development. 
Another aspect potentially indicating the importance of PfUT for the parasite’s intraerythrocytic life 
cycle concerns difficulties in terms of its genetic manipulation. Despite multiple attempts to diversely 
modify either the N- or C-terminus of PfUT (Appendix I, Fig. I.5), only the incorporation of a small HA-
tag was successful. Inability to inactivate PfUT’s HECT catalytic domain may further support the 
relevance of this ubiquitin ligase to be fully functional for parasite’s viability. Nonetheless, it might 
not necessarily point to PfUT’s indispensability, but instead be linked to the technical bottlenecks of 
working with P. falciparum. On the one hand, parasite genome with an AT content of 80.6% (Gardner 
et al., 2002) makes genetic engineering challenging and prone to errors. Another limitation includes 
the availability of the fully sequenced P. falciparum genome only for the 3D7 strain, restricting the 
design of efficient guide RNAs and instead increasing the risk of possible off-target sites of RNA-
guided Cas9 endonuclease in other parasite strains. Presumably, this might be a reason why the HA-
glmS recombination was possible in the 3D7, but not in Dd2 strain, despite multiple attempts. In any 
case, one cannot rule out with complete confidence the possibility that the issue lies in parasites’ 
genetic background carrying either the wild type or mutant PfUT variant, and alteration of the latter 
might be potentially more harmful for the drug resistant parasite, such as Dd2. Furthermore, 
efficiencies of the available transfection methods remain relatively low, representing a serious 
limitation for the successful genetic engineering-based experiment (Hasenkamp et al., 2012; Skinner-
Adams et al., 2003). Although there is no universal rule regarding the number of gene truncation 
trials, which permit definitive conclusions about protein’s indispensability, the reliance solely on 
inability to delete or disrupt a gene is a relatively poor indicator of its essentiality. Therefore, another 
attempt to conditionally downregulate PfUT appears to be desired for an unambiguous conclusion 
with respect to its significance for the parasite. 
Based on PfUT interacting networks, it seems that the function of PfUT might be associated with the 
ERAD pathway and proteasomal degradation. However, the prominent size of the protein and the 
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fact that it is being post-translationally modified may indicate that PfUT has multiple, yet undefined 
roles. For example, a recently reported activity-based profiling of mammalian E3 ligases revealed one 
with an esterification activity (Pao et al., 2018). Interestingly, this particular E3 ligase displayed 
threonine selectivity and even contained two catalytic cysteines involved in thioester intermediate 
formation. Such an activity-based protein profiling has been already approached in P. falciparum, as 
shown on the example of PfUCH54, for which deubiquitinating and deneddylating activities were 
found (Artavanis-Tsakonas et al., 2006). Therefore, one could also consider attempting this technique 
to unravel the potential activities of PfUT. 
4.2.4. Association of PfUT with resistance to quinine and quinidine 
PfUT has been previously suggested as a novel candidate gene of multifactorial resistance to QN, as it 
altered responses to this drug in parasite strains bearing mutated PfCRT background (Sanchez et al., 
2014). Although P. falciparum 3D7 carries PfCRT sensitive alleles, it still shows a semi-resistance 
profile with regard to quinine. To that end, the PfUT-HA-glmS line was tested for responses to 
various quinoline drugs, revealing increased susceptibility to QN and QD, not affecting the CQ 
control. Given that QN targets the mature trophozoites and that the S phase of the PfUT-HA-glmS 
line is extended, it seems reasonable to observe an increased susceptibility of these parasites, as the 
drug had more time to act on their late stage forms. On the other hand, bearing in mind that QN 
blocks the haemoglobin detoxification pathway causing specific oxidative stress, in parasites with 
likely imbalanced homeostasis due to PfUT overexpression, QN might have even more pronounced 
toxic effect. Nonetheless, if the presence of QN increases protein oxidation, so does CQ, which also 
prevents hemozoin biocrystallization. Thus, the PfUT-HA-glmS parasites should also exhibit increased 
sensitivity towards CQ, yet they do not. However, in case of average IC50 values at 10 nM the 
potential differences might be just difficult to detect. To test whether the observed differences in 
quinine responsiveness between WT and HA-glmS lines result from the prolonged drug-parasite 
contact or if it is rather a response of enhanced environmental toxicity, the measurements of IC50 
values could be repeated including a drug from other than the quinolines class of antimalarials. It 
would be beneficial not only to select a drug to which resistance is determined by a particular gene 
unlikely to be involved in responses to QN, but at the same time displaying higher IC50 values for a 
transparent interpretation of results. No differences observed for additionally tested compounds 
might suggest that the observed herein phenotypic drug susceptibility of HA-glmS transgenic line is 
linked to the elongated exposure of late stage parasites to the drug. 
For definitive proof of PfUT being implicated in resistance to quinine, an allelic exchange should be 
approached. Replacement of the five conserved polymorphic residues within PfUT (chapter 1.3.3, Fig. 
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1.9) in the resistant Dd2 strain by the sensitive alleles from 3D7 strain, followed by analysis of the 
drug responsiveness profiles of these mutants could possibly validate whether or not this HECT 
ubiquitin ligase is associated with resistance to the mentioned quinoline drug. Multiple CRISPR-Cas9-
mediated attempts to generate allelic exchange mutants were unsuccessful, likely due to potential 
RNA-guided off-target effects in the Dd2 strain, for which the genomic sequence is not fully resolved. 
An alternative method for the identification of drug resistance determinants may be the in vitro 
development of resistance forced by a gradual increase of drug pressure in the parasite culture 
(Menard et al., 2015; Nzila & Mwai, 2010; Oduola & Bowdre, 1988; Witkowski et al., 2009). The 
progress of the resistance rising due to the emergence of adaptive mutations could be monitored via 
IC50 measurements. Whole genome sequencing would then reveal the genes associated with the 
notably reduced drug susceptibility, which might include factors commonly found in field isolates, 
but also genes so far not linked to the drug resistance profile. Although the development of a quinine 
resistant line has been attempted in P. falciparum Dd2 strain, it did not prove successful. In fact, the 
increase of the quinine IC50 values has been observed along with the applied pressure, but parasite 
freezing-thawing events (required, for example, after unfortunate culture contamination) revealed a 
significant drop in the quinine response, almost to the initial levels, which raised again upon 
exposure to high QN doses (Appendix I, Fig. I.6). Interestingly, parasites under treatment seemed to 
grow slower than the untreated control culture, yet still appeared morphologically healthy despite 
the applied concentration of the drug (data not shown). This might be an indication of adaptive 
epigenetic changes driving parasite’s survival under pressure, rather than the development of 
mutations. Several reports have demonstrated that P. falciparum is capable of directing 
transcriptional responses as an adaptation to changing environmental conditions (Merrick & 
Duraisingh, 2010; Rovira-Graells et al., 2012) and that it maintains the epigenetic memory to ensure 
its survival (Chookajorn et al., 2007; Voss et al., 2014). Therefore, it could be interesting to conduct a 
transcriptomic analysis of these quinine pressured parasites aiming to identify factors responsible for 
their intriguing phenotype. If PfUT is indeed associated with quinine resistance then this analysis 
could potentially reveal one of PfUT’s interacting partners. As aforementioned, the experiment was 
carried out using a Dd2 strain as a “baseline“, bearing mutated variants of PfCRT and PfUT and 
displaying moderate levels of quinine resistance. Numerous studies have shown that strains already 
resistant to at least one drug are more amenable to give rise to the resistance to another drug (Nzila 
& Mwai, 2010). Hence, for future investigations, one could consider to use a parasite strain with 
resistance already developed but against a drug other than quinine. 
It has just recently been revealed that quinine targets a component of the P. falciparum purine 
salvage pathway, a purine nucleoside phosphorylase PfPNP (Dziekan et al., 2019). Since in various 
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organisms PNP is also involved in nicotinate and nicotinamide metabolism (MetaCyc and KEGG 
databases), which in turn is associated with tryptophan metabolism, theoretically there might be an 
indirect connection between the PfUT and PfPNP, so that the PfUT-mediated alteration of this 
pathways could potentially assure parasite’s resistance to quinine. It has been suggested that P. 
falciparum nicotinamide adenine dinucleotide (NAD+) pathway relies on the uptake of exogenous 
nicotinic acid and nicotinamide, which in most eukaryotes are biosynthesized from tryptophan 
(O’Hara et al., 2014). Nevertheless, the NAD metabolism is not yet fully understood in P. falciparum, 
and since resistant parasites have been shown to maintain enhanced metabolic flexibility (Carey et 
al., 2017), it is possible that the parasite contains a parallel biosynthetic pathway, which is utilized 
differently by sensitive and resistant parasites. 
Apart from the previously mentioned alteration of the cell cycle G1 phase and Kelch13-mediated 
increase of PIP3 levels, resistance to artemisinin is also associated with an upregulation of genes 
encoding unfolded protein response (UPR), including arrest of protein translation, increased 
production of chaperons and degradation of unfolded and misfolded proteins (Dogovski et al., 2015; 
Mok et al., 2015). Resistance to quinine might be likewise associated with an increased ability to 
manage oxidative stress and alteration of the genes involved in cell cycle regulation. PfUT could 
potentially play a role in mediating the resistance, as indicated by similarities of the cellular 
processes implicated in reduced artemisinin susceptibility and the ones influenced by PfUT. PfUT 
seems not only to control the cell cycle progression and the levels of indole-derivative indirectly 
regulating production of IP3, but its localization at ER/Golgi suggests that it might be also implicated 
in modulation of ER homeostasis via UPR. Along the same lines, PfUT partially colocalizes with 
proteins belonging to the UPR pathway, namely BiP and ERC (Fig. 3.13), which were upregulated in 
artemisinin resistant parasites (Mok et al., 2015; Paloque et al., 2016). To investigate these 
speculations one could challenge the quinine resistant parasites (e.g. Dd2 or an in vitro developed 
resistant strain) with compounds causing oxidative damage and inducing ER stress, such as H2O2 and 
DTT, respectively (Rocamora et al., 2018). If the mechanism underlying quinine susceptibility is 
indeed associated with stress responses to the oxidative damage and the UPR, then these parasites 
should also reveal resistance to the mentioned inhibitors. 
Unravelling the importance of PfUT for the parasite development as well as its contribution to the 
quinine resistance might make PfUT an interesting drug target candidate. A drug therapy consisting 
of quinine combined with a PfUT inhibitor could potentially preserve an application of this valuable 
antimalarial drug. 
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5. Conclusion 
This project was undertaken to evaluate the impact of phosphorylation and ubiquitination on the 
intraerythrocytic development and drug susceptibility of the human malaria parasite P. falciparum.  
Phosphorylation of PfCRT’s serine 33 has been shown to regulate the drug resistance-mediating 
function of this transporter. A natural progression of this work is to identify the kinase implicated in 
this phenomenon. Provided that the defined kinase exhibits no homology to human enzymes or at 
least distinct binding sites for potential inhibitors, it could be a valuable target of antimalarial agents. 
Combination therapy comprising the kinase inhibitor and chloroquine or quinine could potentially 
reduce or prevent the further spread of resistance to these valuable drugs.  
The second major finding concerns the PfUT-mediated regulation of the parasite cycle progression. 
Nevertheless, a comprehensive understanding of the mechanisms underpinning the cell cycle 
lengthening of the transgenic PfUT-HA-glmS line requires identification of natural substrates of PfUT. 
Such an investigation might also reveal other cellular functions of this prominent HECT E3 ubiquitin 
ligase. Although mutant parasites displayed altered responses to quinine and quinidine, a direct 
proof of PfUT’s association with the reduced susceptibility to these quinolines requires further 
efforts. Nonetheless, given the importance of the ubiquitin-proteasome pathway in controlling 
fundamental aspects of P. falciparum biology, its components, including PfUT, are appealing targets 
for malaria therapeutic intervention.  
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Appendix I: Supplementary figures 
 
 
 
Figure I.1. STRING protein-protein interaction network depicted for PfCRT. Colourful nodes 
represent interacting partners of PfCRT (central, red) in P. falciparum. Filled nodes indicate proteins 
for which 3D structure is known or predicted. Line thickness indicates the strength of data support. 
Adapted from www.string-db.org.  
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Figure I.2. STRING protein-protein interaction network depicted for PfUT. Colourful nodes 
represent interacting partners of PfUT (central, red) in P. falciparum. Filled nodes indicate proteins 
for which 3D structure is known or predicted. Line thickness indicates the strength of data support. 
Adapted from www.string-db.org.  
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Figure I.3. Western blot analysis of PfUT-HA-glmS. A full, uncropped view of western blot membrane 
fragments depicted in Figure 3.11.A (chapter 3.2.1.3). A. Top bands represent labelling with N-
terminal anti-PfUT antibody. Bottom bands indicate staining with anti-α-tubulin. B. Top bands 
represent labelling with anti-HA antibody. Bottom bands indicate staining with anti-α-tubulin. C. Top 
bands represent labelling with C-terminal anti-PfUT antibody. Bottom bands indicate staining with 
anti-α-tubulin. 
 
 
Figure I.4. Growth inhibition assays of 3D7 wild type and PfUT-HA-glmS parasites in the presence of 
2.5 mM GlcN. Half-maximal inhibitory concentrations (IC50) were determined for chloroquine (CQ, 
control drug), quinine (QN) and quinidine (QD, stereoisomer of QN). Each symbol represents an 
independent biological replicate. A thick black line indicates the mean value of each data set in a box 
plot analysis. The differences between the data sets consisting of 3-4 independent measurements for 
each clone were not significant according to One Way ANOVA Holm-Sidak. 
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Figure I.5. Modifications attempted in PfUT. HA-hemagglutinin tag; glmS ribo – glmS ribozyme; 
HECT* - HECT catalytic domain with replacement of cysteine active site by a serine residue; BirA – 
biotin ligase; myc – myc tag; APEX2 - ascorbate peroxidise; AlEx – allelic exchange of conserved 
polymorphic residues in resistant PfUT by their sensitive alleles; GFP – green fluorescent protein tag; 
Neo-R – neomycin resistance gene; * - stop codon. 
 
Figure I.6. Effect of the stepwise increase of quinine pressure on drug susceptibility of P. falciparum 
Dd2 strain. Above graph displays results of a representative culture flask (out of the initial pool of 8 
that were cultivated in parallel), showing the strongest response to the increasing drug pressure over 
time. Susceptibility of parasites was determined by measuring IC50 values for quinine (QN), quinidine 
(QD), along with chloroquine (CQ) as a control. Each symbol represents a mean ± SD of 2-5 IC50 
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determinations. Dashed lines signify the measurements conducted within a week after parasites’ 
freezing and thawing (F/T). Initially, with the stepwise increase of QN concentrations, similar 
increases in IC50 values for both QN and QD have been observed, indicating that the parasites are 
adapting to the applied drug pressure. Parasites freezing and thawing (e.g. after culture 
contamination) led to a decrease in IC50 values, indicating that previously observed changes do not 
arise from adaptive mutations but rather some reversible epigenetic mechanisms, which allow 
parasites to acquire and revert from drug resistant phenotypes. 
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Appendix II: Plasmid maps 
CRISPR-Cas9 plasmids 
 
Figure II.1. pUF1-Cas9 encoding the Cas9 endonuclease. The sequence of Cas9 is flanked by nuclear 
localization signals (NLS) and its expression is regulated by the promoter region of heat shock protein 
86 (5’ hsp) and 3’UTR region of the P. berghei dihydrofolate reductase (3’ Pb dhfr). Upon transfection 
the plasmid is selected using yeast dihydroorotate dehydrogenase marker (ydhodh), conferring 
resistance to DSM1. The plasmid was kindly provided by Dr. José Juan Lopez Rubio (Ghorbal et al., 
2014). 
 
Figure II.2. pL6-HA-glmS-based constructs for PfUT downregulation. The plasmid contains the 
sequences of triple hemagglutinin (3xHA tag) and glmS ribozyme integrated into the backbone. Left 
and right homology regions of pL6-PfUT-HA-glmS-UTR (A) were amplified with primers 1-2 and 3-4, 
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cloned into the vector using enzymes SpeI-BssHII and NarI-AflII, respectively. pL6-HECT-C2S-HA-glmS-
UTR (B) was generated by replacing the left homology region in pL6-PfUT-HA-glmS-UTR with a DNA 
fragment amplified using primers 12-13. Expression of guide RNA is regulated by the promoter and 
the 3’UTR region of the P. falciparum U6 small nuclear RNA polymerase III (5’ U6). The original pL6 
vector was digested with the enzyme BtgZI and the guide RNA 1 (primers 5 and 6, chapter 2.1.5.6) 
was cloned into the pL6 vector using the In Fusion cloning technology. The plasmid is selected using 
human dihydrofolate reductase marker (hDHFR), whereas the negative selection is carried out by 
means of bifunctional yeast cytosine deaminase and uridyl phosphoribosyl transferase (FCU). The 
original pL6 plasmid was kindly provided by Dr. José Juan Lopez Rubio (Ghorbal et al., 2014). 
 
Figure II.3. pL6-PfUT-BirA-myc-UTR. The construct was generated by replacing the HA-glmS 
sequence from the pL6-PfUT-HA-glmS-UTR with a sequence encoding a biotin ligase (BirA) fused to 
triple Myc-tag (primers 15-16) using enzymes BssHII and NarI.  
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Figure II.4. pL6-B-based plasmids for N-terminal BirA fusion (A) and allelic exchange (B). The pL6-B 
is a modified version of pL6 in which FCU K7 cassette is removed and a U6 cassette is shortened. A. 
pL6-B-UTR-BirA-myc-PfUT. A sequence of BirA-myc was amplified using primers 33 and 34, and 
cloned into the pL6-B using enzymes AflII and NotI. Left and right homology regions of pL6-PfUT-HA-
glmS-UTR (A) were amplified with primers 29-30 and 31-32, cloned into the vector using enzymes 
SpeI-AflII and NotI-SacII, respectively. The guide RNA 4 was amplified using primers 35 and 36. B. 
pL6-B-AlEx was generated by cloning of the PfUT allelic exchange fragment (AlEx), aiming to replace 
the resistant alleles by sensitive ones using enzymes AflII and SacII. The AlEx mutagenesis was carried 
out using primers 21-24. The guide RNA 3 was amplified using primers 25 and 26. The pL6-B plasmid 
was kindly provided by Dr. José Juan Lopez Rubio (Ghorbal et al., 2014), designed jointly with Marcus 
Lee (Sanger Institute). 
 
SLI plasmids 
 
 
Figure II.5. pSLI plasmids for BioID (A) and gene disruption (B). The PfUT homology region (HR) in 
pSLI-PfUT-APEX2 (A) was amplified with primers and cloned using enzymes NotI and MluI. An 
ascorbate peroxidase (APEX2) fused to triple Myc (3xMyc tag) is separated from the HR with a linker. 
The N-terminal PfUT fragment in pSLI-TGD-PfUT (B) was amplified using primers 17 and 18 and 
cloned to the vector using enzymes NotI and MluI. Selection of pSLI construct is carried out using 
human dihydrofolate reductase marker (hDHFR), conferring resistance to WR99210. The parasites 
which integrated the plasmid (“integrants”) are selected with the neomycin phosphotransferase 
resistance marker (Neo-R), conferring resistance to G418. The Neo-R is separated from the fusion 
protein (APEX2 or GFP) with a T2A skip peptide. The pSLI-APEX2 plasmid was kindly provided by Dr. 
Markus Ganter. The pSLI-TGD plasmid was kindly provided by Dr. Tobias Spielmann (Birnbaum et al., 
2017).  
 
     
147 
Appendix III: DNA sequences 
III.1. Homology regions 
The homology regions used during cloning of the transfection vectors are indicated below. The 
coding sequence and introns are indicated in capital and small letters, respectively. The sequences 
recognized by primers used for amplification (chapter 2.1.5.6) are underlined. 
 DNA fragments of PfUT used in constructs for glmS ribozyme-based conditional 
knockdown and BirA C-terminal fusion (CRISPR-Cas9 system): 
Left homology region: C-terminal PfUT (primers 1 and 2) 
TTAATGAAAGTTGTTAAGAAGGAGGACAATAATGATTTACCAAGTGTGATGACTTGTACAAATTATTTAAAAATA
CCAGATTATAAAAATAAAGAAAAACTAAGGAACAGATTAATTTATGCCATTAATGAAGGtatatatataatatat
ataatatatataatatatatatatatgtatatatatttataaaaaaaaaagaaaaaaaaaaaattaagtgaaaag
taaaaaaaaaatttttttttttttttttttaaatagtgcattaatatatacatatatatataataatatgtttat
gtatacttatattattatatgcccttttacgtaaatatatattaatacggctatttattatatatatatgtatat
atgtatatatttatttataagcacacatacatacatatatatatatatttatttattattatttcttcttaggCC
AAAAGAATTTTTCCCTTTCTG 
The shield mutations are indicated with grey distinctions. 
Right homology region: 3’ UTR (primers 3 and 4) 
TTTTTGTTTGCGACCCGATGTATTATAATTTTTTTTTTTTAACTCATAAAATATAAACCTTGAGACTTTAATCAG
GTATTATAATATTAAAATGAGAGATTCCCCCAAATGTTAAAAAGGAAAAATTTATACATATAAATATATATATAT
ATATATATATGATTTTCCTTATTTTACGCATAGTTCAAAAAAAAAAAAAAATATATATATATAATATATATATAT
ATTTAAAATATTAGTCTTGTGTATTTTATAATGTGTGTATATAATATATTATATATTTTCTTATGTGTATTATTT
ATTATTATTATTTATTTTTCTTTGCATGCAATAAATATATGAATATATTTTATTATTTTTTTTTTTTTTTTATAT
ATATTACTTACAAACATTGTGTATATATGGAATAATAGGAAATACAAAATTGTGTTATTATGTTTACTTTTAAAA
GAAATAATATACACACATATATAAAAATAAAATATATAATATAATATAATATACATATATATATATATATATATA
TATATATTAATATATATGTGTATATATTATATATGTCAAGGACATATACATTAAAGA 
 DNA fragments of PfUT used in construct for active cysteine to serine replacement in 
PfUT’s HECT catalytic domain (CRISPR-Cas9 system): 
Left homology region: C-terminal PfUT (primers 11 and 2) 
agATATACGAACGATTCAATTACTTTTATTACATTAATTGAAATACTTTCCGAATTTAATAAGGAAGAGAGAAAA
CAATTTGTAAAATTTTGTACGGGAACATCTGCCCTACCTAATAATGGCTTTGCAGCATTAAAGtaataattatat
atatatattatatatatatatatgtgaaatgctgtttatattatatatatatatatatatatatatgtgtgtgtg
tgtgtgtgtgtgtatgtatttattataatacttcatatattatttttattattttttttattattactttttata
attttaggCCCTTAATGAAAGTTGTTAAGAAGGAGGACAATAATGATTTACCAAGTGTGATGACTTCTACAAATT
ATTTAAAAATACCAGATTATAAAAATAAAGAAAAACTAAGGAACAGATTAATTTATGCCATTAATGAAGGtatat
atataatatatataatatatataatatatatatatatgtatatatatttataaaaaaaaaagaaaaaaaaaaaat
taagtgaaaagtaaaaaaaaaatttttttttttttttttttaaatagtgcattaatatatacatatatatataat
aatatgtttatgtatacttatattattatatgcccttttacgtaaatatatattaatacggctatttattatata
tatatgtatatatgtatatatttatttataagcacacatacatacatatatatatatatttatttattattattt
cttcttaggCCAAAAGAATTTTTCCCTTTCTG 
 
A point mutation resulting in a cysteine to serine replacement (TGT → TCT) is highlighted with black 
distinction, whereas the shield mutations are indicated with grey distinctions. 
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Right homology region: 3’ UTR (primers 3 and 4) 
TTTTTGTTTGCGACCCGATGTATTATAATTTTTTTTTTTTAACTCATAAAATATAAACCTTGAGACTTTAATCAG
GTATTATAATATTAAAATGAGAGATTCCCCCAAATGTTAAAAAGGAAAAATTTATACATATAAATATATATATAT
ATATATATATGATTTTCCTTATTTTACGCATAGTTCAAAAAAAAAAAAAAATATATATATATAATATATATATAT
ATTTAAAATATTAGTCTTGTGTATTTTATAATGTGTGTATATAATATATTATATATTTTCTTATGTGTATTATTT
ATTATTATTATTTATTTTTCTTTGCATGCAATAAATATATGAATATATTTTATTATTTTTTTTTTTTTTTTATAT
ATATTACTTACAAACATTGTGTATATATGGAATAATAGGAAATACAAAATTGTGTTATTATGTTTACTTTTAAAA
GAAATAATATACACACATATATAAAAATAAAATATATAATATAATATAATATACATATATATATATATATATATA
TATATATTAATATATATGTGTATATATTATATATGTCAAGGACATATACATTAAAGA 
 
 DNA fragments of PfUT used in construct for targeted gene disruption (SLI-TGD 
approach): 
N-terminal PfUT (primers 17 and 18) 
taaAATGGAGATGAATCTGAAATGgtaaatataataatatttggataatgcaatgttaagaatgtgtgaattgtt
tatattattgtgtaatcatattatatatatatatatatatatatatatttaattttttttatttatttttttatt
tttttatatttatttttttttttttttttttttttttttttttttttttactttttagCTAGCTGCGCTGAACGA
TTTTTATGAACAATTGAATTTGTCAGCTGACGGAGGTTTGAGCAATTCGACTTTAGAAGAATATATGAACGTGCT
TATTCACGTAATAAAAAGTCCTCACATAAGTTATAATAGTGTTTACGGAAGAAATGAGAACAACAACAACAATAA
TAATAATAATAAAAAGAAGAATGTGAAAAATTCCACAAACGACAAGAAAGGAAATTCTTCTGAAAGGATAAATGA
GGTTGTAGGTAG 
The intentionally added stop codon (TAA) required for the success of the system is highlighted with 
grey distinction. 
 
 DNA fragments of PfUT used in construct for BirA N-terminal fusion (CRISPR-Cas9 
system): 
Left homology region: 5’ UTR (primers 29 and 30) 
TTTTGCAGTTCATACATATATCTGTGAAAAAAAAAATGAAATAAATAAATAAATAAATAAATATATATATATATA
TATATATATATATATATATATATAATATAATATAGTATAATTTATATGTTGAAGAATGAAATACAATATATTATA
TTTCATAATAGTAATATTTATATTTATAACGAGAGCACACTTATTTATATAAATATAACAATAATATATATATAT
ATATATATATTGATGTCATATATTTTACGTCATTTTTTTCCATATTAAGTTTTATTTTTGAGAAAAGCTACATAT
ATATAATTTAGGGCATCTCATAAAAAGAAAATAAAAAGGAATTAACACATAATTTGATTTCAATATAATTCTGTA
AATTATATATTTCAATAAATAGAAATATATTATATTATATATGTATATTTATATGATATATCTTTATTTCTACAT
CATGCTTTAAGTATAATATATATATATAATTTTAGTTAAAGAATAA 
Right homology region: N-terminal PfUT (primers 31 and 32) 
TTGAAGAAATACTTGCTCTTTGAAAATTCCCAGTATTCCTATATTATTAACAGTATAAAAAATGGAGATGAATCT
GAAATGgtaaatataataatatttggataatgcaatgttaagaatgtgtgaattgtttatattattgtgtaatca
tattatatatatatatatatatatatatatttaattttttttatttatttttttatttttttatatttatttttt
tttttttttttttttttttttttttttttttactttttagCTAGCTGCGCTGAACGATTTTTATGAACAATTGAA
TTTGTCAGCTGACGGAGGTTTGAGCAATTCGACTTTAGAAGAATATATGAACGTGCTTATTCACGTAATAAAAAG
TCCTCACATAAGTTATAATAGTGTTTACGGAAGAAATGAGAACAACAACAACAATAATAATAATAATAAAAAGAA
GAATGTGAAAAATTCCACAAACGACAAGAAAGGAAATTCTTCTGAAAGGATAAATGAGGTTGTAGGTAGT 
The shield mutations are indicated with grey distinctions.  
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 DNA fragments of PfUT used in constructs for APEX2 C-terminal fusion (SLI system): 
C-terminal PfUT (primers 38 and 39) 
TAATGAAAGTTGTTAAGAAGGAGGACAATAATGATTTACCAAGTGTGATGACTTGTACAAATTATTTAAAAATAC
CAGATTATAAAAATAAAGAAAAACTAAGGAACAGATTAATTTATGCCATTAATGAAGgtatatatataatatata
taatatatataatatatatatatatgtatatatatttataaaaaaaaaagaaaaaaaaaaaattaagtgaaaagt
aaaaaaaaaatttttttttttttttttttaaatagtgcattaatatatacatatatatataataatatgtttatg
tatacttatattattatatgcccttttacgtaaatatatattaatacggctatttattatatatatatgtatata
tgtatatatttatttataagcacacatacatacatatatatatatatttatttattattatttcttcttagGCCA
AAAGAACTTTTCACTTTCT 
 
 DNA fragments of PfUT used in construct for allelic exchange replacing PfUT resistant 
alleles by conserved ones (CRISPR-Cas9 system): 
Central part of PfUT (primers 21-24) 
TCTAAATACTATACGCAAGATATGATAATTAAAGAGAAGAATAAAATGGATGTTTTGGAATTATTAAAAAGTATT
GATAGAAATATTCGTTTATATATATTTTTATATGCTTTATTATTTGTTAATAATAAAAGAAAAGAAGATATGGTA
CATGGTTTATTTTTGAATAGTATAAAAAGGATATATAAAATATTTTCAGAAAATATGTTAGGAGAAAAAAATATA
GAAGATATTAATAGTAATGATATTATGCATATAAAATCATTAGTTGTAAAAATATTTGATTCATATCATTATTAT
TTAATAATTAATAATTTATCATTTAAAAGTTGTTATGAACTTATAAAAATAATCAAGGAATGTTTAAATATTTAT
GATCACTTTCCTATATATTTTTTCAAAGATAATTTTTCAAATAAGAATAATACGAAAAGGGTATGTCCTAATAAA
TATTATGATTATATAAACGTGAATGACCCGAAAGGTAAAGGTGATGGTGAATGTGATGGTGAAGGTGAAGGTGAA
GATGACGATGAAGATGATGATGATAATAATAATAATAATAAGGACGATGGGAATGGAAAAAAGAAAAAGAAAGAG
AGAGAGAGAGAAAAAAAAAAAAATGAATTATTTTATGAATGGAAAAAGGAATATGATGAATTTCCATCATTAAGA
CAAGATTTTTCATATAATGTATATTCGAGGAATAGAAAATCTAGCGAGCTATCAAAAAATAGCAAGCCAAAAAAG
AAGAAGGACAATAAAAATGTTTCATGTGGTAGTTCTCCCAATATGGATAGTATAAATAATAATGAAATAATAAAA
AATACGAATGAAAATAAGAACAATTGTGATTATAATATTAAGGAGGATGATGAATCTGGTAGT 
Conserved polymorphic residues characteristic for sensitive variant of PfUT are highlighted with black 
distinction, whereas the shield mutations are indicated with grey distinctions. 
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III.2. Sequencing results 
Alignment of a respective fragment of pL6-PfUT-HA-glmS-UTR plasmid (Sequence_2) with 
the DNA sequencing results of PfUT-HA-glmS parasite transgenic line (Seqence_1), shown for 
the representative clone:  
 
 
PfUT C-terminal   : [2872 : 3342 - CW] 
3xHA tag          : [3351 : 3449 - CW] 
Riboswitch        : [3461 : 3705 - CW] 
3' UTR            : [3712 : 4293 - CW] 
ACTAGT       : restriction enzymes 
 
Seq_1  1     ---------------------c-at-GgCCCcTTtCgcGGgAagCTaG-gTTTAaTGAAa  36 
                                  | || | ||| || |||||| ||     ||||||||||| 
Seq_2  2821  ATGGAATACTAAATATATATCCAATGGCCCCTTTccgcggggaggACTAGTTTAATGAAA  2880 
 
Seq_1  37    GTTGttAaGAAGGaggaCAATAATGATTTAccaagtGTGATGACttgTACAAATTATTTA  96 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  2881  GTTGTTAAGAAGGAGGACAATAATGATTTACCAAGTGTGATGACTTGTACAAATTATTTA  2940 
 
Seq_1  97    AAAATACCAGATTATAAAAATAAAGAAAAACTAAGGAACAGATTAATTTATGCCATTAAT  156 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  2941  AAAATACCAGATTATAAAAATAAAGAAAAACTAAGGAACAGATTAATTTATGCCATTAAT  3000 
 
Seq_1  157   GAAGGTATATATATAATATATATAATATATATAATATATATATATATGTATATATATTTA  216 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  3001  GAAGGtatatatataatatatataatatatataatatatatatatatgtatatatattta  3060 
 
Seq_1  217   TAAAAAAAAAaGAAAAAAAAAAAaTTAAGTGAAAAGTAAAAAAAAAaTTTTTTTTTTTTT  276 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  3061  taaaaaaaaaagaaaaaaaaaaaattaagtgaaaagtaaaaaaaaaattttttttttttt  3120 
 
Seq_1  277   TTTTTTAAATAGTGCATTAATATATACATATATATATAATAATATGTTTATGTATACTTA  606 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  3121  ttttttaaatagtgcattaatatatacatatatatataataatatgtttatgtatactta  3180 
 
Seq_1  337   TATTATTATATGCCCTTTTACGTAAATATATATTAATACGGCTATTTATTATATATATAT  546 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  3181  tattattatatgcccttttacgtaaatatatattaatacggctatttattatatatatat  3240 
 
Seq_1  397   GTATATATGTATATATTTATTTATAAGCACACATACATACATATATATATATATTTATTT  486 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  3241  gtatatatgtatatatttatttataagcacacatacatacatatatatatatatttattt  3300 
 
Seq_1  457   ATTATTATTTCTTCTTAGGCCAAAAGAATTTTTCCCTTTCTGGCGCGCCAGGCGGTGGAT  426 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  3301  attattatttcttcttaggCCAAAAGAATTTTTCCCTTTCTGGcGCGCCaggcggtggaT  3360 
 
Seq_1  517   ACCCTTACGATGTGCCTGATTACGCGTATCCCTATGACGTACCAGACTATGCGTACCCTT  366 
             |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||| 
Seq_2  3361  ACCCTTACGATGTGCCTGATTACGCGTAtCCcTAtGAcGTaCCaGAcTAtGCaTACCCtT  3420 
 
Seq_1  577   ATGACGTTCCGGATTATGCTCACGGGGTGTAAGCGGCCGCGGTCTTGTTCTTATTTTCTC  306 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  3421  AtGAcGTtCCgGATTAtGCtcacggggtgTAAGCGGCCGCGGTCTTGTTCTTATTTTCTC  3480 
 
Seq_1  637   AATAGGAAAAGAAGACGGGATTATTGCTTTACCTATAATTATAGCGCCCGAACTAAGCGC  246 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  3481  AATAGGAAAAGAAGACGGGATTATTGCTTTACCTATAATTATAGCGCCCGAACTAAGCGC  3540 
 
Seq_1  697   CCGGAAAAAGGCTTAGTTGACGAGGATGGAGGTTATCGAATTTTCGGCGGATGCCTCCCG  186 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  3541  CCGGAAAAAGGCTTAGTTGACGAGGATGGAGGTTATCGAATTTTCGGCGGATGCCTCCCG  3600 
     
151 
 
Seq_1  757   GCTGAGTGTGCAGATCACAGCCGTAAGGATTTCTTCAAACCAAGGGGGTGACTCCTTGAA  126 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  3601  GCTGAGTGTGCAGATCACAGCCGTAAGGATTTCTTCAAACCAAGGGGGTGACTCCTTGAA  3660 
 
Seq_1  817   CAAAGAGAAATCACATGATCTTCCAAAAAACATGTAGGAGGGGACGGCGCCTTTTTGTTT  66 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  3661  CAAAGAGAAATCACATGATCTTCCAAAAAACATGTAGGAGGGGACggcgccTTTTTGTTT  3720 
 
Seq_1  877   TGCGACCCGATGTATTATAATTTTTTTTTTTTAACTCATAAAATATAAACCTTGAGACTT  595 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  3720  TGCGACCCGATGTATTATAATTTTTTTTTTTTAACTCATAAAATATAAACCTTGAGACTT  3779 
 
Seq_1  937   TAATCAGGTATTATAATATTAAAATGAGAGATTCCCTCAAATGTTAAAAAGGAAAAATTT  535 
             |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||| 
Seq_2  3780  TAATCAGGTATTATAATATTAAAATGAGAGATTCCCCCAAATGTTAAAAAGGAAAAATTT  3839 
 
Seq_1  996   ATACATATAAATATATATATATATATATATATATATATATTATTTTCCTTATTTTACGCA  475 
             ||||||||||||||||||||||||||||||||         ||||||||||||||||||| 
Seq_2  3840  ATACATATAAATATATATATATATATATATATG--------ATTTTCCTTATTTTACGCA  3891 
 
Seq_1  1056  TAGTTCAAAAAAAAAAAAAAAAATATATATATATAATATATATATATATATATTTAAAAT  415 
             |||||||||||||||||||||  ||||||||||||||||||||||||||    ||||||| 
Seq_2  3892  TAGTTCAAAAAAAAAAAAAAA--TATATATATATAATATATATATATAT----TTAAAAT  3945 
 
Seq_1  1116  ATTAGTCTTGTGTATTTTATAATGTGTGTATATAATATATTATATATTTTCTTATGTGTA  355 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  3946  ATTAGTCTTGTGTATTTTATAATGTGTGTATATAATATATTATATATTTTCTTATGTGTA  4005 
 
Seq_1  1176  TTATTTATTATTATTATTTATTTTTCTTTGCATGCAATAAATATATGAATATATTTTATT  295 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  4006  TTATTTATTATTATTATTTATTTTTCTTTGCATGCAATAAATATATGAATATATTTTATT  4065 
 
Seq_1  1236  ATTTTTTTTTTTTTTT-ATATATATTACTTACAAACATTGTGTATATATGGAATAATAGG  236 
             |||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  4066  ATTTTTTTTTTTTTTTTATATATATTACTTACAAACATTGTGTATATATGGAATAATAGG  4125 
 
Seq_1  1296  AAATACAAAATTGTGTTATTATGTTTACTTATAAAAGAAATAATATACACACATATATAA  176 
             |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||| 
Seq_2  4126  AAATACAAAATTGTGTTATTATGTTTACTTTTAAAAGAAATAATATACACACATATATAA  4185 
 
Seq_1  1356  AAATAAAATATATAATATAATATACATA---ATATATATATATATATATATATATAT--T  121 
             |||||||||||||||||||||||| |||   ||||||||||||||||||||||||||  | 
Seq_2  4186  AAATAAAATATATAATATAATATA-ATATACATATATATATATATATATATATATATATT  4244 
 
Seq_1  1416  AATATATATGTGTATATATTATATATGTCAAGGACATATACATTAAAGACTTAAGCATtt  61 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||      
Seq_2  4245  AATATATATGTGTATATATTATATATGTCAAGGACATATACATTAAAGACttaag-----  4299 
 
 
